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Abstract: Cellular mechanisms of oxygen sensing in human coronary artery 
smooth muscle cells (HCASMCs) 
 
Hypoxic coronary vasodilation is an important mechanism that ensures adequate 
oxygenated blood is provided to metabolically active heart. Although it is beyond 
doubt that this phenomenon plays a central role in matching oxygen supply and 
increased demand of cardiac myocytes, the underlying mechanisms have proved 
difficult to disentangle. This study investigated the cellular targets of hypoxic 
coronary vasodilation with testing the main hypothesis that KATP channels play an 
important role in hypoxic vasodilation by coupling cellular metabolism to cell 
excitability.  
Seahorse experiments showed HCASMCs preferentially rely on oxidative 
phosphorylation (OXPHOS) to generate ATP (~54.53%), in which O2 acts as the 
final electron acceptor of electron transport chain (ETC). Intracellular ATP was 
measured by CellTiter Glo Luminescent Assay and ATP:ADP ratio was examined by 
genetically encoded biosensors Perceval/PercevalHR. FUGW-pHRed was also used 
to monitor pH. Either inhibiting glycolysis or OXPHOS with metabolic inhibitors 
caused a reduction in intracellular ATP and ATP:ADP ratio. A further change was 
observed when blocking both glycolysis and OXPHOS. There was no obvious 
change of ATP:ADP ratio reported using PercevalHR in cells infected with lentivirus 
under hypoxia (1% O2). Rhodamine123, a mitochondrial membrane potential (ψm) 
sensitive dye showed hypoxia didn’t cause a significant change in ψm further 
indicated that low level O2 in this study did not change ATP:ADP ratio.  
Live cell imaging with HCASMCs loaded with Fluo-4 and DiBAC4(3) was 
used to assess the changes in intracellular Ca
2+
 ([Ca
2+
]i) and membrane potential, 
respectively. Using K
+
 channel modulators, it was characterized the presence of KATP, 
BKCa, SKCa/IKCa and Kv channels in HCASMCs, and of those, KATP and Kir channels 
play an essential role in setting resting membrane potential. Application of metabolic 
inhibitors (e.g. rotenone and antimycin) of OXPHOS caused hyperpolarization, and 
the effects were inhibited by either 10 µM glibenclamide or 60 mM K
+
, indicating a 
role of KATP channels. Hypoxia caused a decrease in spontaneous Ca
2+
 oscillations 
and oscillations induced by vasoconstrictors. Exposure to hypoxia resulted in 
membrane hyperpolarization which was completely abolished by 60 mM K
+
, but not 
by a single K
+
 channel inhibitor. 
ATP:ADP ratio in the close vicinity of KATP channels may be more important 
than its global level which PercevalHR reports. Further experiments were designed 
to examine ATP:ADP ratio in the cell membrane microdomains using a membrane 
targeted PercevalHR and TRIF imaging. Preliminary experiments showed successful 
measurement of ATP:ADP ratio in the cell membrane microdomains. 
Taken together, hypoxia may cause coronary artery smooth muscle relaxation by 
modulating [Ca
2+
]i and K
+
 channels. The identity of K
+
 channels involved in hypoxia 
induced hyperpolarization is unknown.  
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Introduction 
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1.1 General introduction  
Oxygen (also referred as O2 in this thesis) is an absolute requirement for 
multicellular organisms that generally require higher level of energy. In vertebrates, it 
is transported throughout the body by hemoglobin (Hb) in red blood cells (RBCs) so 
that every cell can perform aerobic energy production. Shortage and lack of O2, 
hypoxia and anoxia, could result in serious and irreversible damage to vital organs. 
Sensing and responding appropriately to O2 deprivation is therefore of great 
importance and required for survival of all forms of aerobic life. Ensuring 
appropriate O2 supply is particularly important for energy hungry organs such as 
heart, brain and kidney [1], and acute O2 deficiency is usually resolved by increasing 
blood flow. Thus, hypoxia causes arteries to dilate, increasing blood supply. An 
exception to this is the pulmonary artery which constricts and shunts the blood to 
better ventilated areas of the lung to maintain the ventilation perfusion ratio. Despite 
the above well-established phenomenon in the vasculature, the underlying 
mechanisms have proved to be complicated and difficult to disentangle [2]. 
Hypoxic vasodilation of coronary arteries is a physiologically protective 
response to match blood flow to increased O2 demand of the heart. For most of the 
tissues, O2 extraction is no more than 25%. However, myocardium extracts a high 
proportion (65-75%) of O2 in coronary blood at baseline conditions [1]. Therefore, 
O2 reserve of the heart is small, leaving little spare for further extraction [1, 3, 4]. 
When there is an increase in cardiac workload, the coronary blood flow may increase 
more than 5 fold almost instantly [1, 2]. A number of processes may be involved and 
work in concert in metabolic vasodilation, thus link cell metabolism to cell viability 
and function [2]. 
Although coronary artery vasodilation during hypoxia is a well-known 
phenomenon for many years, its mechanism is still controversial, and this thesis aims 
to shed light on this fundamental yet unresolved question. Combination of molecular 
and cellular techniques was used, and attempts were made to permit mechanistic and 
quantitative investigations wherever possible. Experiments were performed using 
smooth muscle cells (SMCs) obtained from human coronary artery. As a cardiologist, 
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this is a cell model of my interest, and I begin the introduction discussing human 
cardiovascular system. 
 
1.2 Human cardiovascular system 
The cardiovascular system, also called the circulatory system, is a network 
comprised of heart, blood and blood vessels. The heart is a hollow muscular organ 
with four chambers: left atrium, right atrium, left ventricle and right ventricle. 
De-oxygenated blood returns to right atrium through superior and inferior vena cava 
and then right ventricle and travels to the lung through pulmonary trunks. Blood is 
oxygenated in the lung via a short and low pressure circulation (the pulmonary 
circulation) [1] (Figure 1.1) and goes to left atrium, and then left ventricle. Left 
ventricle pumps the oxygenated blood out of the heart to arterial vessels, and delivers 
O2 and energetic substrates to the tissues of the body at high pressure (the 
general/systemic circulation). Pulmonary circulation is different from that of 
systemic circulation as pulmonary artery carries deoxygenated blood and pulmonary 
vein carries oxygenated blood. Blood delivers O2, nutrients (e.g. glucose), 
electrolytes, enzymes, hormones to the organs, tissues, and cells of the body. 
Subsequent metabolic waste products (e.g. CO2, H
+
) are removed at the same time. 
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Figure 1.1: Human cardiovascular system. Systemic circulation and pulmonary 
circulation. 
(Source:highered.mheducation.com/sites/dl/free/0073403490/578766/sample_chapte
r10.pdf). 
 
1.3 Human coronary circulation 
1.3.1 Structure and function of coronary circulation 
The chambers of the heart contain blood, but ironically cardiac muscle is unable 
to obtain O2 directly from it. This is because diffusion distance of O2 is very short, 
and so the heart requires its own circulation where blood is provided by coronary 
arteries. Left main and right coronary arteries (LMCA and RCA) branch off the 
ascending aorta just above the aortic valve, and LMCA is further divided into left 
anterior descending (LAD) and left circumflex (LCX) as LMCA is very short 
(Figure 1.2). Thus, it is LAD, LCX and RCA that extend over the heart’s surface as 
they traverse away from the aorta. Three main coronary arteries branch out into 
progressively smaller arteries which penetrate the epicardium to supply transmural 
myocardium with O2 and nourishment. Ultimately, blood is channeled to capillaries, 
5 
 
and the cardiac myocyte is unusual in the body in having a cell to capillary ratio of 1 
to 1 [1]. Various branches of coronary arteries were summarized and divided into 
different patterns based on the arteries distribution [5] as shown in Figure 1.3. 
Because of the compressive force taking place during systole, the transmural blood 
supply is received mainly during ventricular relaxation in the left ventricle.  
 
 
 
Figure 1.2: Distribution of main coronary arteries. The major human coronary 
arteries of the heart from both anterior and posterior, most of them are epicedial 
vessels (Reproduced from Robert J. Tomanek, 2013 [5]). 
 
 
 
Anterior view Posterior view 
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Figure 1.3: Branch patterns of human coronary artery. Type I: Intramural 
branches; Type II: Branches directed mainly to the subendocardial myocardium; 
Type III: Short branches supplying subepicardial myocardium. The figure in the inset 
shows the generations of branches (2, 3, 4, 5). (Reproduced from Tomanek, 2013 
[5]) 
 
1.3.2 Anatomy of human coronary arteries 
Blood pressure (BP) and blood flow are controlled in the body through 
constricting and dilating of the vessels. With the exception of capillaries, the wall of 
blood vessels is comprised of three layers [1, 5]. The tunica intima (inner coat) of the 
vessel is formed with a single layer of squamous endothelial cells (ECs) and 
separates vascular SMCs (VSMCs) from the plasma. Multiple layers of spindle 
shaped SMCs form the tunica media (middle coat), providing the contractile 
machinery of the vessels. The tunica adventitia (outer coat) mainly consists of 
connective tissue with a variety of cells such as nerves within. Even though the three 
layers are separated physically from each other by internal and external elastic 
lamina, the signal from intima can be transmitted to media by the myo-endothelial 
junction. Figure 1.4 represents the main components of a coronary artery. Figure 1.5 
shows the structure of canine coronary artery under electron micrographs [5]. 
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Figure 1.4: Structure of the artery wall. The three layers of the artery wall: Intima 
(endothelium and subendothelium); media (external elastic lamina and smooth 
muscle); and adventitia. 
 
 
Figure 1.5: Micrographs of canine coronary artery (A) and arterioles (B&C). (A) 
Epicardial artery with a media consisting of SMCs (blue elongated structures) and 
connective tissue (light blue). VV: vasa vasora; FC: fat cells; EC: endothelial cell. (B) 
A small arteriole with an endothelium and one layer of smooth muscle. The arrows 
indicate the nerve bundle in the adventitia. (C) Arrows indicate plasma membrane 
vesicles or caveolae. Arrowhead indicates a gap junction. (Reproduced from 
Tomanek, 2013 [5]) 
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1.4 O2 delivery 
1.4.1 O2 carrier 
In vertebrates, there are three main steps for the O2 delivery to the cells: 
breathing of O2 by the lung, transporting of O2 in the blood and delivering of O2 to 
cells. Passively dissolving O2 to blood is completely inadequate for the purpose, and 
a more efficient way to ferry around O2 is required. It is Hb in RBCs that acts as O2 
carrier binding to O2 in the lung and releasing it to tissues upon arriving to capillaries 
where the partial pressure of O2 (PO2) is very low. In a normal individual, a RBC has 
a lifespan of ~115 days, varying between 70 and 140 days [6]. RBCs maintain a 
relatively constant number of about 5x10
11
 cells/dL [7], and equilibrium in number is 
achieved between the scavenging activity by macrophages and RBC production [8]. 
RBCs can produce polypeptide chains (α- and β-globin) and protoporphyrin, and 
these and Fe
2+
 form a functional adult Hb molecule. At the places where O2 level is 
high (e.g. lung), Hb binds to O2 with a structure change from T state to R state (one 
pair of αβ subunits shifts with respect to the other by a rotation of 15 degrees) [9, 10] 
(Figure 1.6).  
 
       
Figure 1.6: Structure of Hb. (A) Quaternary structure of Hb. Hb consists of two α 
chains and two β chains, and functions as a pair of αβ dimers (Reproduced from Berg 
et al., 2002 [10]). (B) Switches of Hb between T state (left) and R state (right). 
 
1.4.2 O2 tension, exchange and gradient 
Once O2 is delivered to the cells, it acts as the final electron acceptor of electron 
transport chain (ETC), the final step of cellular respiration. The PO2 at sea level is 
A B 
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approximately 21 KPa, corresponding to ~21% of atmospheric pressure. Due to 
longitudinal and radial gradients during delivery from trachea to the cells, PO2 
decreases dramatically [11-14] (Figure 1.7). It is suggested that the median PO2 is 
approximately 7 KPa (~7%) in systemic arteries, and 3-4 Kpa (~3-4%) in arterioles 
and capillaries [11]. Many investigations have consistently shown that a great 
amount of O2 is lost from arterioles while the change in the capillaries is small. This 
has been suggested to be related to the metabolic state of the organ [14]. Possible 
reasons for the loss of O2 in arterioles include O2 consumption by nearby 
parenchymal cells, diffusion of O2 to neighboring microvessels, increased O2 
solubility in cell membrane as well as O2 consumption by SMCs and ECs in the 
vessel wall [11, 14-16]. The destination of O2 is mitochondria, and to reach there 
from a microvessel, O2 needs to pass through a series of structures (e.g. cell 
membrane, cytosol) [12] (Figure 1.8). Such barriers may further contribute to O2 
gradients that shift according to change in metabolic demand. Myoglobin 
microspectrophotometry identified a gradient of O2 across the sarcolemma of cardiac 
myocyte [17]. Studies in human skeletal muscle showed an intracellular PO2 (PiO2) 
of ~32 mmHg at rest that decreased to ~3-6 mmHg during moderate to heavy 
exercise [18, 19]. 
      
Figure 1.7: Regional distribution of O2 partial pressure from airways to cytosol. 
The thickness of the line represents the variation of the value. (Reproduced from 
Ward, 2008 [11]) 
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Figure 1.8: Graphical representation of a simplified diffusion equation and 
typical barriers. O2 diffuses from capillaries to mitochondria through a series of 
barriers including extracellular fluid, plasma membrane, cytosol and mitochondria 
membrane. PcO2, capillary PO2; PsO2, cell surface PO2; PiO2, intracellular PO2; R is 
resistance to diffusion, inverse of conductance, G. (Modified from Clanton et al., 
2013 [12]) 
 
1.5 O2 sensing mechanisms: a role for O2 sensors 
1.5.1 Overview 
Adequate O2 supply is of upmost importance for cell function and survival. A 
deficit of O2, though a useful trigger for many physiological processes, could lead to 
pathogenesis of many diseases if it becomes harmful [20-24]. Understanding how 
altered O2 causes adaptive changes in the cells requires knowledge of how the cells 
sense O2 in the first place. A number of mechanisms have been suggested in the 
cardiovascular system which assess and sense the concentration of O2 [2, 11, 12, 21, 
22, 25].     
 
1.5.2 Carotid body 
Carotid body is made of chemoreceptors that are responsible for fast, 
cardiorespiratory, and circulatory systemic reflexes (e.g. hyperventilation or 
11 
 
sympathetic activation). Chemoreceptors respond to a decrease in PO2 and rise in 
partial pressure of CO2 and H
+
. When hypoxia occurs, chemoreceptors respond 
immediately, increasing O2 uptake [26-28]. Chemoreceptors are classified into two 
categories, central and peripheral chemoreceptors, and the carotid body belongs to 
the latter. Central receptors are in the medulla oblongata and respond to the changes 
in pH and CO2 [29]. In addition to carotid body, peripheral chemoreceptors are 
located in aortic bodies, neuroepithelial bodies and adrenomedullary chromaffin 
bodies, and they are more important in sensing global O2 tension. Peripheral 
chemoreceptors have neurosecretory cells which can release neurotransmitters when 
PO2 decrease (<60 mmHg). Although many chemoreceptors exist, carotid body is the 
major arterial chemoreceptor that controls the hyperventilatory response to hypoxia, 
and therefore I will focus on the carotid body [21, 28]. 
The pair of carotid bodies are located near the bifurcation of the carotid arteries 
and contain glomus cells (Type I cell) which respond to hypoxia. O2 sensitive, 
neuron-like glomus cells are innervated by sensory fibers, and they can transmit the 
signal to central nervous system when O2 tension changes in the artery. O2 sensitive 
cells in arterial chemoreceptors and other organs are important in homeostatic O2 
sensing system, and well known for their ability in adaption to acute perturbation of 
environmental PO2. However, the mechanisms by which these chemoreceptors sense 
O2 tension remain controversial, and possibly more than one pathway may be 
working in concert [12, 27, 30]. It is acknowledged that hypoxia activation of glomus 
cells of all mammalian species is correlated with the O2 sensitive K
+
 channels. A 
decrease in K
+
 channel conductance results in cell depolarization and subsequent 
Ca
2+
 influx, releasing neurotransmitters to activate the nerve fibers [28, 31]. However, 
more work remains to be done to shed light on the molecular mechanisms in the 
regulation of ion channel conductance in different tissues when O2 tension changes.  
 
1.5.3 O2 sensitive ion channels 
1.5.3.1 K
+
 channels 
Since the initial finding of an O2 sensitive K
+
 channel in rabbit carotid body 
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[32], many studies have been carried out to investigate O2 sensitive K
+
 channels in a 
wide range of tissues. It is now known that many K
+
 channel subtypes alter their 
activity with acute hypoxia, and changes in the expression level of different K
+
 
channels were observed under prolonged hypoxia [21]. ATP-sensitive K
+
 channels 
(KATP) are activated by intracellular ADP and inhibited by ATP. Due to their 
sensitivity to intracellular nucleotides, KATP channels can couple cellular metabolism 
to cell excitability, possibly making them uniquely positioned in the process of 
hypoxic vasodilation in systemic arteries [33, 34]. However, it is still under debate 
whether hypoxia causes a sufficient change in cellular nucleotides for activation of 
KATP channels [33]. It is also uncertain whether the effect on K
+
 channels is a direct 
effect from hypoxia, or secondary from other molecules produced during hypoxia. 
Evidence on excised membrane patch and recombinant systems has suggested 
hypoxia may modulate K
+
 channels directly [35-37]. However, other studies 
suggested an indirect effect on K
+
 channels from intracellular O2 sensitive signaling 
molecules such as reactive oxygen species (ROS) and haem oxygenase (HO) [21, 22, 
38, 39]. 
 
1.5.3.2 Ca
2+
 channels 
Ca
2+
 enters VSMCs mainly through voltage dependent Ca
2+
 channels (VDCCs) 
where an increase in intracellular free Ca
2+
 concentration ([Ca
2+
]i) results in SMC 
contraction. VDCCs are a group of voltage-gated Ca
2+
 channels which are regulated 
by membrane potential. Hypoxia causes an increase in [Ca
2+
]i and pulmonary artery 
SMC contraction while it causes a decrease in [Ca
2+
]i and systemic artery SMC 
relaxation [40]. The relationship between changes of membrane potential and 
increase in open probability (Po) of VDCCs is very steep where a few millivolts (mV) 
depolarization will cause several fold change in [Ca
2+
]i [41-43]. As the membrane 
potential in VSMC is thought to be determined primarily by K
+
 channels, the 
changes in [Ca
2+
]i may be secondary to changes in activity of K
+
 channels. On the 
other hand, there is also evidence for a direct effect of hypoxia on [Ca
2+
]i 
independent of membrane potential [44, 45]. 
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1.5.4 Mitochondria 
The mitochondrion is a double membrane organelle existing in most cells. It is 
where the biochemical process of O2 respiration happens, generating the bulk of ATP 
in cells. Due to their crucial and ubiquitous task in producing ATP, it is recognized as 
the energy factory of the cell. However, mitochondria appear increasingly 
multi-tasking organelles with other roles including cell signaling, cell differentiation, 
cell cycle and cell death [46, 47]. To generate ATP via oxidative phosphorylation 
(OXPHOS), it requires mitochondria to use O2 as the final electron acceptor. Thus, 
mitochondrial F1F0-ATPase works in a forward mode and consumes proton motive 
force (PMF) to produce ATP. On the other hand, when hypoxia/anoxia prevails, ETC 
is ceased and cells begin to utilize energy from glycolysis. Based on these, 
mitochondria are well positioned as promising candidates for cellular O2 sensing [11, 
47]. However, because the main O2 sensitive enzyme cytochrome oxidase has a low 
apparent concentration for 1/2 maximum velocity (Km) for O2, it is still saturated 
until O2 tension decreases to a very low level (<1 mm Hg). The O2 level at which 
respiratory rate is 50% of maximum (P50) of cytochrome aa3 is ~0.07 kPa PO2 (~0.7 
µM), which was measured in systemic cells [48]. Therefore mitochondria may 
function well as a sensor of anoxia but are unable to sense a moderate change in O2 
tension in the cells [49]. If true, mitochondria cannot be a major player in hypoxic 
vasodilation that occurs at much higher O2 levels [2]. It should be noted, however, 
that the measurement of the O2 concentration at Km is usually carried out in isolated 
enzyme, so it is very likely to be different in the whole intact cell especially when 
taking into consideration of O2 longitudinal and radial gradients (See Figure 1.7 and 
1.8).    
Although this thesis does not address the issue experimentally, by-products of 
cellular metabolism may be important when considering hypoxic response. The 
redox state and mitochondrial ROS production resulting from mitochondrial 
inhibition are usually unrelated to energy state of the cells. During electron transport 
in the ETC, ROS in the form of superoxide can be formed at several sites when 
single electrons are lost to O2. Studies also suggested about 3% of O2 consumed is 
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not reduced effectively and there is evidence indicating electron lost at the same time 
[50, 51]. The formation of ROS needs O2 as substrate, so the question would be 
whether there is enough O2 to make ROS during hypoxia. However, even at an 
intracellular PO2 of 1 Torr, there is still ~1.4 µmol/L O2 in the cytosol and ~5-7 
µmol/L O2 in the cell membrane [12]. Increased mitochondrial redox state and ROS 
production during hypoxia/anoxic conditions may therefore act as a signaling 
mediator [11, 12, 26] (Figure 1.9). 
 
 
Figure 1.9: Redox mechanism for O2 sensing. ROS are produced from 
mitochondria, NADPH oxidase and redox couples. Redox signaling may regulate K
+
 
channels on the cell membrane and Ca
2+
 entry. The same redox signaling may control 
Ca
2+
 in the sarcoplasmic reticulum. SOD: superoxide dismutase; H2O2: hydrogen 
peroxide; GSH: glutathione; GSSG: oxidized glutathione. (Modified from Weir et al., 
2005 [26]) 
 
1.5.5 Hypoxia-inducible factor (HIF) 
Response to hypoxia is not restricted to an acute one such as relaxation of 
systemic artery. Chronic hypoxia can initiate adaptive mechanisms. One such 
example is hypoxia-inducible factor (HIF) which is a transcription factor. HIF is a 
dimer composed of one of the HIF α subunits (1α, 2α, or 3α) and a β subunit. Among 
three subtypes (HIF-1, HIF-2 and HIF-3), HIF-1 is most studied [52]. HIF 1β, also 
named aryl hydrocarbon receptor nuclear translocator (ARNT), is constitutively 
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expressed. HIF 1α is responsible for O2 dependent prolyl and asparaginyl 
hydroxylation that causes increasing angiogenic gene expression [53]. Under 
normoxia, HIF 1α is hydroxylated by prolyl-hydroxylase (PHD), taking an ubiquitin 
dependent degradation pathway. Hypoxia inactivates and stabilizes PHD. Together 
with HIF 1β, HIF 1α binds to hypoxia responsive element (HRE), leading to 
activation of genes responsible for erythropoiesis, angiogenesis, expression of ion 
channels and activation of glycolytic energy production [11, 22, 54]. O2 sensitivity of 
HIF 1α is presented in Figure 1.10. Together with other transcriptional factors such 
as early growth response factor (Egr-1), nuclear factor-κB (NF-κB), as well as 
activator-protein 1 (AP-1), HIF-1 protects cells from injuries during prolonged 
hypoxia [55-57]. HIF 1α deficient (HIF 1α-/-) mouse embryos die at mid-gestation 
with defects in the cardiovascular system [53]. Pulmonary artery SMCs from wild 
type mice respond to hypoxia with increased [Ca
2+
]i and decreased voltage-gated K
+
 
currents while these effects were lost in HIF1α+/- mice [58]. In the same study, it has 
been shown that even though carotid bodies isolated from Hif 1α+/- mice maintained 
normal histology, they are unable to response to hypoxia [58]. 
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Figure 1.10: Structure and regulation of HIF-1. (A) HIF 1α structure (Modified 
from Yeom et al., 2011 [59]). (B) Pathways of HIF-1 regulation under normoxia and 
hypoxia (Reproduced from Cavadas et al., 2013 [60]). HIF: hypoxia-inducible factor; 
PHD: prolyl-hydroxylase; ARD1: arrest defective-1; FIH: factor inhibiting HIF; 
bHLH: basic helix-loop-helix; PAS: Per Arnt Sim domain; ODD: oxygen-dependent 
degradation; N(/C)TAD: N(/C)-terminal two transactivation domain; NLS: nuclear 
localizing signal; VHL: von Hippel-Lindau; HRE: hypoxia responsive element. 
 
1.5.6 Other O2 sensors 
Besides what are generally considered to be major mechanisms mentioned 
above, many other mediators (e.g. NADPH oxidase, HO, cytochrome P-450 4A, 
pentose phosphate pathway) may play a role in O2 sensing [11, 22, 38, 61]. 
Mitochondria are not the only ROS production site. NADPH oxidase on the cell 
membrane is an enzyme that can catalyze the production of superoxide anion radical 
(O
2-
) from O2 and NADPH (Figure 1.9). Haem oxygenase-2 has been reported as an 
O2 sensor in carotid body activation by hypoxia [62], and its deletion in mouse 
caused impaired immunity and abnormal O2 sensing [63]. Compared to other cells, 
mitochondria in glomus cells and pulmonary artery SMCs showed much higher 
sensitivity to low O2 [11, 39], and the opposite responses of systemic artery and 
pulmonary artery may rise from a fundamental difference in their mitochondria [64]. 
It should be noted that some O2 sensors may be more important in some specialized 
A 
B 
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cells than others, and the ways via which O2 sensors transduce signal to their ultimate 
effector can be different [11].  
In summary, over physiological hypoxia, a wide range of O2 sensors are 
activated to serve different functions with shared goals to provide more O2, enhance 
the efficiency to use available O2, and protect cell viability and function. 
 
1.6 Metabolic/hypoxic vasodilation 
1.6.1 Definitions 
Even though the PO2 in the air is ~21%, it decreases to 3-4% when reaching 
arterioles and capillaries [11] and lower still in the cytosol [12]. Therefore, hypoxia is 
a relative term, indicating conditions in which failure of delivery and/or use of O2 
(O2 starvation) affect the function of the tissue. Hypoxia is different from ischemia as 
the latter is a decrease in blood flow to the tissue, and so resulting inadequate 
oxygenation is secondary. Ischemia can always cause hypoxia, but hypoxia can occur 
without ischemia (e.g. high altitude, anemia). Depending on the causes, hypoxia may 
be classified as four subtypes  according to the primary origin of the defect: 
hypoxic hypoxia occurs when the PO2 of arterial blood falls, anemic hypoxia occurs 
when there is a decrease in the oxygen carrying ability of the blood, stagnant hypoxia 
occurs when the blood flow is abnormally low, and histotoxic hypoxia occurs when 
mitochondrial ATP production decreases due to a defect in O2 usage [65]. Hypoxia 
can also be divided into acute and sustained (continuous and intermittent) as 
discussed earlier, and this causes different response and insults of the tissue. A 
general reduction of O2 in the arteries usually causes activation of sympathetic 
system that would lead to a rapid increase in BP. The local responses to hypoxia is a 
different matter altogether and may vary widely, such as acute vasodilation and 
vasoconstriction. 
Hypoxic vasodilation is a conserved adaptive response to match blood supply to 
local metabolic demand in response to an acute reduction in arterial PO2. The 
restoration of O2 delivery re-balances the acute O2 supply-demand mismatch, thus 
protecting the cells from O2 deficit and subsequent malfunction. This highly 
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conserved physiological response was first depicted by Roy and Brown in 1880 
where they found a temporary cessation of local blood resulted in dilation of 
arterioles, capillaries and veins along with an increased blood flow [66]. On the other 
hand, pulmonary arteries constrict in hypoxia (~20-60 mmHg PO2) in order to 
maintain the ventilation-perfusion ratio [67]. Although hypoxic vasodilation of 
systemic arteries is beyond debate, the fundamental physiological processes in 
sensing hypoxia still remain uncertain [2]. In general, the effects of hypoxia on 
systemic arteries can be ascribed to indirect effects (e.g. vasodilator metabolites from 
adjacent tissues) and direct effects (e.g. SMC K
+
 channel activation) on arterial 
VSMCs. 
 
1.6.2 Indirect vasodilatory effect of hypoxia on SMCs 
Increases in systemic blood flow confer cellular protection against hypoxia. One 
of the major hypotheses accounting for hypoxic vasodilation is the release of 
vasodilating metabolites from adjacent tissues. Blood vessels are innervated and thus 
receive the input from neuroendocrine system. During exercise, sympathetic 
β-adrenoceptor mediated arteriolar vasodilation contributes ~25% of the increased 
coronary blood flow through the activation of β2-adrenoceptors on coronary vascular 
myocytes [1]. Meantime, α-adrenoceptors (α1 and α2) mediates vasoconstriction of 
medium to large coronary arteries, the significance of this being maintenance of 
blood flow to the vulnerable sub-endocardium [68]. Thus, apparently opposite effects 
(contraction and dilation) serve to achieve shared goal, supplying blood to 
sub-endocardium, the area where vast majority of cardiac ischemic injury arises. 
More importantly from the point of this thesis, studies also suggested that hypoxia is 
capable of increasing local blood flow in isolated organs, therefore this phenomenon 
can happen independently of neural-mediated reflex mechanisms [69, 70]. The 
cross-talk communication between cellular metabolites from cardiac myocytes and 
VSMCs may play a crucial role here. Under hypoxia, cardiac myocytes produce 
adenosine, H
+
 and a rise in extracellular K
+
, resulting in SMC relaxation, in part 
through the activation of K
+
 channels [71-73]. In addition to vasodilator metabolites 
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from cardiac myocytes, ECs and erythrocytes also release vasodilator substrates 
including NO, prostaglandins and endothelium derived hyperpolarizing factor. The 
identity of the last item is currently unknown but candidates include CO, H2O2, or 
ONOO
-
 [74-76]. 
 
1.6.3 Direct vasodilatory effect of hypoxia on VSMCs 
Besides the events mediated by cardiac myocytes and ECs, hypoxia can exert 
direct effects on VSMCs [77, 78]. Even though there is difference between different 
arteries, hypoxia has been shown to activate a series of K
+
 channels in VSMCs, 
resulting in membrane potential hyperpolarization, a decrease in [Ca
2+
]i and 
vasodilation [21, 34, 38]. This is because the concentration of intracellular K
+
 ([K
+
]i  
~140 mM) is much higher than that of extracellular ([K
+
]o ~5 mM) making K
+
 
equilibrium potential (EK) calculated from Nernst equation in SMCs very negative 
(-88.7 mV). However, membrane potential (Em) of SMC is almost always positive to 
EK, and opening of K
+
 channels therefore leads to hyperpolarization due to net K
+
 
efflux. When membrane potential is hyperpolarized, VDCCs will close, leading to 
decrease in [Ca
2+
]i. When [K
+
]o is elevated (80 mM and above), EK will shift to a 
more positive value where opening of K
+
 channels will no longer cause 
hyperpolarization as net K
+
 efflux no longer occurs. Although K
+
 channels are likely 
to be involved in hypoxia induced vasodilation, other mechanisms are almost 
certainly involved, ensuring the proper blood supply is ensured. Smani et al. (2002) 
showed that hypoxia (~20 mmHg) relaxed vascular smooth muscle in the presence of 
high [K
+
]o, suggesting relaxation is independent of K
+
 channels [77]. The study by 
Calderón-Sánchez et al. (2009) suggested that besides a reduction of Ca
2+
 entry via 
VDCCs, a mechanism in which a Ca
2+
 channel-induced Ca
2+
 release (metabotropic 
CCICR) from sarcoplasmic reticulum (SR) is involved [79]. 
 
1.7 Vascular tone and contraction 
1.7.1 Vascular tone 
The myogenic response of vasculature was first described by Sir William 
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Bayliss in 1902 (Bayliss effect) [80]. Myogenic tone is independent of central 
nervous system, and artery muscles respond to a stretching force by contraction and 
diminution of tension by relaxation [80]. Myogenic tone is intrinsic to smooth 
muscle and by doing so, small arteries and arterioles maintain the flow constant 
when BP changes. Without such a mechanism, blood flow to the brain where the 
constant and stable blood supply is crucial may change all the time (e.g. standing 
from lying down). The microcirculation of coronary arterioles with a diameter of 
50-200 µm was reported to account for ~60% of the coronary resistance [81]. 
However, myogenic tone is not substantial in medium to large arteries and in veins 
[81, 82]. 
Myogenic response has been observed both in vivo and in vitro. However, the 
regulation of vasomotor tone is not homogenous, involving different mediators at 
different sites of specific microcirculation. Various membrane receptors and ion 
channels in both ECs and VSMCs coordinate together to modulate microcirculation 
vasomotor tone. 
 
1.7.2 SMC contraction 
1.7.2.1 Ca
2+
 regulation 
In arteries, vasomotor tone is determined by contraction of VSMCs in the vessel 
wall, and contraction is generally triggered by an increase in [Ca
2+
]i. The force of the 
vessel is developed by cross-bridge cycling in VSMCs where Ca
2+
 plays an 
important role [83]. In general, the increase in [Ca
2+
]i of SMCs is dependent 
on two sources: (i) Ca
2+
 entry from extracellular space (e.g. VDCCs); (ii) 
Ca
2+
 release from intracellular stores, principally the SR. VDCCs are the major route 
of Ca
2+
 entry, but Ca
2+
 influx also occurs via voltage-independent, receptor-operated 
Ca
2+
 channels. The increases in [Ca
2+
]i can occur by release from the SR via inositol 
1,4,5-trisphosphate receptors (IP3Rs) and ryanodine receptors (RyRs). 
The force of systemic arteries, particularly small resistance arteries and 
arterioles, has a close relationship with [Ca
2+
]i. Notwithstanding the level of Ca
2+
 is 
very high in the extracellular space (~2 mM), [Ca
2+
]i is considerably lower and very 
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tightly controlled [83, 84]. The main routes for Ca
2+
 removal are plasma membrane 
Ca
2+
 ATPase (PMCA), SR Ca
2+
-ATPase (SERCA) and sarcolemmal Na
+
-Ca
2+
 
exchanger (NCX). Figure 1.11 shows the routes through which Ca
2+
 is modulated in 
SMCs. 
 
 
Figure 1.11: Ca
2+
 channels and transporters in VSMCs. Mito: mitochondria; SR: 
sarcoplasmic reticulum; MCU: mitochondrial Ca
2+
 uniporter; MTP: mitochondrial 
permeability transition pore; NCE: Na
+
-Ca
2+
 exchanger; SERCA: sarcoplasmic 
reticulum ATPase; TRP: transient receptor potential family of channels; VDCC: 
voltage dependent Ca
2+
 channel. 
 
1.7.2.2 Cross-bridge and cell contraction 
Like striated muscle, the contraction of SMCs is caused by the interaction 
between thin and thick, actin and myosin, contractile filaments. In VSMCs, the thin 
filaments are rooted in dense bands instead of Z lines in the case of cardiac myocytes. 
Because these dense bodies are patchy plaques and not regularly and systematically 
aligned, VSMCs lack the striated banding pattern found in cardiac and skeletal 
muscle [1]. Furthermore, unlike cardiac and skeletal muscle, VSMCs do not 
normally fire action potentials, and as a result, the contraction is graded, sustained 
and tends to be small. Although there are some differences from striated muscles, 
contractile force in SMCs does depend on the formation of cross-bridges between 
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thick myosin and thin actin filaments (Figure 1.12).  
In addition to [Ca
2+
]i entry through VDCCs, release of Ca
2+
 from SR is also 
responsible for increase in [Ca
2+
]i. An increase in [Ca
2+
]i enhances Ca
2+
 binding to 
calmodulin, four Ca
2+
 ions bind to four EF-hand motifs of calmodulin and form 
Ca
2+
/calmodulin complex. The interaction between Ca
2+
 and calmodulin 
subsequently causes the activation of the enzyme myosin light chain kinase (MLCK), 
which phosphorylates one of the two myosin light chains (MLCs). This process 
involves the hydrolysis of ATP, and transfer of an inorganic phosphate (Pi) to MLC. 
Phosphorylating MLC of myosin causes the cycling of cross-bridges and thus 
contraction, and de-phosphorylation will cause relaxation [85], the latter is mediated 
by myosin light chain phosphatase (MLCP).  
 
 
Figure 1.12: VSMC actin-myosin cross-bridge. (A) Sliding movement of actin 
filaments and cross-bridge formation. (B) Actin-activated myosin ATPase cycle 
involves association and disassociation of ATP to myosin heads (Adapted from 
Spudich, 2001 [86]). 
 
1.7.3 Ca
2+
 sensitization 
Ca
2+
 sensitization is the mechanism by which contraction can occur in the 
absence of increase in [Ca
2+
]i. This mechanism is directly related to the RhoA/Rho 
kinase pathway, in which de-phosphorylation of MLC by MLCP is inhibited by 
Rho-kinase-dependent phosphorylation, and thus vascular force is maintained [87]. 
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Therefore, the contractile state of VSMCs is dependent on the concentration of 
[Ca
2+
]i, as well as the sensitivity of the contractile proteins. Given the major roles of 
MLCK and MLCP in MLC phosphorylation/de-phosphorylation, either Ca
2+
 removal 
or myosin phosphatase activation will lead to VSMCs relaxation. 
 
1.8 Ion channels in VSMCs 
1.8.1 K
+
 channels in VSMCs 
1.8.1.1 Classification of K
+
 channels  
In evolutionary terms, K
+
 channels are the first ion channel to emerge. They are 
expressed in every cell of the body forming the largest ion channel family 
and influence processes as diverse as cognition, cell excitability, cell cycle and 
proliferation. In SMCs, K
+
 channels dominate membrane conductance at rest, and 
therefore determine Em. K
+
 channels are also involved in cell volume and cell cycle 
regulation, giving them an important role in cell proliferation and apoptosis. The 
controlling of vascular tone by K
+
 channels is essential in determining the contractile 
force of VSMCs. A small change in membrane potential can lead to several fold 
change in Ca
2+
 entry through VDCCs and therefore SMC contraction [43]. As Em is 
normally more positive to EK, the opening of K
+
 channels will cause K
+
 efflux in 
VSMCs. The outward K
+
 current causes SMC hyperpolarization, a closure of 
VDCCs, and systemic artery vasodilation with a subsequent increased blood flow to 
meet the high demand of the tissue.   
In VSMCs, there are traditionally four types of K
+
 channels identified according 
to their electrophysiological and pharmacological features [43, 88]. They are 
voltage-activated K
+
 (Kv) channels, Ca
2+
-dependent K
+ 
(KCa) channels, KATP 
channels and inward rectifier K
+
 (Kir) channels. Ca
2+
-dependent K
+
 channels can be 
further divided into three different subtypes according to their conductance, large 
conductance K
+
 (BKCa) channels, intermediate conductance K
+
 (IKCa) channels and 
small conductance K
+
 (SKCa) channels. Besides the above four classical K
+
 channels, 
a new family of K
+
 channels, two-pore domain K
+
 channels (K2P) were found in 
mid-1990s. They are background leak channels and may be involved in setting 
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resting membrane potential [89-91]. These K
+
 channels are not modulated by 
traditional K
+
 channel activators and inhibitors, and lack of specific inhibitors 
particularly hampered the understanding role of K2P channels. 
 
1.8.1.2 Properties of K
+
 channels 
It is almost always the case that cells express more than one type of K
+
 channel.  
Classical K
+
 channels have distinctive characteristics, and their fingerprints can be 
detected by manipulation of membrane potential combined with use of 
pharmacological agents in patch clamp experiments. Such traditional classification of 
ion channels is further enforced and clarified by molecular biology techniques, 
uncovering many more subtypes than perhaps anticipated. For example, more than 
40 KV channel subunits have been identified, and they are expressed in a variety of 
vascular tissues [92]. Activation of Kv channels allows a K
+
 outward current in 
response to depolarization. Thus, KV channels may act as a break when membrane 
potential depolarizes from resting state. KCa channels are divided into three main 
subtypes based on single channel conductance: BKCa (100-300 pS), IKCa (25-100 pS) 
and SKCa (2-25 pS), pS (pico Siemens) being the unit for conductance. BKCa 
channels in VSMCs have a conductance ranging 100-250 pS and are the most 
abundant K
+
 channels and their activity increases with depolarization (-60 to -30 mV) 
or a rise in [Ca
2+
]i (100-600 nM) [43, 93, 94]. Although both Kv and BKCa are 
activated by depolarization, activity of BKCa channel is less sensitive to voltage when 
compared to other voltage dependent K
+
 channels [95]. IKCa and SKCa are generally 
not at all or very poorly expressed in contractile phenotype SMCs, but their 
expression increases dramatically in synthetic phenotype [96, 97]. KATP channels 
were first reported in cardiac myocytes, and then identified in a variety of vascular 
beds [98]. They are activated by intracellular ADP and inhibited by ATP. As 
mentioned earlier, the nucleotide sensitivity of KATP channels couples cellular 
metabolism to cell excitability. Kir channels are named so as they allow current/K
+
 
more easily in the inward direction (into the cell) than outward direction. Moreover, 
it is the only K
+
 channel whose Po is increased when there is a small rise in [K
+
]o 
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over physiological Em in VSMCs [1]. Electrophysiological studies have suggested the 
existence of Kir channel in cerebral, mesenteric and coronary arteries, especially in 
resistance small arteries [93, 99].  
Kv channels and BKCa channels have similar structures, comprising four pore 
forming α-subunits, each with an ancillary β-subunit (α:β, 1:1). Α-subunit of Kv 
channels have 6 transmembrane domains (S1-S6) and BKCa channels have 7 (S0-S6), 
where S4 is the voltage sensor, and the pore-forming re-entrant P-loop is situated 
between S5 and S6 (Figure 1.13). Kir channels form as tetramers, each subunit has 
only two transmembrane domains with one pore loop (Figure 1.13). In 
hetero-octameric KATP channels, four Kir (6.1/6.2) subunits form the pore in the 
middle with four sulphonylurea (SUR) receptors associated to each pore forming 
subunit. SUR serves as regulatory subunit where ATP and sulphonylurea such as 
glibenclamide bind. More detailed information regarding KATP channels structure 
will be discussed in section 1.9.1. Different from the aforementioned K
+
 channels, 
K2P channels are formed as dimers with each subunit having two pore loops (Figure 
1.13). 
 
 
Figure 1.13: K
+
 channels subunits. The typical structure of six transmembrane 
segments and one pore domain (left), two transmembrane segments and one pore 
domain (middle), four transmembrane segments and two pore domains (right). 
(Modified from Es-Salah-Lamoureux et al., 2010 [100]) 
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1.8.1.3 Modulation of K
+
 channels 
K
+
 channels in the cell membrane are regulated by a wide variety of vasoactive 
substances. Vasoconstrictors (e.g. angiotension, endothelin) act on cell membrane 
receptors and cause activation of protein kinase C (PKC) isoforms with subsequent 
inhibition of K
+
 channel activity [94, 101]. Besides PKC, it has been reported that 
activation of the novel cyclic AMP (cAMP) sensor, exchange protein activated by 
cAMP (EPAC), inhibits KATP channels in VSMCs [102]. Many vasodilators (e.g. 
adenosine, β-adrenergic agonists) induce vasodilation through the activation of 
cAMP dependent protein kinase A (PKA) while others (e.g. NO, atrial natriuretic 
factor) increase cyclic GMP (cGMP), activating cGMP dependent protein kinase G 
(PKG) and causing subsequent K
+
 channel opening [43, 92, 94, 101].  
Although electrophysiological properties of ion channels can reveal their 
identity in patch clamp experiments, pharmacological agents are invaluable tools in 
investigating K
+
 channels. KATP channels are activated by many drugs such as 
diazoxide, pinacidil, nicorandil, cromakalim [43, 93]. KATP channels in vascular 
smooth muscle are inhibited by sulfonylurea agents (e.g. glibenclamide, tolbutamine), 
U-37883A and external Ba
2+
, and glibenclamide is thought to be the ‘gold standard’ 
[43, 94]. NS004 and NS1619 have been shown to open BKCa channels [103, 104]. A 
novel BKCa channel activator NS11021 was also reported with better specificity and 
higher potency [105]. Tetraethylammonium (TEA), charybdotoxin and iberiotoxin all 
inhibit BKCa channels with variable specificity, and iberiotoxin is considered to be 
the most specific [43, 92, 94]. IKCa and SKCa channels have been proposed to be 
affected by tram34 and apamin, respectively [106-108]. Kir channels are blocked by 
low concentration of extracellular Ba
2+
 and Cs
+
 [43]. KV channels are inhibited by 
4-aminopyridine (4-AP), TEA and Ba
2+
, and 4-AP is suggested to be the most 
selective of these relatively non-selective inhibitors [43, 92]. A potent and selective 
inhibitor of KV7 channels, XE991, was used in our project [109]. 
 
1.8.2 Ca
2+
 channels in VSMCs 
There are two main types of Ca
2+
 channels: (i) VDCCs such as L-type VDCC 
27 
 
and T-type VDCC; (ii) voltage independent Ca
2+
 channels, such as receptor-operated 
Ca
2+
 channels (ROCs) and store-operated Ca
2+
 channels (SOCs). In recent years, a 
novel class of voltage-independent, non-selective cation channels named transient 
receptor potential (TRP) channels have been studied, and moreover they have also 
been suggested to participate in the formation of functional ROC and SOC in 
vasculature [110]. 
Based on their electrophysiological and pharmacological features, VDCCs can 
be further classified broadly into two groups according to voltage dependence of 
activation. High voltage activated (HVA) channels includes L-type, P-type, N-type 
channels; low voltage activated (LVA) channels are T-type Ca
2+
 channels (Figure 
1.14) [111, 112]. Both L-type and T-type VDCCs have been identified in various 
vascular beds, such as aorta, mesenteric artery, coronary artery, and renal arteries 
[113-116]. 
L-type Ca
2+
 channels are specific differentiation markers of VSMCs [117], and 
have been indicated as the major Ca
2+
 influx pathways from extracellular 
environment [118]. They can be activated directly by a depolarization of membrane 
potential (e.g. high K
+
) or indirectly by agonists (e.g. noradrenaline) [42, 43]. 
Different from T-type, L-type VDCCs are very sensitive to dihydropyridines, such as 
nifedipine, felodipine, as well as other organic and inorganic Ca
2+
 antagonists [112]. 
Ca
2+
 channel blockers targeting L-type VDCCs have been widely prescribed as 
antihypertensive drugs for many years [113]. Bay K8644 is a structural analogue of 
the 1,4-dihydropyridines and a selective activator of L-type VDCC in its S 
enantiomer, causing vasoconstriction [119]. 
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VDCC subtypes 
L-type Cav1.1, Cav1.2, Cav1.3, Cav1.4 
P/Q type Cav2.1 
N-type Cav2.2 
R-type Cav2.3 
T-type Cav3.1, Cav3.2, Cav3.3 
 
 
Figure 1.14: Voltage-gated Ca
2+
 channels. (A) Schematic VDCC structure. VDCCs 
are comprised of four homologous domains of α1 subunit, and auxiliary β, γ, α2δ 
subunits. (B) Structure of α1 subunit. AID: α interacting domain, by which α subunit 
interact with β subunit. (Modified from Bourinet et al., 2014, and Hool et al., 2007 
[111, 120]) 
 
1.9 KATP channels 
1.9.1 Structure and distribution of KATP channels 
It has been over 3 decades since KATP currents was first described in guinea pig  
cardiac myocytes by Noma, who also showed the channel activity was inhibited by 
an increase in intracellular ATP level ([ATP]i) [98]. Since this initial finding, KATP 
channels have been shown to play an important role in a variety of cell functions 
including pancreatic β-cell insulin secretion, vascular smooth muscle relaxation, and 
skeletal muscle excitability [43, 121, 122]. Perhaps unique among channels 
expressed in plasmalemma, KATP channels also have been reported to express in 
mitochondrial and nuclear membranes (mito and nuclear KATP channels) [122, 123]. 
A 
B 
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KATP channels are weak inwardly rectifying K
+
 channels and their hallmark 
sensitivity to intracellular nucleotides makes KATP channel a target sensor in coupling 
cellular metabolic change to excitability. Regulation of KATP channels has been 
studied for a number of years, yet many fundamental questions remain unanswered.  
KATP channels are hetero-octameric complexes composed of two different 
subunits, Kir6x pore-forming and sulphonylurea receptor (SURx) regulatory subunits 
(Figure 1.15). Pore forming subunits Kir6.1 and Kir6.2 of mammalian species have 
two transmembrane domains encoded by KCNJ8 and KCNJ11 genes respectively 
[122, 123]. Recently, another Kir6.x isoform Kir6.3 was found and characterized in 
zebra fish [124]. The regulatory SUR subunits are encoded by two important SUR 
genes, ABCC8 (SUR1) and ABCC9 (SUR2) [123], the latter SUR2 has two splice 
variants, SUR2A and SUR2B. VSMCs mainly express Kir6.1/SUR2B isoform, and 
isoforms of KATP channels in other tissues are summarized in Table 1.1 and 1.2. 
Auxiliary SUR proteins belong to the superfamily of ATP-binding cassette (ABC) 
proteins. However, instead of transporting various molecules across cell membranes 
as other ABC proteins at the expense of ATP hydrolysis, SUR is part of the functional 
KATP channel and possesses intracellular nucleotide binding domains. Both of the 
nucleotide binding domains (NBD1 and BND2) are not surprisingly on the 
cytoplasmic side, one is between transmembrane domain 1 (TMD1) and TMD2 and 
the other is at the C-terminal. It is generally recognized that the pore forming Kir6 
subunit mainly confers selectivity, inward rectification and unitary conductance, and 
the SUR subunit is primarily associated with the nucleotide sensitivity and 
pharmacological modulation [125, 126]. 
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Table 1.1: Different combinations of KATP channels subunits in various tissues. 
Tissue Subunit composition 
 Cardiovascular tissues: 
Ventricle 
Conduction system 
Atrium 
Vascular smooth muscle 
Endothelium 
Mitochondria 
Other tissues: 
pancreatic β-cell/neuronal 
Non-vascular smooth muscle 
Skeletal myocytes 
 
Kir6.2/SUR2A 
Kir6.1/Kir6.2/SUR2B 
Kir6.2/SUR1/SUR2A 
Kir6.1/SUR2B 
Kir6.1/Kir6.2/SUR2B 
Kir1.1 and/or SUR2A-55 
 
Kir6.2/SUR1 
Kir6.2/SUR2B 
Kir6.2/SUR2A 
(Modified from Foster et al., 2016 [123]) 
 
Table 1.2: KATP channel subunit genes. 
Protein Gene Chromosome 
Kir6.1 
Kir6.2 
SUR1 
SUR2 
KCNJ8 
KCNJ11 
ABCC8 
ABCC9 
12p11.23 
11p15.1 
11p15.1 
12p12.1 
(Modified from Foster et al., 2016 [123]) 
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Figure 1.15: Organization of KATP channels. (A) Topology of KATP channel. Four 
pore forming subunits (top orange) and four auxiliary SUR subunits (top blue) form 
hetero-octameric (4:4 stoichiometry) KATP channels (bottom). TMD0 domain and the 
linker region of SURx interact closely and modulate gating of Kir6. NBDs are ATP 
binding sites and responsible for the reaction of ATP hydrolysis. (B) 3D structure 
model of KATP channel. Side (left) and top (right) views of KATP channel complex 
structural details, respectively (Reproduced from Mikhailov et al., 2005 [127]). NBD: 
nucleotide binding domain; TMD: transmembrane domain; WA: Walker A motif; WB: 
Walker B motif. Kir6.2 is indicated in blue, SUR1 minus TMD0 in red, TMD0 in 
yellow, and ATP molecules are shown in green. 
 
A 
B 
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1.9.2 Nucleotide sensitivity and KATP channel gating 
KATP channels are named due to their response to cytoplasmic concentration of 
ATP [98] (Figure 1.16). In traditional electrophysiology, sensitive is the term used 
for inhibitory effector while dependent usually means activated by. The changes in 
the open possibility (Po) of KATP channels provide a unique feedback between 
cellular metabolism and cell electrical activity [33, 43]. The optimal concentration of 
[ATP]i required to inhibit KATP channels is determined by various factors (e.g. KATP 
channel types, species) [128]. In the cardiovascular system, it is reported that ATP 
sensitivity of atrium and ventricle are highest, followed by smooth muscle, cardiac 
conduction system and mitochondria [123]. 
Although SURs are ABCs and so regarded as the nucleotide binding site, it is 
now shown that both Kir6.0 and SUR subunits provide binding sites for nucleotides 
and cause the conformational changes during channels opening or closure [129]. ATP 
exerts an inhibitory effect on the channels by binding to the intracellular sites of Kir 
subunits, while the activity of the channels are increased when nucleotides bind to 
NBDs of SUR subunits in the presence of Mg
2+
 [130]. Under physiological 
concentrations, [ATP]i is in millimolar range and stable, negatively regulating KATP 
channels at rest against other substances which activate the channels [1, 131, 132]. 
Although full length Kir6 subunit alone does not express functionally, Tunker et al. 
(1997) found that truncated Kir6.2 (Kir6.2ΔC26, Kir6.2ΔC36) produced ATP sensitive 
currents in a Mg
2+
 independent manner, indicating the existence of ATP binding site 
in Kir6.2 subunit with intrinsic ATP inhibitory effect [133]. ATP interacts with Kir6.2 
without Mg
2+
, and non-hydrolysable ATP analogues also cause inhibition indicating 
ATP hydrolysis is not required [134]. In addition to ATP, other nucleotides (e.g. ADP, 
CTP, GTP, AMP) can also exhibit an inhibitory effect when binding to Kir6.2 subunit, 
but with much less potency compared with ATP [123]. However, it is still not 
completely known how ATP binding is translated into the closure of Kir pore. 
SUR subunits are generally responsible for the increase of KATP activity to 
Mg
2+
-nucleotides as mutation in NBD2 abolished the effect of MgATP and caused 
persistent hyperinsulinemic hypoglycemia of infancy (PHHI) [130, 135]. When 
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compared to channels consisting of truncated Kir6.2 alone (Kir6.2ΔC26), 
co-expressing with SUR1 increased channel sensitivity to ATP by ~10 times (IC50: 
~10-20 µM of Kir6.2/SUR1 vs ~140 µM of Kir6.2) [133, 136]. ATP occupies both of 
the NBDs, in which Walker A and Walker B motifs provide the binding sites with 
ATPase activity. Studies have suggested that MgATP bound to NBD2 is hydrolyzed 
to MgADP, and a much higher ATPase activity was reported for purified NBD2 than 
NBD1of SUR2 [123, 137, 138]. On the other hand, NBD1 can bind to ATP without 
Mg
2+
 and has much less ATPase activity therefore hydrolysing ATP very slowly [123, 
139]. More recent studies have suggested that the hydrolysis is not necessary for 
channel activation [140]. Therefore hydrolyzed MgADP may have a direct access to 
NBD2 and the trapping of nucleotides causes channel activation [123]. The initial 
conformational change in NBD2 by binding of MgADP causes subsequent 
conformational change in NBD1 stabilizing its ATP binding. Mirroring this, removal 
of MgADP from NBD2 resulted in ATP dissociation from NBD1 and a subsequent 
reduction in KATP channel activity [141]. It has been suggested that the regulation of 
Kir6.2 gating by SUR is through TMD0 domain and the linker region L0 [136], the 
latter is in close proximity to the N-terminal of Kir6.2 [127]. The conformational 
‘activated’ state that overrides ATP inhibition at the Kir6.2 subunit results in channel 
activation. 
 
 
Figure 1.16: KATP channel regulation by intracellular ATP. (Data by John Quayle, 
Used with permission) 
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1.9.3 Cellular function of KATP channels in vascular smooth muscle 
Different from classical KATP channels in the heart and pancreas, the 
predominant vascular smooth muscle KATP channel subtypes are inactive in isolated 
membrane patches, and their Po increases when there are nucleotide diphosphate and 
Mg
2+
 [33]. Studies with transgenic mice with ATP insensitive KATP channels showed 
that the channels were persistently opened in pancreatic β-cells [142], but closed in 
cardiac cells [143]. Amongst all the KATP channel subtypes, the physiological role of 
those in insulin-secreting pancreatic β-cell are the best studied. In human β-cells, 
glucose metabolism is coupled to insulin secretion that is governed by KATP channel 
activity [144]. When blood glucose increases, it causes an increase in [ATP]i, or more 
precisely an increase in ATP:ADP ratio. This causes KATP channels to close, resulting 
in membrane depolarization and activation of VDCCs. Increase in [Ca
2+
]i causes 
exocytosis of insulin-containing granules and therefore insulin secretion. Once blood 
insulin level goes up, blood glucose level will go down, leading to a decrease in 
[ATP]i. Reduced [ATP]i will lead to the removal of KATP channel inhibition, 
completing the cycle of events. The opening of KATP channels under conditions of 
metabolic inhibition, such as ischemia and hypoxia, has a protective effect to cardiac 
myocytes [98, 145, 146]. This protective effect comes from the shortening of the 
action potential duration by activation of KATP channels, and therefore contraction 
will be shorter which conserves energy. Several years after the discovery of the 
channel and its role in heart protection, an important phenomenon, ischemic 
preconditioning, was reported by Murry [147]. Ischemic preconditioning is a process 
in which exposing the heart to transient brief episodes of ischemia has been shown to 
protect it from subsequent episodes of prolonged ischemia. However, there is still 
debate lying in whether plasma membrane or mitochondrial KATP channels are 
important in ischemic preconditioning. Although there is much less density of KATP 
channel expression in VSMCs (~300 KATP channels/cell, ~1channel/10 µm
2
) than 
that in cardiac myocytes (~50,000 KATP channels/cell, ~100 channel/10 µm
2
) [43, 72, 
148], KATP channels play an important role in both resting membrane potential and 
regulation of vascular tone [1, 43]. For example, genetically modified mice (Kir6.1
-/-
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or SUR2
-/-
) have exhibited incidences of coronary vasospasm, resembling human 
Prinzmetal angina [33, 123]. 
 
1.9.4 Pharmacological regulation of KATP channel 
KATP channels can be pharmacologically manipulated by a number of 
compounds, including a group of KATP channel openers (KCOs) and inhibitors [43]. 
However, the effects of pharmacological agents differ among subtypes of KATP 
channels and those in different tissues. Examples of KCOs include pinacidil, 
cromakalim, minoxidil sulfate, nicorandil, dizoxide, RP-49356. However, they may 
come into effect through different means. Some of them such as pinacidil and 
cromakalim, increase channel Po at a given concentration of [ATP]i by reducing the 
channel sensitivity to ATP. Others require intracellular ADP for activity, in which 
nicorandil is used clinically for treating angina and diazoxide for hyper-secretion of 
insulin associated with congenital hyperinsulinism (CHI) [123, 130]. 
Pharmacological agents that inhibit KATP channels are antidiabetic sulfonylurea drugs 
(e.g. tolbutamide, glibenclamide), as well as U-37883A and external Ba
2+ 
(Ki of ~100 
µM at -80 mV)
 
[43, 94]. Other K
+
 channel inhibitors (e.g. apamin, charybdotoxin, 
IbTX, TEA) do not inhibit KATP channels [43, 149]. Both antidiabetic sulphonylureas 
and KCOs act on SUR subunits with only a few exceptions, for example U37883A, 
which exhibits an inhibitory effect through the Kir pore and is more selective for 
Kir6.1 than Kir6.2 [150-152]. The effectiveness of KATP channel modulators varies 
depending on the state of ATP:ADP ratio. Pancreatic β-cell KATP channel activation 
by diazoxide is related to intracellular Mg
2+
 and MgATP/MgADP, therefore 
dependent on the ATPase activity of NBD2 domain [123]. The inhibiting effect of 
KATP channels by glibenclamide was also relieved during metabolic inhibition [153, 
154]. 
 
1.9.5 Cell membrane microenvironment and KATP channels 
The distinct lipid structures of cell membrane containing over 2000 species of 
lipids are generally constituted of liquid-disordered phase (Ld) micro-domains and 
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liquid-ordered phase (Lo) micro-domains, the latter is also called ‘lipid raft’ [155]. 
Phospholipids, sphingolipids with saturated acyl chains and cholesterol pack together 
and form lipid rafts [155, 156]. There has been an increasing accumulation of 
evidence suggesting a wide range of ion channel localization in lipid rafts [157-159]. 
Thus, far from being a simple fluid mosaic model originally proposed by Singer and 
Nicolson [160], cell membrane has a very sophisticated structure where many 
signaling molecules are compartmentalized. Furthermore, it is reported ion channels 
are modulated by some structures in the lipid rafts (e.g. cholesterol, caveolin) [159, 
161]. The role of phosphatidylinositol 4,5-biphosphate (PIP2) has been well 
described, its application increases KATP channel Po through competing with the 
binding of ATP [33, 162]. After gene transcription, KATP channel subunits are 
synthesized by ribosomes in ER into functional (Kir6/SUR)4 and destined for the 
plasma membrane. When Kir6 and SUR subunits come together, the ER retention 
sequences (arginine-lysine-arginine, RKR sequence) in both of them are masked, and 
therefore trafficked to cell membrane to exert function [163]. Caveolae are 
recognized as a subtype of lipid raft with identifiable morphology [159]. KATP 
channels have been shown to be localized to caveolae and its function is modulated 
by proteins tucked within these specialized microdomains [157, 159, 161, 164]. 
Co-localization of KATP channels and protein kinases in caveolae appears vital for 
channel modulating signaling pathways [157, 159, 165]. Although [ATP]i is usually 
high enough to inhibit KATP channels, they may not sense global cytosolic ATP 
([ATP]c). Instead, local concentrations of nucleotides in the area of membrane 
microdomains close to KATP channels are crucial, and it is conceivable that 
subcellular nucleotide concentrations dynamically change due to the activities of 
membrane ATPases and phosphotransfer enzymes. The ATP binding site on Kir6.2 
subunit has estimated to be ~2 nm below the membrane and at the interface between 
adjacent Kir6.2 [166]. Studies in intact cells suggested that local submembrane 
nucleotide concentrations are modulated by metabolic enzymes including adenylate 
kinase (AK), creatine kinase (CK), AMP-activated protein kinase (AMPK) and 
lactate dehydrogenase (LDH) [33, 123, 167]. KATP channel protein complex has also 
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been suggested to include other metabolically active protein subunits such as AK, 
CK and LDH [168-170]. A model integrating two major phosphotransfer enzymes, 
CK and AK was analyzed and described in cardiac KATP channels, indicating local 
nucleotide level is modified when bulk ATP was transmitted over diffusional barrier 
into sub-membrane space [167]. The interactions between the channel and metabolic 
enzymes may therefore enable the channels to be more sensitive to small changes in 
cellular ATP [171]. 
 
1.10 Cellular metabolism 
1.10.1 ATP Production 
Energy storing molecule ATP fuels a variety of cell functions such as 
maintaining the cell structure, generating transmembrane ionic gradients, cell 
proliferation and migration, and muscle contraction. ATP is also an important 
non-adrenergic, non-cholinergic neurotransmitter. It also acts as an intracellular 
signaling molecule which coordinates pathophysiological responses to cellular 
energy status. ATP is a nucleotide comprised of three parts, adenosine, a ribose and a 
triphosphate. Due to its two phosphoanhydride bonds, a large amount of free energy 
is liberated when ATP is hydrolyzed into ADP/AMP and phosphate(s) [172]. Cellular 
metabolic processes are linked directly or indirectly to the free energy through 
hydrolysis of ATP. Dysfunction in cellular metabolism is therefore involved in many 
diseases such as diabetes mellitus, inherited mitochondrial disorders and metabolic 
syndrome. 
In general, the supply of ATP is maintained through two metabolic pathways: (i) 
Glycolysis: where cytoplasmic reactions proceed without the need for O2; (ii) 
OXPHOS: reactions proceed in mitochondria and O2 is required [173] (Figure 1.17). 
Except for a few exceptions (eg. immune cells, erythrocytes) [174], OXPHOS is the 
preferential pathway to synthesize ATP in cells [175]. Amongst all the substrates, 
monosaccharide glucose (C6H12O6), present in most dietary carbohydrates, is the key 
source for ATP generation. In mammalian cells, glucose enters the cytosol through 
facilitated diffusion via glucose transporters (GLUTs) and sodium-dependent glucose 
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transporters (SGLT). Glycolysis happens in the cytoplasm where one molecular 
glucose is converted into two molecules of pyruvate with the concomitant release of 
two H
+
 and a net production of two molecules of ATP [172]. Glycolysis in the 
cytoplasm does not need O2, in which the reactions are conducted by a series of 
enzymes. The rate of glycolysis is regulated by the intracellular level of three 
glycolytic enzymes hexokinase (HK), phosphor-fructo-kinase (PFK) and pyruvate 
kinase (PK), among them PFK is considered to be the key controlling point (Figure 
1.17).  
In the presence of enough O2, pyruvate generated from glycolysis is 
decarboxylated into acetyl coenzyme A (AcCoA) in mitochondria, then together with 
AcCoA generated from other substrates (fatty acids, amino acids) enters tricarboxylic 
acid (TCA) cycle (or Krebs cycle) to produce ATP. However, in hypoxia or anoxia, 
pyruvate is converted into lactate and H
+
, the nicotinamide adenine dinucleotide 
(NAD
+
) yielded in the process is returned back to be recycled in glycolysis. As the 
final common route for substrate (carbohydrates, fatty acids and amino acids) 
oxidation, AcCoA undergoes a stepwise oxidation controlled by a series of enzymes, 
resulting in the production of CO2 [172]. During the TCA cycle, high energy 
electrons are harvested and used to form eight reduced nicotinamide adenine 
dinucleotide (NADH) and two reduced flavin adenine dinucleotide (FADH2) per one 
molecule glucose. Two ATP are generated in TCA cycle per one molecule glucose. 
The free energy stored within NADH and FADH2 is finally used to generate PMF, 
thus drive ATP synthase to convert ADP to ATP [172, 176]. Altogether, thirty six 
molecules of ATP can be generated per one molecule glucose consumed in optimal 
conditions, including thirty two molecules of ATP from OXPHOS, two from TCA 
cycle and a further two from glycolysis. However, it has been reported that there is 
an approximately ~20% of mitochondrial proton leak in a range of vertebrate and 
invertebrate species [173, 177]. Therefore, proton leak across the inner membrane 
determines the coupling efficiency between respiration and ATP synthesis [172, 178]. 
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Figure 1.17: Flow diagram of key cellular energy metabolic pathways. Glucose 
enters the cells and produces ATP through glycolysis. Pyruvate generated from 
glycolysis is catalyzed into lactate or converted into AcCoA in mitochondria. 
Together with AcCoA from other pathways, AcCoA proceeds into OXPHOS and 
more ATP is generated. AK, adenylate kinase; CK, creatine kinase; FADH2, reduced 
flavin adenine dinucleotide; FBP, fructose-1,6-biphosphate; G3P, 
glyceraldehyde-3-phosphate; G6P, glucose-6-phosphate; G6PD, glucose-6-phosphate 
dehydrogenase; HK, hexokinase; IMS: mitochondrial intermembrane space; NADH, 
reduced nicotinamide adenine dinucleotide; 6PGlac, 6-P-gluconolactone; 6PGluc, 
6-P-gluconate; PFK, phosphor-fructo-kinase; PGI, phosphoglucose isomerase; PK, 
pyruvate kinase; PDH, pyruvate dehydrogenase; PPP, pentose phosphate pathway; 
PEP, phosphoenol pyruvate; R5P, ribose-5-phosphate. (Modified from 
Liemburg-Apers et al., 2011, and Flagg et al., 2010 [33, 176]) 
 
1.10.2 Mitochondria as ATP consumers 
The primary role of mitochondria is to couple respiration to ATP synthesis. ETC 
is central to mitochondria function by generating an electrochemical proton gradient 
as electrons jump from one carrier to another, which establishes the PMF, i.e. the 
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sum of mitochondrial membrane potential (ψm) and pH gradient. Four major protein 
complexes (complex I-IV) are bound to the inner membrane of the mitochondria, 
which transfer high energy electrons from TCA to O2 (Figure 1.18A). Complex I and 
complex II receive electrons from reduced nicotinamide adenine dinucleotide 
(NADH) and reduced flavin adenine dinucleotide (FADH2) respectively and pass 
them to Coenzyme Q (CoQ). The continual regeneration of ψm ensures ATP synthase 
to run in a direction of net ATP synthesis (Figure 1.18B). When mitochondrial 
homeostasis is compromised (e.g. inhibition of ETC), ATP synthase works in reverse 
and consumes ATP from glycolysis in favor of maintaining ψm (Figure 1.18C). 
Therefore, ATP synthase functions as an ATPase and hydrolyzes ATP during 
mitochondrial dysfunction [178, 179]. The ‘null-point’ assay has been suggested as a 
convenient means to assess mitochondria function, in which oligomycin, an ATP 
synthase inhibitor, causes ψm hyperpolarization when ATP synthase is generating 
ATP from ADP while if ATP synthase works in a reverse mode, the reverse will occur 
(depolarization of ψm) [178]. This is because there is a small proton leak when ATP 
synthase works in forward mode, causing a small depolarization, prevention of which 
will lead to a small hyperpolarization. 
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Figure 1.18：Schematic presentation of mitochondrial ETC and ATP synthase. 
(A) Electron transport in ETC. (B) Forward mode of ATP synthase. (C) Reverse 
mode of ATP synthase. (Modified from Berg et al., 2015 and Campanella et al., 2009 
[172, 179]) 
 
 
 
 
A 
B 
C 
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1.10.3 Methods to study cellular metabolism 
1.10.3.1 Metabolic inhibitors 
With access to a wide range of metabolic inhibitors, it is possible to study the 
cellular metabolism of glycolysis and OXPHOS by inhibiting different sites of the 
pathways. 2-Deoxy-D-glucose (2-DG) and iodoacetate (IAA) are typical inhibitors of 
glycolysis. Rotenone, antimycin A, thenoyltrifluoroacetone (TTFA) and cyanide are 
important inhibitors which block different sites of ETC. Oligomycin B inhibits ATP 
synthase. Protonophores such as carbonyl cyanide m-chlorophenyl hydrazone (CCCP) 
and carbonyl cyanide p-trifluoromethoxyphenylhydrazone (FCCP) cause metabolic 
inhibition indirectly. In this project, 2-DG, rotenone, antimycin A, oligomycin B, 
FCCP and CCCP were applied to investigate cell metabolism (Figure 1.19). 2-DG is 
a glucose analog with the 2-hydroxyl group replaced by hydrogen. When entering the 
cell, 2-DG is phosphorylated by HK, but the product 2-deoxyglucose-6-phosphate 
cannot undergo further glycolysis. The product from 2-DG is then trapped in the cell 
and cannot be metabolized, and therefore acts as a competitive inhibitor of 
phosphoglucoisomerase resulting in a decrease in [ATP]i. Rotenone inhibits complex 
I of ETC, therefore its application will lead to the block of respiration with 
NAD-linked substrates, but the FAD-linked respiration can still proceed. Antimycin 
A is the inhibitor of complex III, which blocks both NAD-linked and FAD-linked 
respiration (Figure 1.20). Oligomycin B is an inhibitor of ATP synthase which 
blocks its proton channel (Fo subunit), and therefore prevents state 3 respiration and 
stops OXPHOS of ADP to ATP. CCCP is an uncoupling agent which belongs to the 
group of carbonyl cyanide phenylhydrazones. Application of CCCP causes 
unstrained O2 consumption without ADP until O2 is run out. However, no ATP is 
produced during the above oxidation process, as the energy is dissipated as heat. The 
effects of rotenone and antimycin A are not affected by CCCP, because they act 
directly on mitochondrial ETC.       
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Figure 1.19: Chemical structure of metabolic inhibitors. 
 
 
 
Figure 1.20: Metabolic inhibition of ETC. CoQ, coenzyme Q; Cyt b, cytochrome b; 
Cyt c, cytochrome c; Cyt c1, cytochrome c1; FeS, iron-sulphur; NADH, reduced 
nicotinamide adenine dinucleotide. 
 
1.10.3.2 Cell based assay and molecular probes 
Cell bioenergetics and changes in [ATP]i can be characterized by a variety of 
methods such as cell based assays and fluorescent tools. Seahorse technique is 
designed to monitor cell oxygen consumption rate (OCR) and extracellular 
acidification rate (ECAR) simultaneously. This highly sensitive and rapid analysis 
allows real time quantification of both glycolysis and OXPHOS [180, 181]. 
Luciferase-based bioluminescent assay is a well-established method and has been 
used widely to report ATP levels in the cells under various pathophysiological 
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conditions [182]. CellTiter-Glo luminescent viability assay was applied in this 
project, the luminescence generated was proportional to ATP and the number of 
viable cells [183]. Recombinant luciferase can be introduced to the cells by transient 
transfection, and it can be targeted to specific areas, so not only bulk ATP levels but 
ATP in the subcellular compartments can be examined [182, 184]. Fluorescent and 
fluorescent resonance energy transfer (FRET) based probes allow the measurement 
of ATP and ATP:ADP ratio in the cells [185-187]. Unlike enzyme based assays, these 
probes do not consume ATP, and ratiometric measurement enables the analysis to be 
independent of biosensor concentration in the cells [187]. By introducing a specific 
targeting sequence to the biosensor, it permits the measuring of ATP:ADP ratio in 
related cellular compartments [188]. For example, a palmitoylation and 
myristoylation modification sequence will favor the protein to be localized in the 
lipid rafts of cell membrane [188, 189]. Most recently, total internal reflection 
fluorescence microscopy (TIRF) imaging allows the fluorophores to be selectively 
imaged in the plasmalemmal surface and subplasmalemmal zone [190, 191], thus it 
directly reports ATP or ATP:ADP ratio in KATP channel microenvironment. 
 
1.11 Hypothesis  
The overall aim of this study is to investigate cellular mechanisms underlying 
direct hypoxic vasodilation of human coronary artery SMCs (HCASMCs). We tested 
the main hypothesis that hypoxia would lead to a decrease in [ATP]i and a rise in 
ADP concentration, thus activating KATP channels and resulting in membrane 
potential hyperpolarization and vasodilation (Figure 1.21). In addition, we also 
tested the possible effect of hypoxia on other K
+
 channels, including Kir, BKCa, Kv 
channels. It could be argued that this is an ambitious project for a PhD thesis when 
hypoxic vasodilation very much remains as a conundrum despite the efforts of many 
investigators. However, the subject is very much of my core interest, and my goal 
was to make small contributions to the understanding of coronary hypoxic 
vasodilation.       
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Figure 1.21: KATP channel modal for hypoxic vasodilation. Hypoxia causes 
activation of KATP channels through the inhibition of OXPHOS, followed by 
membrane potential hyperpolarization and a closure of VDCCs, thus SMC 
relaxation. 
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2.1 Materials  
2.1.1 Cell culture 
Cryopreserved HCASMCs (Cat no. C12511, Lot no. 9052004.5 and 3100203.10) 
were purchased from Promocell (Heidelberg, Germany) at passage 2 (P2) (Table 2.1). 
HCASMCs were cultured in Promocell smooth muscle cell growth medium 2 (Cat 
no. C-22062) supplemented with Promocell smooth muscle cell growth medium 2 
supplement mix (Cat no. C-39267) with a final supplement concentration of (per ml): 
5% v/v fetal calf serum, 0.5 ng epidermal growth factor (recombinant human), 2 ng 
basic fibroblast growth factor (recombinant human) and 5 μg insulin (recombinant 
human).  
HEK293 cells were cultured in minimum essential media (MEM) supplemented 
with GlutaMAX
TM
-I and Earle’s salts (Cat no. 41090-028, Gibco, Life Technologies) 
and 10% (v/v) fetal bovine serum (FBS) (Cat no. 10500-064, Gibco, Life 
Technologies) 
HEK293T cells were obtained from Christina Parkes (University of Liverpool) 
and cultured in Dulbecco’s modification of Eagle’s medium (DMEM) with 4.5 g/l 
glucose and non-essential amino acids (NEAA) (Cat no. 10938-025, Gibco, Life 
Technologies). FBS was added to the medium with a final concentration of 10% 
(v/v). 
Penicillin/streptomycin (Cat no. 15140-122, Gibco, Life Technologies) was 
added to all cell culture medium with a final concentration of 100 U/ml and 100 
μg/ml respectively, unless otherwise stated. 
 
 
 
 
 
 
 
 
48 
 
Table 2.1: HCASMC inventory. Lot and donor specific information of HCASMCs 
used in this project.  
Catalogue 
# 
Lot # Age Gender Race Viability* Population 
doubling time (h) 
C-12511 9052004.5 54 Male Caucasian 80% 46.0 
C-12511 3100203.10 32 Male Caucasian 93% 35.4 
*Adherence of cells could vary (data provided by Promocell). 
 
2.1.2 Antibodies 
Tables 2.2 and 2.3 summarize the primary antibodies and secondary antibodies 
used in Western blot (WB) and immunocytochemistry (ICC). 
 
Table 2.2 Primary antibodies  
Primary 
Antibody 
Company Type Isotype Dilutions 
WB ICC 
Anti-human 
vWF 
Dako, Denmark 
(Cat no. A0082) 
Polyclonal Rabbit 
IgG 
 1:300 
Anti-human 
CD31 
Dako, Denmark 
(Cat no. M0823) 
Monoclonal Mouse 
IgG 
 1:300 
Anti α-actin Sigma-Aldrich (Cat 
no. A 2547) 
Monoclonal Mouse 
IgG 
1:500 1:300 
Anti-calponin Sigma-Aldrich (Cat 
no. C2687) 
Monoclonal Mouse 
IgG 
1:500 1:300 
Anti-MHC Novocastra (Cat 
no. NCL-MHCs) 
Monoclonal Mouse 
IgG 
 1:300 
Anti actin Sigma-Aldrich (Cat 
no. A 4700) 
Monoclonal Mouse 
IgG 
1:500  
Anti-Anterior 
Gradient 2 
Abcam (Cat no. 
ab56703) 
Monoclonal Mouse 
IgG 
 1:200 
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Table 2.3 Secondary antibodies 
Secondary 
Antibody 
Company Produced 
in 
Conjugate Dilutions 
WB ICC 
Anti-mouse Fitzgerald Industries 
International (Cat no. 
43C-CB1569-FIT, 
Stratech, Suffolk, 
England) 
Goat HRP 1:10,000  
Anti-rabbit Molecular Probes, 
USA (Cat no. 
A-11034) 
Goat Alexa fluor 
488 
 1:500 
Anti-mouse Molecular Probes, 
USA (Cat no. 
A-11029) 
Goat Alexa fluor 
488 
 1:500 
 
2.1.3 Plasmids DNA 
pEGFP-N1 plasmid was provided by Dr. Owain Llyr Roberts (University of 
Liverpool), GW1CMV-Perceval (Cat no. 21737), GW1-PercevalHR (Cat no. 49082), 
FUGW-PercevalHR (Cat no. 49083) and GW1-pHRed (Cat no. 31473) were 
obtained from Addgene. FUGW-pHRed was constructed by ligation of pHRed with 
the lentiviral vector from FUGW-PercevalHR. Lyn-FUGW-PercevalHR was made by 
inserting a 5’ myristoylation and palmitoylation lipid modification sequence 
(GCIKSKRKDK) into FUGW-PercevalHR. Rev, Rev-responsive element (RRE) and 
vesicular stomatitis virus glycoprotein (VSV-G) were given by Joanna Wardyn 
(University of Liverpool). 
 
2.1.4 Primers 
All primers and oligonucleotides used for the studies were purchased from 
Sigma and summarized in Table 2.4. 
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Table 2.4 Summary of primers and oligonucleotides 
Primer/oligonucleotide 
 
Sequence Tm 
(°C) 
Purpose 
hUBCpro-F (Human 
Ubiquitin C (UbC) promoter, 
forward primer) 
TGAAGCTCCGGTTTTGAAC
T 
63.6 Sequencing primer for 
FUGW-pHRed and 
Lyn-FUGW-PercevalHR 
WPRE-R (5' end of WPRE, 
reverse primer) 
CATAGCGTAAAAGGAGCAA
CA 
61.7 Sequencing primer for 
FUGW-pHRed and 
Lyn-FUGW-PercevalHR 
PercevalHR 
Forward 
TGCCTGAGGCCTCTAGAAT
G 
64.4 Sequencing primer for 
Lyn-PercevalHR 
PercevalHR 
Reverse 
GACCTGATTCCTAAGGTGA
AGATC 
62.9 Sequencing primer for 
Lyn-PercevalHR 
Lyn-PercevalHR and 
Lyn-FUGW-PercevalHR 
Forward 
TCTAGAATGGGCTGCATCA
AGAGCAAGCGCAAGGACA
AGATGAAAAAGGTTGAATC
CATC 
88.6 PCR cloning 
Lyn-PercevalHR and 
Lyn-FUGW-PercevalHR 
Reverse 
GAATTCTCACAGTGCTTCC
TTGCC 
68.9 PCR cloning 
Oligonucleotide 1 
(Lipid raft targeting sequence 
1) 
GCAGGTCGACTCTAGAATG
GGCTGCATCAAGAGCAAG
CGCAAGGACAAGCACTAG
ACCACCATGAA 
92.5 Membrane targeting 
Oligonucleotide 2 
(Lipid raft targeting sequence 
2) 
TTCATGGTGGTCTAGTGCTT
GTCCTTGCGCTTGCTCTTG
ATGCAGCCCATTCTAGAGT
CGACCTGC 
92.5 Membrane targeting 
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2.1.5 Fluorescent probes  
Bis-(1,3-Dibutylbarbituric Acid) Trimethine Oxonol (DiBAC4(3) (Cat no. 
B-438), Fluo-4 AM (Cat no. F14201), Fura-Red AM (Cat no. F3021), MitoTracker 
(Cat no. M7512), rhodamine123 (Cat no. R302), and 4’,6’-diamidino-2-phenylindole 
(DAPI) (Cat no. D3571) were purchased from Molecular Probes and used following 
manufacture’s instruction.   
 
2.1.6 Agonists 
Human platelet-derived growth factor BB (PDGF-BB) (Cell Signaling, USA, 
Cat no. 8912), (R)-(−)-phenylephrine hydrochloride (Sigma, Cat no. P-6126), 
prostaglandin F2α tris salt (PGF2α) (Sigma, Cat no. P0424), U46619 (Tocris 
Bioscience, Cat no. 1932), pinacidil monohydrate (Sigma, Cat no. P154), NS1619 
(Sigma, Cat no. N170), SKA31 (Sigma, S5576), and adenosine (Sigma, Cat no. 
A9251) were used in this study. NS11021 was kindly given by Bo Hjorth Bentzen 
(University of Copenhagen, Denmark). 
 
2.1.7 Antagonists 
2-Deoxy-D-glucose (2-DG) (Calbiochem, Cat no. 25972), rotenone (Sigma, 
R8875), antimycin A (Sigma, A8674), oligomycin B (Abcam Biochemicals, Cat no. 
AB143424), CCCP (Sigma, Cat no. C-2759), nimodipine (Sigma, Cat no. N-149), 
glibencalmide (Sigma, G0639), iberitoxin (Sigma, Cat no. I2141), penitrem A 
(Alomone labs, Israel, Cat no. P-650), BaCl2 (Sigma, Cat no. B-0750), XE991 
(Tocris Bioscience, Cat no. 2000), apamin (Tocris Bioscience, Cat no. 1652), and 
tram34 (Sigma, Cat no. T6700) were used in this study. 
 
2.1.8 Reagents 
Standard reagents were purchased from Sigma-Aldrich (Gillingham), BDH 
(Poole) or Fisher Scientific (Loughborough) unless otherwise stated. Solutions were 
made using ultra high quality (UHQ) or Milli-Q (MQ) water with a minimum 
resistance of 18.2 MΩ. 
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2.2 Cell culture 
2.2.1 Routine passage of HCASMCs 
HCASMCs were grown in T75 cm
2 
flasks with 15 ml fully supplemented 
smooth muscle growth medium 2 in a 5% CO2 humidified incubator at a temperature 
of 37°C. Cells were routinely passaged every 48-72 hours when reaching about 
70-80% confluency. Cell culture medium was aspirated, and the cells were washed 
with 15 ml pre-warmed Dulbecco’s Phosphate Buffered Saline (DPBS, no Ca2+/Mg2+, 
Cat no. 14190-144, Gibco) or HEPES Buffered Saline Solution (HepesBSS). Cells 
were then trypsinised with 1.5 ml versene (Gibco) containing 0.025% trypsin (Gibco) 
or 100 µl per cm
2
 Trypsin/EDTA Solution (0.04%/0.03%) for approximately 1 min. 
Enzyme was neutralized by addition of 8 ml fully supplemented cell culture medium 
or 100 µl per cm
2
 Trypsin Neutralizing Solution (TNS). HepesBSS, Trypsin/EDTA 
Solution and TNS were all contained in Promocell DetachKit (Cat no. C-41200). 
Cells were then re-suspended in fully supplemented fresh cell culture medium and 
cultured in T75 cm
2 
flasks at a volume of 15 ml or 10 cm cell culture dishes at a 
volume of 10 ml. 
 
2.2.2 Freezing and storing of HCASMCs  
Cells were grown to 70-80% confluency, harvested and counted using either a 
hemocytometer or Z1 Coulter
®
 Particle Counter (Beckman Coulter). Cell 
suspensions were centrifuged at 220 g for 3 minutes, and supernatant was removed. 
Pelleted cells were re-suspended in Cryo-SFM (Promocell, Cat no. C-29910) or 
in-house freezing medium (90% (v/v) FBS, 10% (v/v) DMSO) at a density of ~1.2 
million cells/ml. 1 mL cell suspension was aliquoted into each cryovial (Star Lab, 
Cat no. E3090-6222). Cryovials were placed into Nalgene
 
Mr. Frosty
®
 Cryo 1°C 
Freezing Container (Thermo Scientific) or CoolCell (Biocision) and frozen at -80°C 
overnight. Cells were kept at -135°C or liquid nitrogen (-196°C) for long-term 
storage. 
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2.2.3 Resuscitation of HCASMCs 
A frozen vial was taken out and placed on dry ice for transport. Cells were 
quickly thawed in 37°C water bath by gently swirling the vial for about 1 minute or 
until ~90% thawed. Cells were completely thawed by the time when the vial was 
cleaned and taken into the hood where they were gently pipetted into a T75 cm
2
 flask 
containing 15 ml pre-warmed medium or 10 cm cell culture dish with 10 ml 
pre-warmed medium. Medium was replaced with fully supplemented fresh medium 
after 16-24 hours once cells were adhered to surface. 
 
2.2.4 Culturing of HEK293 and HEK293T cells 
Cells were rapidly thawed in a 37°C water bath by gently swirling or until 
~90% thawed and plated into 10 ml fully supplemented medium in a 10 cm cell 
culture Petri dish. After 24 hours, the medium was replaced with fully supplemented 
fresh growth medium. Cells were sub-cultured every 48-72 hours when they reached 
about 70-80% confluence. The cells were washed with 10 ml DPBS and incubated 
with 1 ml trypsin solution (0.025% in versene) for about 1 minute in a 37°C 
incubator until all cells became detached. Trypsin was neutralized by addition of 3 
ml fully supplemented cell culture medium, and the cells were seeded into 10 cm 
Petri dishes with a total of 10 ml pre-warmed medium at a ratio of 1:8 to 1:16 as 
required. 
 
2.3 Cell transfection 
2.3.1 Transient transfection 
Cells were transfected with the transfection reagents listed in the Table 2.5. 
Cells were seeded 24 hours prior to transfection normally at a density of 2.0×10
6
 for 
HEK293 and HEK293T cells and 1.25x10
5
 for HCASMCs per well in 6-well cell 
culture plates or 35 mm glass-bottom dishes (see cell number optimization for 
transfection in chapter 3.3.1). Note that cell seeding number may be modified 
according to the passage of the cells and the growth rate of the cells. On the day of 
transfection, cells were transfected following the protocols provided by the 
54 
 
manufacturer. 
 
Table 2.5 Transfection reagents used in the study 
Name Company 
Lipofectamin
TM
 2000 (LF2000) Invitrogen (Cat no. 11668-027) 
FuGENE
®
 6 Promega (Cat no. E2691) 
FuGENE
®
 HD Promega (Cat no. E2313) 
X-tremeGENE 9 DNA Roche (Cat no. 06 366 511001) 
X-tremeGENE HP DNA Roche (Cat no. 06 365 752001) 
TransIT
®
-LT1 Cambridge Bioscience (Product no. MIR 
2310) 
TransIT-X2
®
 Dynamic Delivery System Cambridge Bioscience (Product no. MIR 
6010) 
Promofectin Promocell (Cat No. PK-CT-2000-100) 
 
2.3.2 Lentivirus based biosensors 
2.3.2.1 Production of lentivirus third generation virus stocks  
Lentivirus based biosensors were prepared in two ways, calcium precipitation 
method and transfection reagent method. 
In calcium chloride method, HEK293T cells were maintained in DMEM high 
glucose medium, and cells at early passages were used. Cells were seeded a day 
before the transfection at a density of 6.0x10
6
 into 15 cm dishes and left overnight in 
a 37°C/5%CO2 incubator. Next day, cells were fed with 20 ml fully supplemented 
medium 2 hours before transfection. Transfection mixture for five 15 cm dishes was 
prepared as shown in Table 2.6 using a 50 ml sterile falcon tube, and was left at 
room temperature for 5-30 mins for incubation. 2.25 ml of the mixture was then 
added to each 15 cm dish. The dishes were left in a 37°C/5%CO2 incubator overnight. 
Early next morning the medium was discarded and replaced with 16 ml fresh DMEM 
medium or smooth muscle cell growth medium 2, and incubated in 37°C/5%CO2 
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incubator. After 24 hours incubation, medium was collected and spun down in a 
centrifuge at the speed of 500 g for 5 minutes, and the supernatant was stored at 4°C. 
Cells were incubated for another 24 hours in 16 ml fresh DMEM or smooth muscle 
cell growth medium 2. On next morning, the second batch of medium was collected 
and spun down at the speed of 500 g for 5 minutes. The supernatant was reserved, 
and the cells were discarded. The above two batches of medium were combined and 
filtered twice through 0.22 μm PES filter (Merck Millipore, Cat no. SLGP033RS). 
Filtered medium was then aliquoted and kept in -80℃ freezer.  
 
Table 2.6 Preparation of transfection mixture 
0.1x TE buffer 3.3 ml 
FUGW-PercevalHR/Lyn- FUGW-PercevalHR 
pCMV-VSV-G 
pMDLg/pRRE 
pRSV-Rev 
112.5 μg 
39.5 μg 
73 μg 
73 μg 
Buffered water 1.75 ml 
2.5 M CaCl2 565 μl 
2x HEBS buffer 5.7 ml 
Note: Volume should be scaled according to the number of dishes needed 
 
Buffered water 
50 ml MQ water 
125 μl 1 M HEPES  
pH 7.3 
Filter sterile  
Store up to 6 months at 4℃ 
 
2.5 M CaCl2 
9.18 g CaCl2•2H2O (Sigma, Cat no. 
C3881 ) 
25 ml MQ water 
Filter sterile 
Store at 4℃ 
 
 
Lentivirus could also be produced by using transfection reagents such as 
LF2000 and Promofectin. HEK293T cells were cultured in DMEM high glucose 
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medium, and cells at early passages were used. Cells were seeded a day before the 
transfection at a density of 2.0×10
6
 into 10 cm dishes and left overnight in a 
37°C/5%CO2 incubator. Transfection was performed on the following day. In general, 
45.0 μl of LF2000 was gently mixed with 1.5 ml Opti-MEM medium (Gibco, Cat no. 
51985-034) and incubated at room temperature for about 5 minutes. 9.0 μg vector 
plasmid (FUGW-PercevalHR or FUGW-pHRed or Lyn-FUGW-PercevalHR), 4.5 μg 
pMDLg/pRRE, 1.8 μg pRSV-Rev and 2.7 μg pCMV-VSV-G were gently mixed into 
another 1.5 ml Opti-MEM medium. DNA and LF2000 mixture were then gently 
mixed together and incubated at room temperature for 20 minutes to allow DNA and 
lipid to form complexes. During incubation, cell culture medium of HEK293T cells 
was replaced with 5.0 ml DMEM medium containing 10% FBS without antibiotics. 
3.0 ml DNA-LF2000 complexes was added to 10 cm HEK293T cell dish. Same 
procedure was performed when using Promofectin to transfect the cells. Transfection 
conditions were summarized in the Table 2.7. Virus collection and freezing were 
performed in the same way as calcium precipitation method.   
 
Table 2.7 Transfection mixture for one 10 cm dish using transfection reagent 
FUGW-PercevalHR/FUGW-pHRed/Lyn- FUGW-PercevalHR 
Gag-Pol expression vector (pMDLg/pRRE) 
Rev expression vector (pRSV-Rev) 
VSV-G expression vector (pCMV-VSV-G) 
9.0 μg 
4.5 μg 
1.8 μg 
2.7 μg 
Total plasmid DNA  18 μg 
Lipofectamine™2000/ Promofectin 45 μl/36 μl 
Total Opti-MEM 3 ml 
Vol. of DMEM 5 ml 
 
2.3.2.3 Infection of the cells with lentivirus 
HCASMCs were plated at a density of 2.0x10
4
 in 35 mm glass-bottom dishes or 
6 well plates about 24 hour prior to transduction. On the day of transduction, cells 
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were fed with fresh medium 2 hours before being treated with lentivirus. For the 
transduction of 10 cm dishes, cells that reached about 40-50% confluence were fed 
with fresh medium 2 hours before lentivirus treatment. After 2 hours, 2 ml of media 
containing lentivirus was added to 35 mm dishes or wells of the 6 well plate, and 10 
ml of media containing lentivirus was added to the 10 cm dishes. Cells were 
incubated in a 37°C/5%CO2 incubator for around 16 hours. Early next morning, the 
medium was changed with fresh smooth muscle growth medium 2. Counting the 
discarding of lentivirus containing media as day one, cells are normally imaged from 
day 3 onwards. In some cases such as when the concentration of lentivirus was low, 
cells were infected twice in order to boost transfection efficiency.  
 
2.4 Cell-based assays 
CellTiter-Glo
®
 Luminescent Cell Viability Assay (Promega, Cat no. G7572) was 
used to measure intracellular ATP level. Proliferation of HCASMCs was assessed 
using a 3-(4,5 dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT, Sigma, 
Cat no. M2128) assay, and cell migration was characterized by scratch-wound assay 
and transwell migration assay. 
 
2.4.1 CellTiter Glo
®
 Luminescent Cell Viability Assay 
HCASMCs were grown to 70-80% confluence on the day of seeding for assay. 
After lifting, cells were counted with the Z1 Coulter
®
 particle counter and 
resuspended at the density of 25,000 cells/ml. 100 μl of the cell suspension was then 
plated into each well of a 96-well flat bottom black polystyrene plate (Costar, Cat No. 
3916) and left in a 37°C/5%CO2 incubator for 24-48 hours. On the day of assay, test 
compounds were added to experimental wells for the allocated time. 100 μl of 
CellTiter-Glo
®
 reagent (equal to the volume of cell culture medium present in each 
well) was added to each well, and cell lysis was induced by 2 minutes of incubation 
on an orbital shaker. The plate was allowed to incubate further at room temperature 
for 10 minutes to stabilize luminescent signal and luminescence was recorded in a 
plate reader (FLUOstar Omega, BMG LABTECH). 
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2.4.2 ATP:ADP ratio microplate assay 
FUGW-PercevalHR was transduced into HCASMCs by 3
rd
 generation lentivirus. 
Cells expressing FUGW-PercevalHR were seeded into a 96-well black polystyrene 
plate at a density of 2,500 cells per well. Fluorescence was recorded every 1 minute 
with a plate reader (FLUOstar Omega, BMG LABTECH) with the excitation of 485 
nm and emission of 520 nm. 
 
2.4.3 MTT assay 
Cells were seeded into 96-well cell culture plates (Costar, Cat no. 3596) at a 
density of 2500 cells/well in 100 μl medium. In order to synchronize the cell cycle, 
medium was replaced next day with 100 μl low serum medium where Promocell 
smooth muscle cell growth medium 2 supplement mix was reduced to 0.1% for 48 
hours. Inclusion of a small amount of supplement mix was necessary as HCASMCs 
did not tolerate complete elimination of supplement. Cells were then treated with test 
chemicals or exposed to hypoxia, and incubated according to culture protocol. 5 μl of 
MTT (5 mg/ml in DPBS) was then added to each well, and the plate was shaken with 
a shaker for 1 minute, and cells were incubated in the 37°C/5%CO2 incubator for 
four hours. Next, 50 μl of stop solution (10% SDS in 0.01 M HCl) was added to each 
well and mixed on an orbital shaker for 1 minute. The plate was incubated further in 
the 37°C/5%CO2 incubator overnight. The plate was read at absorption of 570 nm on 
the following day. 
 
2.4.4 Scratch-wound assay 
Cells were plated into 6-well plates and left overnight to reach around 80-90% 
confluence. On the following day, a scratch was made using a 1000 μl blue tip in the 
mid-line of the well. The gap would gradually close as cells at the edges of the 
wound migrate to scratched area (Figure 2.1) [192, 193]. Chemicals of interest such 
as PGDF-BB can be added to the scratched wells, or the plates can be placed into 
hypoxic chambers with different oxygen levels. Images were captured using a 
DC5000 CMEX microscope camera (Euromex) with a 4x objective. Pictures were 
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analyzed using Fiji software, and the degree of migration was determined as 
migration rate where ‘1’ corresponds to the complete closure of the wound, and each 
condition was repeated in 3 wells. 
 
 
 
Figure 2.1 Scratch-wound Assay. A wound was made to the cell monolayer of each 
well (A) by drawing a line using a 1000 μl blue tip (B). The denuded area is imaged 
to measure the boundary of the wound before migration (C) and after cells have 
migrated inward to fill the gap (D). Migration rate was calculated as (d1-d2)/d1.  
 
2.4.5 Transwell migration assay 
When HCASMCs reached about 70% confluent, medium was replaced with low 
serum medium and incubated for 48 hours in a 37°C/5%CO2 incubator to 
synchronize the cell cycle. Cells were then collected in low serum medium and 
resuspended at a density of 2.0x10
5/ml. 100 μl of cell suspension (2.0x104 cells) were 
seeded to the upper chamber of the transwell insert with 8.0 μm pore size (VWR, Cat 
no. 734-1574). Inserts with cells were put into the 24-well plates containing 600 μl 
fully supplemented medium, and cells were allowed to migrate for 8 hours in 
37°C/5%CO2 incubators with different levels of O2. A Reastain Quick Diff kit 
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(Reagena, Cat no. 102164) was used to stain migrated cells, which were 
subsequently counted using a microscope and images were taken using a DC5000 
CMEX microscope camera. Cells from three areas of each insert membrane were 
randomly chosen and counted and each condition was repeated in triplicate. The 
procedure of this assay is briefly summarized in Fugure 2.2. 
 
 
 
Figure 2.2.1 Transwell cell culture plate. Transwell insert with 8.0 μm pores for 
investigation of cell migration. An example of transwell membrane was shown by 
leaving the transwell cell culture insert upside down (see Figure 2.2.2). (Reproduced 
from http://www.coleparmer.com/) 
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Saturate the membrane with 
low serum medium 
Plate 2.0x10
4
 cells to the top 
part of the transwell 
Incubate cells in experimental 
conditions for a required time 
 
Fixing cells 
Stain cells 
Wash off excess dye 
Count under microscope 
Figure 2.2.2: Transwell cell 
migration assay.  
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2.5 Seahorse XF
e
96 analyses of oxygen consumption rate and extracellular 
acidification rate 
Seahorse XF
e
96 Analyser (Figure 2.3) was used to continually monitor both 
aerobic and glycolytic components of cellular bioenergetics. It allows rapid 
measurements of oxygen consumption and lactate production, the former a measure 
of oxidative phosphorylation and the latter, a measure of glycolysis. Seahorse 
technique determines OCR and ECAR from fluorescence intensity of two probes, 
one reading oxygen concentration and the other proton content. All measurements 
were made in an unbuffered XF Base Medium Minimal DMEM assay medium 
(Seahorse Bioscience, Cat no. 102353-100) [183].  
HCASMCs were plated into Seahorse 96-well XF Cell Culture Microplates 
(Seahorse Bioscience, Cat no. 101085-004) at a density of 2.0x10
4
 per well and left 
to form the monolayer overnight. The day before assay, 200 μl of XF Calibrant 
Solution (Seahorse Bioscience, Cat no. 100840-000) was added to each well of 
XF
e
96 FluxPaks (Seahorse Bioscience, Cat no. 102416-100) and incubated overnight 
at 37°C in a CO2 free incubator to hydrate the sensor cartilage. On the day of assay, 
the media of the wells for mitochondrial stress test was replaced with unbuffered 
minimal DMEM containing 1 mM sodium pyruvate, 25 mM D-glucose and 2 mM 
L-glutamine (pH 7.4). Medium for glycolytic stress test was replaced with 
unbuffered minimal DMEM containing 1 mM sodium pyruvate and 2 mM 
L-glutamine (pH 7.4). The cell plate was then incubated at 37°C in a CO2 free 
environment for a minimum period of 1 h before measurement. 
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B 
 
 
Figure 2.3: Seahorse XF Analyzer machinery and an illustration of its working 
principle. (A) The Seahorse XF Analyzer. (B) OCR and ECAR calculation. (C) 
Working Seahorse XF Analyzer plate. (Reproduced from www.seahorsebio.com) 
A 
C 
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2.5.1 Mitochondrial stress test 
Mitochondrial stress test was performed by sequentially adding 
pharmacological inhibitors of OXPHOS using Seahorse technology [180, 181]. First, 
the basal O2 consumption was established corresponding to the total O2 consumption 
including mitochondria as well as other oxidases. Cells were first treated with 
oligomycin (oligo), an ATP synthase inhibitor that causes a cessation of oxidative 
energy generation shutting down the O2 consumption independent of proton leak. To 
estimate the maximal potential respiration of the cells, a proton ionophore FCCP 
(Sigma, Cat no. C2920) was used. O2 consumption increases with uncoupler as the 
mitochondrial inner membrane becomes permeable to protons, eliminating the proton 
gradient. Thus, the difference between application of oligomycin and FCCP is the 
latter measures mitochondrial reserve capacity, calculated by subtracting the basal 
OCR from FCCP-stimulated rate. Finally rotenone and antimycin (R+A) were 
applied to inhibit oxygen consumption related to the activity of complex I and 
complex III. Such pharmacological inhibition of electron transport typically inhibits 
the majority of O2 consumption in the cell, and we attribute the remaining O2 
consumption to non-mitochondrial oxidases in the cell (Figure 2.4). 
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Figure 2.4: Mitochondrial stress test. A typical experiment of mitochondrial stress 
test. The basal O2 consumption of the cells is established first, then sequential 
application of oligomycin, FCCP, and combination of rotenone and antimycin A are 
applied to dissect the relative contribution of ATP synthase-linked O2 consumption, 
non-mitochondrial respiration, proton leak, and the reserve capacity of the cells 
 
2.5.2 Glycolytic stress test 
During glycolysis, the breakdown of one glucose molecule into two pyruvate 
anions generates two H
+
. Therefore, change in glycolytic function can be assessed by 
determining ECAR in response to the addition of glycolysis modulating compounds 
[180, 181]. In this assay, glucose was first added to the cells in glucose free 
unbuffered minimal DMEM Seahorse medium. Next, oligomycin was applied to 
cause a loss of mitochondrial ATP production leading to near maximal level of 
glycolytic rate. Finally, non-glycolytic extracellular acidification can be measured by 
introducing 2-DG as a pseudosubstrate of glucose to determine ECAR due to 
non-glycolytic mechanisms. (Figure 2.5) 
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Figure 2.5: Glycolysis stress test. A typical glycolysis stress test. After basal ECAR 
is allowed to stabilize in the absence of glucose, glucose is added. Next oligomycin 
is added causing near maximal glycolytic rate. The addition of 2-DG at the end 
allows the measurement of non-glycolytic extracellular acidification. 
 
2.5.3 Comparison of bioenergetic phenotype of HCASMCs 
In order to assess the bioenergetic phenotype of the cells and how it may shift in 
response to mitochondrial toxicants, OCR and ECAR were plotted before and after 
treatments. As shown in Figure 2.6, the relative phenotype of the cells can be 
classified as aerobic, energetic, quiescent and glycolytic, based on the possible 4 
combination outcomes of OCR and ECAR measurements. 
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Figure 2.6 Cell bioenergetic phenotype profile. Four cell bioenergetic phenotypes 
characterized from OCR and ECAR measurements. Graph shows an example of cell 
bioenergetic phenotype shifting from a baseline quiescent phenotype (open circle) to 
a stressed energetic phenotype (filled circle). (Reproduced from 
www.seahorsebio.com) 
 
2.5.4 Normalization of OCR and ECAR data  
At the end of each mitochondrial and glycolytic stress test, solution in the wells 
was removed and 20 μl of somatic cell ATP releasing reagent (Sigma, Cat no. 
FLSAR-1VL) was added to each well, followed by 5 minutes vortex in order to fully 
lyse the cells. The total amount of protein in each well was determined by BCA assay 
in a microplate, OCR and ECAR rates were then normalized to μg protein. 
 
2.6 FACS analysis of cell cycle 
2.6.1 Cell preparation 
HCASMCs were seeded into 10 cm dishes and incubated for 24 hours to allow 
adhesion. The following day, the cell culture medium was replaced with low serum 
medium, and all plates were incubated for 48 hours. After this starving period, all 
plates were treated as designed (metabolic inhibitors, hypoxia etc.) for a required 
period. 
 
2.6.2 Sample preparation for flow cytometric analysis 
At the end of each treatment, cells were collected, centrifuged at 1000 rpm for 5 
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mins, and the pellet was re-suspended in 0.5 ml PBS. The cells were fixed by 
transferring the cell suspension to 4.5 ml of 70% ice cold ethanol, and kept at 4°C for 
a minimum period of 30 minutes. Ethanol-suspended cells were centrifuged for 5 
minutes at 2000 rpm, and the pellet was washed with 5 ml PBS. Cells were then 
permeabilised by adding 1 ml of saponin (0.5% in PBS) (Calbiochem, Cat no. 
558255) for 5 minutes. Cells were washed with PBS and centrifuged at 2000 rpm for 
30s twice. 1 ml of DAPI solution (1μg/ml in PBS) was added to each sample for 
FACS analysis. 
 
2.6.3 Analysis on flow cytometer 
All samples were analyzed on the FACSCanto II Flow Cytometer (BD 
biosciences), and a population of 15,000 events was used for each analysis. 
Percentages of cells in each cell cycle were calculated with BD FACSDiva software 
v6.1.3. 
 
2.7 Western blot 
Western blot analysis was used to detect specific proteins in human coronary 
artery endothelial cell (HCAEC) and HCASMC lysates. 
 
2.7.1 Sample preparation 
HCASMC were cultured in 10 cm cell culture petri dishes in 10 ml 
fully-supplemented media until 80-90% confluent, approximately 48-72 hours. The 
dish was then placed on crushed ice, the media was removed and washed with 5 ml 
ice-cold DPBS. The DPBS was removed and replaced with 500 μl ice-cold 1% v/v 
protease inhibitor cocktail (Sigma, Cat no. P8340)/lysis buffer solution (20 mM 
Trizma HCl, 250 mM NaCl, 3 mM EDTA, 3 mM EGTA, 0.5% v/v Triton X-100, pH 
adjusted to 7.6) for 5 minutes, tilting the dish gently to ensure that it covers the 
whole surface area evenly. A 25 cm cell scraper (Sarstedt, Cat no. 83.1830) was used 
to dislodge the cells by scraping across whole surface. Lysates were then collected in 
a pre-chilled 1.5 ml microcentrifuge tube (Eppendorf) and centrifuged at 18,200 g for 
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10 minutes at 4˚C. Usually, 150 μl of the supernatant was reserved and frozen at 
-20˚C for the BCA assay. The volume of remaining supernatant was measured and 
appropriate amount of x2 sample buffer (Sigma, Cat no. S3401) was added and 
gently mixed, and heated at 98˚C in a dry heating block for 10 minutes. Cell lysate 
was cooled down on crushed ice before aliquoting into 0.5 ml microcentrifuge tubes 
(Eppendorf) and stored at -20˚C for up to 4 months if not required immediately. 
HCAEC lysates were provided by Rachael Quinn (University of Liverpool). 
 
2.7.2 BCA protein assay 
Protein concentrations of the sample lysates were determined by a Pierce 
Bicinchoninic Acid (BCA) assay kit (Thermo Scientific, Cat no. 23227). All 
standards and protein lysates were tested by either test-tube procedure or microplate 
procedure.  
 
2.7.2.1 Test-tube procedure (Sample to WR ratio = 1:20) 
The standard protein solutions, bovine serum albumin (BSA) 2000, 1500, 1000, 
750, 500, 250, 125, 25 and 0 μg/ml, were made according to manufacture’s protocol 
using lysis buffer. Working Reagent (WR) was prepared by mixing 50 parts reagent 
A and 1 part reagent B. 50 μl of each protein solution was added to 1.5 ml 
microcentrifuge tubes, followed by 1 ml of WR, and the mixture was vortexed. Each 
condition was duplicated. Tubes were incubated in a water bath at 37˚C for 30 
minutes. After cooling down to room temperature, the protein concentration was 
measured using a Jenway spectrophotometer (Genova, 1690) at the absorbance of 
562 nm.  
 
2.7.2.2 Microplate procedure (Sample to WR ratio = 1:20) 
In the microplate procedure, 10 μl of each sample was added to a 96 well plate 
(Thermo Scientific, Cat no. 15041) in duplicates, followed by 200 μl of WR. The 
plate was mixed thoroughly on a plate shaker for about 30 seconds and incubated in a 
37˚C incubator for 30 minutes. After being cooled down to room temperature, the 
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plate was read at 562 nm in a plate reader (SPECTRAmax, Molecular Devices).  
 
2.7.3 Preparing polyacrylamide gels 
Proteins were separated according to their size by sodium dodecyl sulphate 
polyacrylamide gel electrophoresis (SDS-PAGE). 10% resolving gel was cast using 1 
mm spacer thick glass plates in a vertical casting apparatus (Bio Rad), topped up 
with isopropanol to flatten the gel surface and prevent from drying out, and then 
allowed to polymerize at room temperature for approximately 45 minutes. Once set, 
isopropanol was poured out, and space between glass plates was washed using UHQ 
water. The stacking gel was added onto the resolving gel, and a comb was inserted to 
form 10 wells for the loading. The stacking gel was allowed to set for approximately 
45 minutes at room temperature. 
 
10% Resolving gel 
30% w/v Acrylamide (Biorad, 16100158) 
Resolving buffer (2 M Trizma base, pH 8.8)  
87% v/v glycerol  
10% SDS 
UHQ water  
10% w/v ammonium persulfate (APS) 
TEMED  
4.3 ml 
3.3 ml 
930 μl  
130 μl 
4.4 ml 
60 μl  
13 μl  
 
4% Stacking gel 
30% w/v Acrylamide  
Stacking buffer (0.5 M Trizma base, pH 6.8)   
10% SDS 
UHQ water  
10% w/v ammonium persulfate (APS) 
TEMED  
840 μl 
1.5 ml  
60 μl 
3.8 ml 
53 μl  
11 μl  
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2.7.4 Running polyacrylamide gels 
The cell lysates were briefly mixed by vortex and heated in the dry heating 
block at 98˚C for 5 minutes to ensure complete denaturing of the proteins. 7.0 μl of 
rainbow protein mass marker (Amersham full-range rainbow MW marker, Cat no. 
RPN800E) and 25 μl of each lysate were added to the wells. Gels were placed in a 
vertical gel electrophoresis tank (Bio Rad) and submerged in SDS running buffer (25 
mM Tris base, 192 mM Glycine and 3.5 mM SDS). Gels were run at 120 V for 1 
hour until the rainbow ladder had been fully separated. 
 
2.7.5 Coomassie brilliant blue staining 
Electrophoresed gels were gently removed from the glass plates, and rinsed 
twice in reverse osmosis (RO) water. Gels were then put into Coomassie brilliant 
blue stain solution, and left on an oscillating platform for at least 30 minutes at room 
temperature. The gels were washed again with RO water several times in order to 
remove excess stain. Gels were left in detaining buffer until the protein bands 
became visible and background was reduced. Gels were scanned using an 
ImageScanner III gel scanner (GE Life Sciences). 
 
Coomassie brilliant blue stain solution 
0.1% (w/v) Coomassie brilliant blue stain 
50% (v/v) methanol 
7% (v/v) glacial acetic acid 
 
Destaining buffer 
20% (v/v) methanol 
10% (v/v) glacial acetic acid 
 
 
2.7.6 Western blotting 
Separated proteins were transferred from polyacrylamide gel onto nitrocellulose 
membrane (Amersham Hybond ECL, Cat no. RPN303D) in transfer buffer (25 mM 
Trizma base, 192 mM Glycine and 20% (v/v) methanol) at 110 V for 1 hour in a low 
temperature by placing the tank containing a blue ice pillow into a bucket filled with 
crushed ice. After proteins were transferred, membranes were washed twice in Tris 
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buffered saline with TWEEN 20 (TBST, 20 mM Trizma base, 137 mM NaCl, 0.1% 
v/v TWEEN 20, pH 7.6). As an optional step, the membranes were submerged in 
Ponceau S solution (Sigma, Cat no. P7170) for 5 minutes to check the transfer 
efficiency of the protein, Ponceau S can be washed away by washing the blots with 
TBST on the rocker (Labnet rocker 25) for 5 minutes. Membranes were trimmed and 
blocked for 1 hour at room temperature on the rocker using TBST containing 5% or 
1% w/v non-fat powdered milk (Marvel). Membranes were then put into a 
continuous bag where 1.0 ml of diluted primary antibody was added (see the dilution 
factor in Table 2.2), and bags were heat sealed. The primary antibodies were diluted 
in TBST with 5% or 1% w/v non-fat milk, and incubated overnight at 4˚C. 
Next day, the membranes were quickly washed twice in TBST, followed by 
further three washes with TBST on the rocker (10 minutes each). Horseradish 
peroxidase (HRP)-conjugated secondary antibodies were used at a 10,000 fold 
dilution (anti-mouse) or a 5,000 fold dilution (anti-rabbit) in TBST with non-fat milk 
(5% or 1% w/v). Nitrocellulose membranes were then incubated with 
HRP-conjugated secondary antibodies for over one hour and up to two hours at room 
temperature on the rocker. After incubation with secondary antibody, membranes 
were washed a couple of times with TBST, followed by further three washes on the 
rocker, 10 min each. During wash, enhanced chemiluminescence solution mixture 
was prepared by combining equal volume of ECL solutions 1 and 2 (ECL, 
Amersham, Cat no. RPN2109). The membranes were then incubated in the ECL 
solutions for one minute. Care was taken to ensure that whole membrane was well 
covered with solution by repeatedly spraying it using a 1,000 μl pipette. After 
removing the excess ECL solution, the membranes were carefully put into plastic 
wallets (Lyreco) and fixed onto the hypercassette (Amersham Biosciences) with 
tapes. 
 
2.7.7 Developing the photographic film 
All procedures were carried out in a dark room. Photographic film (Amersham 
hyperfilm ECL high performance chemiluminescence film, Cat no. 28906836) was 
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overlayed onto the membrane in the hypercassette and exposed for 5 mins, 10 mins, 
30 mins or longer if required. The photographic film was processed using Kodak 
photographic solutions (Kodak GBX fixer and developer). After the films were dried, 
bands were sized by referencing to the rainbow ladder. To semi-quantify the darkness 
of the bands, densitometric analysis was processed using Image J software. 
 
2.7.8 Re-blotting 
Even with care, equal loading of wells could not be guaranteed, making 
semi-quantitative comparison difficult. In order to ensure the protein expression 
difference did not arise from uneven loading, expression of housekeeping protein 
(actin) was examined by re-blotting. Used nitrocellulose membranes were 
re-hydrated with TBST for 0.5-1.0 hour, followed by stripping of previous antibodies 
with stripping solution (100 mM β-mercaptoethanol, 2% w/v SDS, and 62.5 mM Tris 
base, pH 6.7) for 10 mins on a rocker, repeated twice. Membranes were then blocked 
using non-fat milk in TBST as before and incubated with primary and secondary 
antibodies as normal Western blotting procedure. 
 
2.8 Immunocytochemistry 
Western blot technique is useful in detecting proteins by virtue of known protein 
size. However, Western blotting does not provide useful information about the 
localization of proteins. Immunocytochemistry is a useful parallel technique to 
Western blotting as the spatial information of expression can be obtained.   
 
2.8.1 Plating HCAECs and HCASMCs 
Flame-sterilized size 1 coverslips (diameter, 13 mm) were coated with 1% v/v 
poly D-lysine (Millipore, Cat no. A-003-E) and incubated for 1-2 hours in a 37°C/5% 
CO2 incubator. HCAECs were provided by Rachael Quinn (University of Liverpool). 
After incubation, coverslips were washed twice with UHQ water and dried in the 
hood before being placed in a 24-well cell culture plate. 
Cells were trypsinised and counted with Z1 Coulter
®
 particle counter. HCAECs 
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were seeded onto coverslips with a density of 100,000 cells per well and HCASMCs 
with a density of 125,000 cells per well, both in 2 ml fully-supplemented cell culture 
medium (Promocell). Empty wells at the edges of the 24-well plate were filled with 
UHQ water to create a humidified environment. Cells were cultured at 37˚C/5%CO2 
typically overnight. 
 
2.8.2 Fixing, quenching and permeabilising of cells 
Culture medium was removed, and cells were washed with 1 ml DPBS. After 
removing DPBS, 1 ml of 2% w/v paraformaldehyde in PBS (in mM: 2.7 KCl, 1.5 
KH2PO4, 137 NaCl, 8.0 Na2HPO4, pH 7.4) was added into each well to fix the cells. 
After incubating for 10 minutes at room temperature, the fixative was removed and 
replaced with 1 ml 100 mM glycine solution (pH 7.4) for 10 minutes at room 
temperature to quench the excess fixative. Cells could then be stored in 4˚C fridge in 
DPBS containing 10 mM sodium azide for future use. Glycine solution/DPBS was 
removed, and a fine-ended glass Pasteur pipette (SLS select, PIP4101) was used to 
add 3 ml permeabilisation solution (0.1% v/v Triton X-100 in PBS, pH adjusted to 
7.4 using 1 M NaOH). Cells were incubated for 10 minutes at room temperature in 
order to make the intracellular space accessible to antibody. 
 
2.8.3 Labelling with antibodies  
Permeabilised cells were rinsed with 2 ml PBS 3 times, 5 minutes each. Next, 
the cells were incubated with 200 μl antibody diluting solution (see below) for 30 
minutes at room temperature to block non-specific binding. After taking off antibody 
diluting solution, 200 μl of diluted primary antibody (see Table 2.2) was added to the 
wells. Cells were incubated with primary antibodies at 4˚C overnight. On the 
following day, the primary antibody was removed and the cells were washed with 1 
ml antibody wash solution (see below) at room temperature three times, 10 minutes 
each. Primary antibodies were indirectly stained using fluorescent Alexa Fluor 
488-conjugated goat anti-rabbit or anti-mouse IgG secondary antibodies at the 
dilution of 1:500. To prevent photo-bleaching, the plate with coverslips was 
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incubated in the dark for a period of at least 1 hour but no more than 2 hours at room 
temperature. The cells were then washed with antibody wash solution three times at 
room temperature, 10 minutes each. Coverslips were taken out of the wells, washed 
quickly with UHQ water twice and left to air dry in the dark. When dry, coverslips 
were mounted onto glass slides with 20 μl mounting medium (Dako, S3023) 
containing 5 nM DAPI for counter staining of the nuclei. Air bubbles were avoided 
during this procedure. Finally, the slides were allowed to dry at room temperature in 
the dark before imaging. 
 
Sodium citrate buffer (SSC) 
NaCl 
Na3Citrate 
250 mM 
15 mM 
 
Antibody diluting solution (pH 7.2) 
SSC with 
2% v/v goat serum 
0.05% v/v Triton X-100 
1% w/v bovine serum albumin 
 
Antibody wash solution (pH 7.2) 
SSC with 
0.05% v/v Triton X-100 
 
 
2.8.4 Confocal microscopy (immunocytochemistry imaging) 
A LSM510 multiphoton laser-scanning confocal microscope was used to 
visualize the labelled cells. Alexa Fluor 488 was excited at 488 nm using an 
argon-ion laser, and emission light was collected at 500-550 nm. For the detection of 
DAPI nuclear staining, a Mai Tai infra-red laser (Spectra-Physics) on LSM510 
multiphoton was used for two-photon excitation at a wavelength of 810 nm, 
providing the working excitation of 405 nm. 
 
2.9 Confocal microscopy (live cell imaging) 
Fluorescence signal was collected with LSM510, LSM510 multiphoton or 
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LSM780 confocal microscopy, all of them allowed control of CO2, humidity and 
temperature. Environmental O2 can be changed in LSM510 and LSM 780, allowing 
cells to be exposed to hypoxic conditions. Software analysis of the data from 
LSM510 and LSM510 multiphoton were carried out by region of interest analysis 
using AIM software, version 3.2 SP2 (Carl Zeiss AG, Oberkochen, Germany). Data 
from LSM780 confocal microscopy were analyzed with Zen SP1 software (Carl 
Zeiss AG, Oberkochen, Germany). 
 
2.9.1 Intracellular ATP:ADP ratio and pH 
GW1CMV-Perceval/GW1-PercevalHR, fluorescent reporters of ATP:ADP ratio, 
were transiently transfected into HEK293 cells or HCASMCs. FUGW-PercevalHR 
and Lyn-FUGW-PercevalHR were transfected into the cells via a 3
rd
 generation 
lentivirus based system to measure intracellular or near membrane ATP:ADP ratio. 
Cells expressing GW1CMV-Perceval, GW1-PercevalHR, FUGW-PercevalHR or 
Lyn-FUGW-PercevalHR were excited with 488 nm light from an argon laser, and 
emitted fluorescence was collected at 500-550 nm. In the experiments of ratio-metric 
excitation measurement, cells expressing FUGW-PercevalHR were excited at 458 
nm and 488 nm, and emission signal was collected at 500-550 nm. 
GW1-pHRed, a genetically encoded pH sensor, was transiently transfected into 
HEK293 cells or HCASMCs. FUGW-pHRed was transfected into the cells via a 3
rd
 
generation lentivirus based system. Cells expressing FUGW-pHRed was excited at 
458 nm and emission signal over 575 nm was collected. For ratiometric measurement, 
FUGW-pHRed was excited at 458 or 561 nm, and emission signal was collected at 
over 575 nm or 575-630 nm respectively. 
With the cells co-transfected with FUGW-PercevalHR and FUGW-pHRed, 
FUGW-PercevalHR were excited at 488 nm, emission signal was collected at 
500-550 nm, FUGW-pHRed were stimulated at 458 or 561 nm, emission signal was 
collected at over 575 nm or 575-630 nm respectively. 
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2.9.2 Ca
2+
 measurement 
HCASMCs were plated into 35 mm glass-bottom dishes (Greiner bio-one, 
Material no. 627861) at a density of 1.0x10
5
-1.25x10
5
 in 2 ml cell culture medium 
and placed in the incubator overnight. On the following day, cells were washed twice 
with 2 ml PBS and incubated with 5 µM Fluo-4 AM or Fura-Red AM in bicarbonate 
buffered physiological saline solution (PSS) containing [mM]: 120 NaCl, 5 KCl, 1 
MgCl2, 2 CaCl2, 0.42 Na2HPO4, 0.44 NaH2PO4, 24 NaHCO3, 10 Glucose for 20 
minutes at 37°C in the dark. Excess dye was then washed off by PSS and the cells 
were incubated for another 20 minutes at 37°C in the dark to achieve 
de-esterification. Cells were viewed using a Carl Zeiss LSM510 high-speed confocal 
laser-scanning microscope. Fluo-4 loaded cells were excited with 488 nm light from 
an argon ion laser and the emitted fluorescence was captured at 500-550 nm. 
Fura-Red was excited at 488 nm and the emission signal was collected over 585nm.  
 
2.9.3 Membrane potential measurement 
HCASMCs were plated into 35 mm glass-bottom dishes a day before 
experiments, as described above. Next day, cells were washed twice with 2 ml PBS, 
then incubated with 1 μM DiBAC4(3) in PSS for 15 minutes in a 37°C/5%CO2 
incubator. Cells were then used without washing the dye as the continued presence of 
the dye in the extracellular media was required for this experiment. DiBAC4(3) 
labelled cells were excited with 488 nm light from an argon ion laser and the emitted 
fluorescence signal was captured at 500-550 nm.  
 
2.9.4 Mitochondrial localization and mitochondrial membrane potential 
measurements 
HCASMCs were plated into 35 mm glass-bottom dishes. To visualize 
mitochondria, cells were washed with 2 ml PBS twice, then incubated in PBS 
containing 500 nM MitoTracker for 20 mins in a 37°C/5%CO2 incubator. The cells 
were then washed twice with calcium/magnesium containing PBS. The dye was 
excited at 561 nm, and the emission signal over 575 nm was collected. 
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In order to measure the change in ψm, cells were washed with bicarbonate 
buffered PSS twice, and then incubated with 10 µg/ml rhodamine123 in PSS for 15 
minutes in a 37°C/5%CO2 incubator. After incubation cells were washed with PSS 
twice. The dye was excited at 514 nm, and emission was collected at 520-555 nm. 
 
2.10 Total Internal Reflection Fluorescence (TIRF) Microscopy 
HCASMCs transduced with FUGW-PercevalHR, Lyn-FUGW-PercevalHR, or 
FUGW-pHRed were seeded into 35 mm glass-bottom dishes in 2 ml cell culture 
medium. Cells were then incubated in the 37°C/5% CO2 incubator overnight to allow 
attachment. Cells expressing FUGW-PercevalHR or Lyn-FUGW-PercevalHR were 
excited with 488 nm laser, and emission signal was collected by a 525/50 band pass 
filter. Cells expressing FUGW-pHRed were excited at 561nm, and emission signal 
was collected by a 630/95 band pass filter. All images were taken using a 100x oil 
immersion objective lens. 
 
2.11 Bacterial transformation, growth and stock 
2.11.1 Preparation of ampicillin stock 
Stock of 100 mg/ml ampicillin (Sigma, Cat no. A9518) in MQ water was filter 
sterilized through a 0.22 μm filter (Merck, Cat no. SLGP033RS) and aliquoted into 
1.5 ml centrifuge tubes and stored at -20°C. 
 
2.11.2 Preparation of LB agar plates  
LB agar (MERCK, Cat no. 1.10283.0500) in MQ water (w/v 3.7%) was 
autoclaved and then cooled at room temperature to approximately hand warm. 
Ampicillin was added to sterilized warm LB agar at a final concentration of 100 
μg/ml. After mixing with ampicillin, agar was immediately dispensed into 10 cm 
Petri dishes (Sarstedt, Cat no. 82.1473) and allowed to set at room temperature in a 
hood. The dishes were used when the agar was set, and spare plates were sealed with 
parafilm (Bemis, Supplier no. PM-992) and kept at 4°C for no longer than 4 weeks. 
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LB agar 
1% (w/v) tryptone 
0.5% (w/v) yeast extract 
1% (w/v) NaCl 
1.5% (w/v) Agar 
 
2.11.3 Amplification of competent E.coli cell 
On day 1, One-shot
®
 Top10 chemically competent E.coli cells (Invitrogen, Cat 
no. C4040-10) was streaked onto LB agar plate without antibiotics. Cells were 
placed in an incubator at 37°C overnight. On day 2, a single colony was picked and 
grown in 100 ml antibiotic free LB broth (MERCK, Cat no. 1.10285.0500) overnight 
in a 37°C incubator. On day 3, 2.5 ml of the culture was diluted into 250 ml 
antibiotic free LB broth and placed in a 37°C incubator with agitation at 250 rpm for 
about 2 hours, from this point optical density (O.D.) at 600 nm was measured until it 
reached a value between 0.6-0.8. Culture was aliquoted into 50 ml Falcon tubes and 
centrifuged at 5000 g at 4°C for 5 minutes, and each pelleted bacteria were 
re-suspended in 20 ml ice-cold filter sterilized TFB1 buffer, followed by further 5 
minutes incubation on ice. The cells were then centrifuged again at the same 
condition for another 5 minutes and each cell pellet was re-suspended in 2 ml 
ice-cold TFB2. The cells were incubated in ice-cold filter-sterilized TFB2 on crushed 
ice for 30 minutes before being aliquoted into autoclaved sterile pre-chilled tubes. 
 
TFB1 (pH 5.8) 
RbCl 100 mM 
KOAc 30 mM 
CaCl2·2H2O 10 mM 
MnCl2·4H2O 50 mM 
Glycerol 15% (v/v) 
 
TFB2 (pH 6.5) 
MOPS 10 mM 
CaCl2·2H2O 75 mM 
RbCl 10 mM 
Glycerol 15% (v/v) 
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2.11.4 Transformation 
One-shot
®
 Top10 chemically competent E.coli cells or Stellar
TM
 competent cells 
(Clontech, Cat no. 636767) were used for the expression of plasmid DNA. 
Competent cells were thawed on crushed ice, and 50 μl was used to incubate with 
plasmid DNA on crushed ice for 20 minutes before being heat shocked at 42°C in a 
water bath (Grant) for 45 seconds. The cells were put back immediately on ice for 
about 4 minutes after heat shock. After being chilled, 250 μl of SOC medium was 
added and mixed with the cells, and the cells were agitated at 240 rpm for 1 hour at 
37°C on the shaker (New Brunswick Scientific, Innova
TM
 4000). 50 μl and 100 μl of 
transformation mixture were then spread onto LB agar plates, respectively, and 
incubated overnight in a humidified incubator at 37°C. On the following day, single 
colonies were picked from the agar plates and inoculated into 5 ml LB broth with 
required antibiotics as the starter culture. The starter was cultured and agitated at 240 
rpm overnight at 37°C. 
 
SOC medium 
2% vegetable peptone 
0.5% yeast extract 
10 mM NaCl 
2.5 mM KCl 
10 mM MgCl2 
10 mM MgSO4 
20 mM glucose 
 
LB broth 
1% (w/v) tryptone 
0.5% (w/v) yeast extract 
1% (w/v) NaCl 
 
 
2.11.5 Glycerol stocks 
1 ml of overnight bacterial culture suspension was added to 667 μl 50% glycerol 
(w/v) in a cryovial, and mixed by gentle pipetting. All the cryovials were frozen and 
stored at -80°C.  
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2.11.6 Plasmid preparation 
Many methods have been developed to purify plasmid DNA from competent 
cells, and these methods invariably involve three steps: growth of the bacterial 
culture, harvest and lysis of the bacteria, and purification of plasmid DNA. QIAprep 
Spin Miniprep Kit (Qiagen, Cat no. 27104), Plasmid Midi Kit (Qiagen, Cat no. 
12143) and HiSpeed Plasmid Maxi Kit (Qiagen, Cat no. 12662) were used in this 
project to extract plasmid DNA from competent cells according to manufacturer’s 
protocols. 
 
2.12 Cloning, PCR and DNA amplification 
2.12.1 Preparation of the vector 
A lentiviral based mammalian expression vector was prepared from 
FUGW-PercevalHR to which the gene of interest was inserted. FUGW-PercevalHR 
was firstly digested with XbaI (New England Biolabs, Cat no. R0145s) and 
EcoRI-HF
TM
 (New England Biolabs, Cat no. R3101s) enzymes in a 37°C water bath 
for a minimum period of 1 hour as instructed by the manufacturer. After the parental 
plasmids had been fully digested, reaction mix was run on a 1.0% (w/v) agarose gel 
to separate the vector from the insert. The vector was excised and purified using a 
QIAQuick Gel Extraction kit (Qiagen, Cat no. 28704) following the manufacturer’s 
protocol. After the concentration of the vector was determined by NanoDrop 
ND-1000, it was stored at -20°C. 
 
2.12.2 Design of the primer 
Some of the commonly used primers for sequence verification are suggested by 
the addgene website (https://www.addgene.org/) such as hUBCpro-F and WPRE-R. 
Primers for PCR cloning were designed using the Invitrogen OligoPerfect
TM
 
Designer. After the primers have been determined, we tended to create a 3’ ending 
with either guanine or cytosine by editing the sequence manually, in order to help the 
primer anchor to the template. In order to make our primers more efficient, 
sometimes a 5’ XbaI restriction site was added ahead of the forward primers and a 5’ 
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EcoRI restriction site was added to the reverse primer respectively as suggested by 
New England Biolabs. In some conditions, further guanine and/or cytosine 
nucleosides were added to the 5’ end of the restriction site to have a better digestion 
of the sequence.  
 
2.12.3 Sub-cloning by PCR 
The open reading frame (ORF) containing PercevalHR was amplified from 
FUGW-PercevalHR using the primers containing a membrane targeting sequence 
derived from Lyn kinase (detail in Table 2.4). With the purpose of achieving high 
fidelity proof reading, KOD Hot Start DNA Polymerase (Novagen, Cat no. 71086) 
was used with the method provided by the manufacture. 
After the amplification procedure, the PCR product was run on a 1.0% (w/v) 
agarose gel to separate the amplified insert containing the membrane targeting Lyn 
sequence. The insert was then cut under UV and purified using a Qiagen QIAQuick 
Gel Extraction kit according to the protocol described by the manufacturer. The 
concentration of the insert was determined by NanoDrop ND-1000. Purified digested 
vector and insert were then mixed at the ratio of 1:1, 1:3, 1:5 and 1:7 in 
microcentrifuge tubes and ligated using T4 DNA ligase (New England Biolabs, Cat 
no. M0202) at room temperature overnight. The ligation protocol was carried out as 
described by the manufacture (Table 2.8), and all molar ratios were calculated using 
NEBioCalculator. 
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PCR reaction mix 
10x Buffer for KOD Hot Start DNA Polymerase 
25 mM MgSO4 
dNTPs (2 mM each) 
PCR Grade Water 
Sense(5’) Primer (10 μM) 
Anti-Sense (3’) Primer (10 μM) 
Template DNA (FUGW-PercevalHR) 
KOD Hot Start NAN Polymerase (1 U/μl) 
5 μl 
3 μl 
5 μl 
32.5 μl 
1.5 μl 
1.5 μl 
0.5 μl 
1.0 μl 
Total reaction volume 50 μl 
 
Reaction setup 
Step Temperature and time 
1. Polymerase activation 95°C for 2 min 
2. Denature 95°C for 20 s 
3. Annealing 48°C for 10 s 
4. Extension 70°C for 4 s 
Repeat steps 2-4 30 cycles 
5. Final elongation 70°C 6 min 
6. Hold 4°C 
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Table 2.8: Ligation protocol with T4 DNA ligase 
Component 20 μl reaction 
10xT4  2 μl 
Vector DNA 0.020 pmol 
Insert DNA 0.060 pmol 
Nuclease-free water to 20 μl  
T4 DNA Ligase 1 μl 
This example table shows a ligation using a molar ratio of 1:3 (vector to insert). 
Ligation at other vector to insert ratios could be calculated in the same way by taking 
this table as a reference.   
 
2.12.4 Verification of constructed plasmids 
Plasmids produced from cloning were verified by running an agarose gel after 
cutting by appropriate restriction enzymes followed by DNA sequencing performed 
by GATC Biotech (European Genome and Diagnostics Centre, Germany). 
 
2.13 Statistical analysis 
All values are expressed as a mean±standard error of mean (SEM) as 
represented through error bars on graphs. N indicates number of cells, wells or plates 
unless otherwise stated. Statistical analyses were performed using SPSS software 
package, version 20.0 (IBM). Statistical significance was evaluated with a Student’s 
t-test (paired and un-paired) or by using ANOVA with Tukey’s test for post hoc 
analysis. Results were deemed significant when p-value was smaller than 0.05. 
Significance in the plots is represented as: * equivalent to P < 0.05, ** equivalent to 
P < 0.01 and *** equivalent to P < 0.001. 
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Chapter 3 
Effect of Hypoxia and Metabolic 
Inhibitors on Cellular Metabolism 
of Single HCASMCs 
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3.1 Introduction 
Metabolic vasodilation is the widening of arteries caused by increased oxygen 
consumption of surrounding tissues. It is an important phenomenon in the heart, as if 
coronary blood flow is insufficient to meet the metabolic demands it will lead to 
pathologies including anginal pain and a pre-disposition to cardiac arrhythmia. It is 
not surprising, therefore, that there are several pathways for coronary artery 
metabolic vasodilation to ensure adequate cardiac perfusion. This includes multiple 
triggering factors that can induce coronary artery dilation including hypoxia, change 
in pH and various metabolites. However, it has proven difficult to elucidate the exact 
mechanisms by which coronary arteries dilate [2]. 
In terms of vascular energy status, ATP concentration and ATP:ADP ratio are 
important indicators. ATP not only serves as the main energy currency, but also links 
metabolic changes to electrical activity, calcium signaling and contractility of 
VSMCs [33, 34, 43]. KATP channels of VSMCs are reported to be sensitive to 
intracellular metabolic change and therefore may play an important role in hypoxic 
vasodilation [43, 101]. One major unresolved issue here is whether relatively mild 
hypoxia (i.e. PO2 ~30 mmHg) known to cause vasodilation can indeed change 
intracellular nucleotide levels sufficiently to activate KATP channels. The lack of 
methods to tackle this fundamental question has prevented investigations in this area. 
Recent development and improvement of bioluminescent and fluorescent tools 
have made it finally possible to address this question directly in live cells. 
Luciferase-based bioluminescence assays allow dynamic measurements of ATP 
content in isolated cells [182]. Recombinant luciferase can be introduced into cells 
by transient transfection, allowing measurement of ATP levels in response to hypoxia. 
Luciferase can be targeted to plasma membrane or mitochondria, giving the potential 
to fully define the metabolic effects of hypoxia in subcellular ATP compartments 
[182, 184]. Recently, FRET based probes have been developed for measurement of 
ATP and ATP:ADP ratio [185-187, 194]. These probes have unique advantages over 
luciferase in that they do not consume cellular ATP and are less sensitive to other 
factors such as H
+
. Mitochondrial membrane potential can be measured by 
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cell-permeant, fluorescent lipophilic cationic dyes such as rhodamine123, 
tetramethylrhodamine methyl (TMRM) and ethyl (TMRE) [195]. Thus, cellular and 
subcellular energy status of single cells as well as effect of hypoxia and metabolic 
modulators can be now investigated. 
In this chapter, cellular nucleotide levels were measured using bioluminescent 
and fluorescent probes (Perceval/PercevalHR). As well as manipulating O2 tension in 
a custom made micro-imaging chamber, metabolic inhibitors were used: glycolysis 
was inhibited with 2-DG, mitochondrial respiratory chain with rotenone, antimycin A, 
and oligomycin B, and electron transfer was uncoupled from ATP generation using 
protonophores such as CCCP. Combined application of these pharmacological agents 
allowed further dissection of cellular metabolism of HCASMCs. The goal of this 
chapter was to determine the relative importance of mitochondrial ATP and 
glycolytic ATP in HCASMCs, and whether hypoxia has any effects on cellular 
metabolism. 
Perceval is a fluorescent biosensor of adenylate nucleotides [185]. It is 
constructed by integrating a yellow cpFP, circularly permuted monomeric Venus 
(cpmVenus), into the T loop of ATP binding bacterial protein GlnK1. ATP and ADP 
bind to the same site of Perceval with very high affinity, so the binding site is always 
occupied at physiological ATP and ADP concentrations. The competition between 
ATP and ADP makes the sensor a reporter of intracellular ATP:ADP ratio [185], 
although at least one paper reported that signal is only dependent on ATP, not ADP 
[196]. PercevalHR is an improved fluorescent biosensor derived from Perceval by 
performing a structure-guided protein engineering strategy and is tuned to sense the 
ATP:ADP ratios expected in healthy mammalian cells [186]. The principle of 
PercevalHR sensing cellular ATP:ADP ratio is illustrated in Figure 3.1. One 
potential issue in using Perceval/PercevalHR, as in the case of other green 
fluorescent protein derived biosensors, is its sensitivity to pH where apparent change 
in signal may not originate from change in ATP:ADP ratio but from pH. Ideally, 
monitoring of pH should be carried out simultaneously with Perceval/PercevalHR 
fluorescence recording, but if not, pH should be measured separately using identical 
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conditions. A genetically encoded pH sensor, pHRed, made by mutagenesis of the 
red fluorescent protein mKeima is a ratiometric biosensor and used in this study 
[197]. 
 
 
Figure 3.1: PercevalHR detects ATP:ADP ratio. Binding of ADP to GInK domain 
(grey partial circle) of PercevalHR shifts the Venus (Green) chromophore charge 
state equilibrium (box), favoring the neutral protonated state. ATP binding, on the 
other hand, shifts protein conformation to the anionic deprotonated state. The 
emission spectrum is not significantly different between the two states. (Reproduced 
from Tantama et al., 2014 [187]) 
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3.2 Aims 
The overall aim of this chapter was to evaluate the effect of hypoxia and 
metabolic inhibitors on HCASMC cellular energy status. First, OCR and ECAR were 
determined by Seahorse technology to characterize oxidative and glycolytic 
contribution to cellular energy status. Second, intracellular ATP level was detected in 
HCASMC populations by bioluminescence assay. Third, ATP:ADP ratio was 
measured in single HCASMCs by genetically encoded biosensor 
Perceval/PercevalHR. Finally, mitochondrial membrane potential was examined by 
rhodamine123. 
 
3.3 Methods and preliminary results 
3.3.1 Optimization of the cell transfection 
Initial optimization of the transfection was carried out using an established cell 
line, HEK293 cells. For the best results, cell density should be ~70% confluent at the 
point of transfection. Thus, cell seeding at 0.8-1.0x10
6
 cells per well of 6-well plate 
was optimal for transfection after 24 hours (Figure 3.2). In preliminary studies, 1 µg, 
2 µg, 4 µg pEGFP-N1, Perceval, and pHRed were transiently transfected to HEK293 
cells using LP2000 according manufacturer’s protocol. Transfection efficiency of 
pEGFP-N1, Perceval, and pHRed was checked after 24 and 48 hours of transfection 
(data not shown). pEGFP-N1 transfection of HEK293 cells showed good transfection 
efficiency both after 24 hours and 48 hours. Although some cells were transfected 
with Perceval after 24 hours, a larger proportion of cells were positive after 48 hours. 
However, very few cells were transfected with pHRed after 24 hours, and there was 
little improvement after 48 hours. Since our aim was to co-transfect the cells with 
Perceval and pHRed, it was necessary to improve the transfection efficiency of 
pHRed. Transfection of pHRed with five different transfection reagents showed that 
Fugene 6 gave the best efficiency after 24 hours (Figure 3.3 and Table 3.1). Fugene 
6 was selected as the transfection reagent, and transfection with pEGFP-N1, Perceval, 
and pHRed was optimized with different plasmid concentrations and transfection 
times. 4 µg pEGFP-N1 gave optimal transfection efficiency after 24 hours (Figure 
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3.4). 48 hour transfection using 4 µg Perceval gave the best efficiency (Figure 3.5). 
4 µg pHRed gave the best efficiency, and a longer time increased the expression of 
pHRed (Figure 3.6). For subsequent experiments, Fugene 6 was used for the 
co-transfection of Perceval and pHRed (Figure 3.7).  
 
 24 hr 48 hr 72 hr 
0.4x10
6
 
   
0.6x10
6
 
   
0.8x10
6
 
   
1.0x10
6
 
   
1.2x10
6
 
   
Figure 3.2: Cell number optimization of HEK293 cells for transfection. Seeding 
density of 0.8-1.0x10 
6
 of HEK293 cells was optimal for transfection after 24 hours.  
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 LP2000 Fugene6 X-tremeGENE HP 
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(458 nm) 
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Figure 3.3: Optimization of pHRed transfection using different reagents. 24 
hours transfection of HEK293 cells with pHRed using five different reagents showed 
that Fugene 6 gave the best transfection efficiency. Results from three reagents are 
shown here with a larger magnification for X-tremeGENE HP (right panels). Scale 
bar is 100 μm. 
 
Table 3.1: Summary of HEK293 cell transfection efficiency of pHRed 
Transfection Reagent Transfection Efficiency 
Lipofectamine 2000 ~ 1-5% 
FuGENE 6 ~ 15-20% 
FuGENE 6 HD ~1-3% 
X-tremeGENE 9 0% 
X-tremeGENE HP ~5-10% 
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Figure 3.4: HEK293 transfection with pEGFP-N1 after 24 hrs. HEK293 cell 
transfection with pEGFP-N1 showed that 4 µg pEGFP-N1 gave optimal transfection 
efficiency after 24 hours. Scale bar is 400 μm. 
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Figure 3.5: Optimization of Perceval transfection. Time course of Perceval 
transfection with different amount of plasmid showed that 48 hour transfection using 
4 µg Perceval gave the best efficiency. Scale bar is 400 μm. 
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Figure 3.6: Optimization of pHRed transfection. Using 4 µg gave the best 
efficiency for pHRed transfection with continued increase in expression during the 
course of observation. Scale bar is 400 μm. 
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Figure 3.7: Co-transfection of Perceval and pHRed in HEK293 cells. 
Co-transfection of HEK293 cells with Perceval (green) and pHRed (red) using 
Fugene 6. Yellow cells (bottom right) indicate co-expression. Scale bar is 20 μm. 
 
3.3.2 Transfection of HCASMCs with Perceval/PercevalHR and/or pHRed 
Transfection of HEK293 cells proved to be successful using Fugene 6. Next, we 
transfected HCASMCs with Perceval/PercevalHR and pHRed. Cell number 
optimization showed that plating at the density of 1.25-1.75x10
5
 is optimal for 
transfection after 24 hours (Figure 3.8). In addition to Fugene 6, Promofectin, LT1 
and LTX2 can be used successfully for the transfection of HCASMCs (Figure 3.9, 
Table 3.2). 
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Figure 3.8: Cell number optimization for transfection of HCASMCs. A seeding 
density about 1.25-1.75x10
5
 of HCASMCs was optimal for transfection after 24 
hours. 
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Figure 3.9: Perceval/PercevalHR and pHRed transfection of HCASMCs. (A) 
HCASMC expressing Perceval (Fugene 6). (B) HCASMC expressing PercevalHR 
(LTX2). (C) HCASMC expressing pHRed (Fugene 6). (D) HCASMC expressing 
Perceval and pHRed (Fugene 6). Scale bar is 50 μm. 
A 
B 
C 
D 
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Table 3.2: Transfection reagents optimized in HCASMCs 
 Perceval PercevalHR pHRed Co-transfection 
LP2000 √ √ - - 
Fugene 6 √ √ √ √ 
Promofectin - √ - - 
LT1 - √ - - 
LTX2 - √ - - 
√: Reagents used in HCASMC transfection. 
 
3.4 Results 
3.4.1 Bioenergetic profile of HCASMCs 
3.4.1.1 Determination of the optimal concentrations of FCCP and oligomycin 
In Seahorse assay, OCR is a measure of OXPHOS and ECAR is a measure of 
glycolysis. Both OCR and ECAR can be compartmentalized by a sequential 
application of OXPHOS inhibitors provided concentrations are carefully chosen [180, 
181, 183]. While oligomycin concentration must be high enough to fully inhibit ATP 
synthase, it is known that a supramaximal dose of oligomycin will continue to 
increase OCR [183]. This OCR component is therefore ATP synthase independent 
and could be due to an increased proton leak related oxygen consumption [198]. The 
stimulation of OCR with FCCP is bell-shaped [180, 183], indicating that FCCP first 
stimulates and then inhibits OCR in a dose-dependent manner. For this reason, 
titration of oligomycin and FCCP is necessary, and the results of this experiment are 
shown in Figure 3.10 and 3.11. Oligomycin and FCCP at a concentration of 1.0 µM 
and 0.75 µM were chosen to study the cellular bioenergetics of HCASMCs.  
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Figure 3.10: Optimization of FCCP and oligomycin concentrations. OCR 
determined with different FCCP concentrations is plotted for given oligomycin 
concentration. FCCP shows a bell-shaped concentration response, and a 
concentration of 0.75 µM is optimal to cause maximal effect at all oligomycin 
concentrations tested (n=4). Metabolic inhibitors were added sequentially as shown 
in Figure 2.4 (see section 2.5.1). 
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Figure 3.11: Determination of oligomycin concentration. OCR changes at 
different concentrations of oligomycin plotted while FCCP concentration is kept 
constant. At optimal FCCP concentration (0.75 µM), oligomycin at 0.5, 1.0 and 1.5 
µM caused a similar effect. However, increasing oligomycin concentration to 2.0 µM 
lead to maximal inhibition of OCR initially, followed by a progressive increase in 
OCR over time. Oligomycin concentration of 1.0 µM was chosen (n=4). Metabolic 
inhibitors were added sequentially as shown in Figure 2.4 (see section 2.5.1). 
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3.4.1.2 Microplate based OCR measurement (Mitochondrial stress test) 
In a mitochondrial stress test (Figure 3.12), basal OCR was 54.69±4.56 
pmol/min per 2x10
4
 cells (initial cell count) and 5.93±0.43 pmol/min per µg protein 
respectively (see Section 2.5.1). Application of oligomycin reduced OCR to 24.48±
3.52 pmol/min per 2x10
4
 cells and 2.66±0.36 pmol/min per µg protein, suggesting 
that ATP synthase-linked O2 consumption accounts for 55.24% of basal respiration. 
FCCP brought cell OCR to 130.49±8.75 pmol/min per 2x104 cells and 14.20±0.85 
pmol/min per µg protein (Figure 3.12). This indicates the high mitochondrial reserve 
capacity that presumably plays a crucial role in response to acute insults. Rotenone 
plus antimycin decreased OCR to 14.98±3.18 pmol/min per 2x104 cells and 1.65±
0.34 pmol/min per µg protein. This remaining OCR reflects non-mitochondrial 
oxygen consumption including substrate oxidation as well as cell surface O2 
consumption [199]. Therefore, basal oxygen consumption of HCASMCs comprises 
of 72.60% of mitochondrial O2 consumption and 27.40% of non-mitochondrial O2 
consumption, and in the former 76.09% of O2 consumption is coupled to ATP 
synthase and 23.91% is due to proton leak. When normalized internally, HCASMCs 
have a coupling efficiency of 56.41±3.34% (100%x[(ATP synthase linked 
respiration)/basal]), stateapparent (=4-(basal-oligo)/(FCCP-oligo)) of 3.71±0.01, 
RCRbasal (=(basal-R/A)/(Oligo-R/A)) of 4.31±0.25, RCRmax (=(FCCP-R/A)/(oligo- 
R/A)) of 12.79±1.26.  
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Figure 3.12: Mitochondrial stress test. Indices of mitochondrial function were 
compartmentalized by a sequential application of pharmacological inhibitors, and the 
changes in OCR of intact cells in real time (A) was calibrated to µg protein (B). The 
proportion of ATP synthase-linked O2 consumption, proton leak related O2 
consumption, non-mitochondrial O2 consumption, and reserve capacity are 
quantified in two ways by taking basal OCR (C) or maximal OCR (D) as 100% 
(n=8). 
 
3.4.1.3 Changes of bioenergetic profile during cell culture 
As phenotype of primary cells is known to change during cell culture, the 
bioenergetic function of HCASMCs at different cell passages was analyzed in vivo. 
Figure 3.13 shows that HCASMCs rely mainly on mitochondrial ATP generation. 
With an increase in passage number, HCASMCs showed less sensitivity to 
oligomycin, increased non-mitochondrial O2 consumption and less reserve capacity. 
These are indications of cells switching from a contractile phenotype to a 
proliferative and migratory phenotype. 
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Figure 3.13: Cellular bioenergetics of HCASMCs during culture. (A) The 
proportion of ATP synthase-linked O2 consumption, proton leak related O2 
consumption, non-mitochondrial O2 consumption were quantified when basal OCR 
is taken as 100%. (B) Above parameters in (A) and reserve capacity were quantified 
when maximal OCR was taken as 100%. Stateapparent, as well as respiratory control 
ratio (RCR) for basal and maximal OCR were also calculated for different passages 
of HCASMCs (n=8). 
 
3.4.1.4 Microplate based ECAR measurement (Glycolysis stress test) 
Basal ECAR in glucose free unbuffered minimal DMEM Seahorse medium was 
26.78±1.50 mpH/min per 2x104 cells (initial cell count) and 3.24±0.18 mpH/min 
per µg protein (Figure 3.14). Application of 10 mM glucose increased ECAR to 
85.27±3.22 mpH/min per 2x104 cells and 10.31±0.40 mpH/min per µg protein. 
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Oligomycin application caused a loss of mitochondrial ATP production and lead to a 
maximal glycolytic rate of 101.14±4.35 mpH/min per 2x104 cells and 12.18±0.50 
mpH/min per µg protein. Finally non-glycolytic acidification was estimated by 
inhibiting glycolysis with 2-DG, which brought ECAR down to 20.24±1.12 
mpH/min per 2x10
4
 cells and 2.45±0.15 mpH/min per µg protein. 
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Figure 3.14: Glycolysis stress test. Evaluation of glycolysis was made by a 
sequential application of pharmacological inhibitors for OXPHOS and glycolysis, 
and change in ECAR of intact cells in real time (A) was calibrated to µg protein (B). 
The contribution of each element to ECAR is shown in (C), and the pie chart gives 
percentages of glycolysis, non-glycolytic acidification and glycolytic reserve when 
maximal ECAR value was taken as 100% (D) (n=8). 
 
3.4.1.5 ATP production rate from glycolysis and OXPHOS 
In order to estimate proportions of ATP generated by glycolysis and OXPHOS 
in HCASMCs, we next assessed oligomycin sensitive O2 consumption and proton 
production rate (PPR). The former reflects OXPHOS while the latter is an indicator 
of glycolysis. Glycolytic rate can be measured by PPR where acidification of assay 
A B 
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medium is used as the measure of lactate and CO2 production [181, 200, 201]. 
During glycolysis, one glucose molecule breaks down into two pyruvates (pKa 2.5), 
releasing two protons. When glucose-derived pyruvate is linked to OXPHOS, 
pyruvate enters the TCA cycle and CO2 is released. For one pyruvate molecule, three 
molecules of CO2 are generated, one from pyruvate dehydrogenase (PDH), the other 
two from the oxidation of 6-carbon molecules through isocitrate dehydrogenase and 
α-ketoglutarate dehydrogenase. CO2 is hydrated to carbonic acid and released as 
HCO3
-
 and H
+
. A parallel study measuring PPR (Figure 3.15B) was carried out along 
with the mitochondrial stress test (Figure 3.15A). By inhibiting PPR using 
oligomycin in the presence of 2-DG, the remaining PPR represents non-glycolytic 
acidification, and this accounted for 23.74% of the total PPR (36.00/151.64) (Figure 
3.15B). In general, generation of 2 ATP from one glucose molecule releases two 
lactate anions (pKa 3.9) and two H
+ 
into the assay medium. The relationship between 
PPR and ATP production is 1:1 [201, 202]. ATP production from OXPHOS was 
calculated from oligomycin sensitive O2 consumption using a phosphate/oxygen ratio 
(P/O ratio) of 2.31 [173]. Our results showed that HCASMCs cultured in high 
glucose DMEM containing 1 mM sodium pyruvate and 2 mM L-glutamate generate 
ATP at a rate of 115.87±3.33 pmol/min per 2x104 cells or 12.69±0.50 pmol/min 
per µg protein from glycolysis, and 138.93±8.88 pmol/min per 2x104 cells or 15.04
±0.59 pmol/min per µg protein from OXPHOS. These results indicate that the cells 
rely on ~54.53% of the total ATP from OXPHOS (Figure 3.15E and 3.15F). 
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Figure 3.15: ATP production rate from glycolysis and OXPHOS. (A) 
Mitochondrial stress test (n=8). (B) Glycolysis stress test (n=8). (C) Quantitative 
analysis of OCR of HCASMCs. (D) Basal ECAR and PPR of HCASMCs. (E) ATP 
production rate from OXPHOS and glycolysis normalized to cell number. (F) ATP 
production rate from OXPHOS and glycolysis normalized to total protein content. 
 
3.4.1.6 Interplay between glycolysis and OXPHOS  
The results above suggest that cultured HCASMCs have active mitochondrial 
respiration and depend on ATP from OXPHOS more than ATP generated from 
glycolysis pathway. The bioenergetics of the cells is regulated by many factors such 
as energy requirements, substrate availability, and overall quality of the 
mitochondrial population. Blocking ETC with R+A decreased OCR, making cells to 
rely more on glycolysis as indicated by increased ECAR. Application of oligomycin 
had no further effect on OCR indicating that R+A stop ETC effectively (Figure 3.16). 
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When PMF was dissipated with application of FCCP, OCR increased dramatically 
along with an increase in ECAR (Figure 3.17). Oligomycin still increased OCR 
slightly in the presence of FCCP (Figure 3.17). As oligomycin reduced ECAR in the 
presence of R+A or CCCP, inhibition of ETC caused ATP synthase to work in a 
reverse mode in favor of maintaining the ∆ψm at a cost of ATP consumption (see 
Figure 1.18B & C, Section 1.10.2). Moreover, application of 2-DG blocked this 
effect (Fig 3.18) further supporting the hypothesis that the ATP synthase is working 
in a reverse mode in the presence of FCCP, utilizing ATP generated by glycolysis.    
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Figure 3.16: Effect of oligomycin after blocking ETC. (A) R+A decreased 
HCASMC oxygen consumption rate, and oligomycin had little effect on OCR in the 
presence of R+A. (B) Mean±SEM of OCR. (C) Mean±SEM of ECAR. (n=8) 
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Figure 3.17: Effect of oligomycin after dissipating ETC. (A) FCCP increased 
HCASMC oxygen consumption, and oligomycin had little effect on OCR in the 
presence of FCCP. (B) Mean±SEM of OCR. (C) Mean±SEM of ECAR. (n=8)  
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Figure 3.18: 2-DG abolished the reverse mode of ATP synthase. (A) FCCP 
increased ECAR which was decreased by 2-DG, and final application of oligomycin 
had no effect. (B) Mean±SEM of OCR. (C) Mean±SEM of ECAR. (n=8)  
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3.4.1.7 Impact of metabolic inhibitors on mitochondrial bioenergetic phenotype 
Mitochondrial function is important in energy production and cell signaling, and 
altered bioenergetics by metabolic inhibitors and hypoxia can cause cell malfunction. 
Seahorse technology was used to determine the bioenergetic phenotype of cultured 
HCASMCs in response to glucose and metabolic inhibitors. Addition of glucose to 
glucose-free DMEM shifted relative HCASMC bioenergetic phenotype from aerobic 
to glycolytic (Figure 3.19A). 2-DG shifted HCASMC bioenergetic phenotype to be 
more aerobic (Figure 3.19B). Rotenone, antimycin and oligomycin caused the cells 
to become a more glycolytic bioenergetic phenotype (Figure 3.19C&D&E), 
indicating that glycolysis allows compensatory production of ATP when OXPHOS is 
inhibited. FCCP shifted relative HCASMC bioenergetic phenotype from quiescent to 
energetic indicated by a large increase in O2 consumption (Figure 3.19F). When 
compared to basal level, OCR decreased by 33.30±0.55% after addition of glucose 
(in glucose-free DMEM), increased by 7.55±3.48% in response to 2-DG, decreased 
by 58.15±1.69% in response to rotenone, by 52.19±2.27% in response to 
antimycin, by 47.84±2.38% in response to oligomycin, and increased by 84.10±
4.33% in response to FCCP (Figure 3.20A). When compared to basal level, ECAR 
increased by 221.18±7.84% after addition of glucose (to glucose-free DMEM), 
decreased by 37.34±1.88% in response to 2-DG, increased by 67.94±5.58% in 
response to rotenone, increased by 75.14±3.74% in response to antimycin, increased 
by 51.66±3.58% in response to oligomycin, and increased by 63.12±1.78% in 
response to FCCP (Figure 3.20B). 
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Figure 3.19: Bioenergetic phenotype in response to metabolic inhibitors. The 
shift of bioenergetic phenotype of HCASMCs after exposure to 10 mM glucose (in 
glucose-free medium) (A, n=8), 5 mM 2-DG (B, n=8), 1 µM rotenone (C, n=8), 1 
µM antimycin (D, n=7), 1 µM oligomycin (E, n=7) and 0.75 µM FCCP (F, n=8). 
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Figure 3.20: Percent change in OCR and ECAR in response to metabolic 
inhibitors. Percent change of OCR (top panel) and ECAR (bottom panel) against the 
basal measurement after exposure to, from left to right, 10 mM glucose (in 
glucose-free DMEM) (n=8), 5 mM 2-DG (n=8), 1 µM rotenone (n=8), 1 µM 
antimycin (n=7), 1 µM oligomycin (n=7) and 0.75 µM FCCP (n=8). 
 
3.4.2 ATP content in HCASMCs 
3.4.2.1 ATP in cultured HCASMC 
Intracellular ATP was determined by CellTiter-Glo luminescent viability assay. 
The luciferase reaction for the assay is shown in Figure 3.21A where luminescent 
signal generated is proportional to the amount of ATP. An ATP standard curve was 
generated by using serial tenfold dilutions of ATP in cell culture medium (1 µM to 10 
nM) according to manufacturer’s protocol (Figure 3.21B). High concentrations of 
ATP caused a saturation of the signal (data not shown). Luminescence signal and 
cell number followed a linear relationship (Figure 3.21C). HCASMCs contained an 
estimated (1.48±0.03) x10-14 mole ATP per cell. The volume of HCASMCs was 
estimated to be ~13.43±2.90 pL (n=10, see section 4.3.7). Assuming this is equal to 
the intracellular space where ATP is dissolved (the upper end of cell volume), the 
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ATP concentration in HCASMCs is therefore calculated to be ~1.10 mM (the lower 
end of ATP concentration). 
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Figure 3.21: CellTiter-Glo luminescent viability assay. (A) Luciferase reaction. 
Mono-oxygenation of luciferin is catalyzed by luciferase in the presence of Mg
2+
, 
ATP and molecular oxygen. (B) ATP standard curve was made by reading 
luminescence output at a serial tenfold dilutions of ATP in cell culture medium (n=6). 
(C) Cell number correlates with luminescence output (n=6, r
2
=0.994). 
 
3.4.2.2 Effect of vasoconstrictors on intracellular ATP 
The ATP level in the cells was measured in cell culture medium as well as 10 
glucose PSS and 0 glucose PSS. Using buffers instead of medium made the 
experiments more flexible and comparable to the condition used for confocal 
experiments. We first tested whether an increase in ATP consumption will cause a 
change in intracellular ATP. PDGF-BB and PGF2α are known vasoconstrictors, and 
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more ATP is hydrolyzed in working cells. In vivo, ATP is consumed during SMC 
contraction, but even if the cultured cells may not be contractile phenotype, if the 
agonists elevate intracellular Ca
2+
 ([Ca
2+
]i), this would lead to increased ATP 
consumption due to the enhanced activities of Ca
2+
ATPase. PDGF-BB and PGF2α 
increased [Ca
2+
]i in HCASMCs (refer to section 5.3.1.3), but both had little effect on 
cellular ATP in PSS containing 10 mM glucose. PDGF-BB did not change ATP in 0 
glucose PSS, PGF2α slightly decreased cellular ATP, but not significantly (Figure 
3.22). We postulate that the cells generate enough ATP for various functions, and a 
high reserve capacity guarantees energy generation when the demand for ATP 
increases at least in the short term.   
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Figure 3.22: Effect of vasoconstrictors on intracellular ATP. (A) Luminescent 
signal changes in response to PDGF-BB in PSS containing 10 mM glucose (n=4, 
vehicle control vs. PDGF P=0.483). (B) Luminescent signal changes in response to 
PDGF-BB in 0 mM glucose PSS (n=4, vehicle control vs. PDGF, P=0.907). (C) 
Luminescent signal changes in response to PGF2α in PSS containing 10 mM glucose 
(n=4, vehicle vs. PGF2α P=0.394). (D) Luminescent signal changes in response to 
PGF2α in 0 mM glucose PSS (n=4, vehicle vs. PGF2α, P=0.062).  
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3.4.2.3 Effect of metabolic inhibitors on intracellular ATP 
In cell culture medium containing 5.55 mM glucose, blocking glycolysis using 5 
mM 2-DG caused 55.24±0.49% reduction in ATP level. A similar effect of 2-DG 
was observed in PSS in the presence and absence of 10 mM glucose (Figure 3.23). 
After inhibiting cellular oxidative phosphorylation with oligomycin, cellular ATP 
level decreased as shown in Figure 3.24. A summary of ATP levels determined in the 
presence of various metabolic inhibitors is shown in Figure 3.25. In cell culture 
medium, ATP level was reduced by 9.16±0.56% (1 µM rotenone), 7.26±3.41% (1 
µM antimycin), 13.31±2.76% (6 µM oligomycin), and 17.96±1.86% (1 µM 
CCCP). In 10 mM glucose PSS, ATP level was reduced by 8.93±1.61% (1 µM 
rotenone), 14.39±1.96% (1 µM antimycin), 13.72±1.76% (6 µM oligomycin), and 
22.73±1.53% (1 µM CCCP). In 0 glucose PSS, ATP level was reduced by 32.33±
1.34% (1 µM rotenone), 36.08±2.69% (1 µM antimycin), 28.93±1.05% (6 µM 
oligomycin), and 60.14±0.86% (1 µM CCCP). The co-application of 2-DG and 
oligomycin caused a larger inhibition than those caused by either of the inhibitors 
alone (Figure 3.26). 
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Figure 3.23: Inhibition of glycolysis with 2-DG caused a decrease in ATP level. 
Blocking glycolysis using 5 mM 2-DG reduced cellular ATP level in cell culture 
medium (A), 10 mM glucose PSS (B), and 0 mM glucose PSS (C) (n=4). Time 0 
represents before 2-DG application. 
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Figure 3.24: Inhibition of OXPHOS caused a decrease in ATP level. Inhibiting 
OXPHOS with 6µM oligomycin decreased ATP level in PSS with (A) and without (B) 
10 mM glucose (n=4). Time 0 represents reading before oligomycin application. 
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Figure 3.25: Effects of metabolic inhibitors on cellular ATP. Effect of metabolic 
inhibitors on cellular ATP in cell culture medium (A), 10 mM glucose PSS (B), and 0 
mM glucose PSS (C) after 10 minutes (n=4). Statistical comparisons were made 
against vehicle control (DMSO). Control represents medium or 10 mM glucose PSS 
or 0 mM glucose PSS. 
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Figure 3.26: Combined inhibition of glycolysis and OXPHOS by 2-DG and 
oligomicin caused further reduction in cellular ATP. Effect of 5 mM 2-DG and 6 
µM oligomycin on ATP in culture medium (A), 10 mM glucose PSS (B), and 0 mM 
glucose PSS (C) after 10 minutes (n=4). Statistics was done against vehicle control 
(DMSO). Control represents medium or 10 mM glucose PSS or 0 mM glucose PSS. 
 
3.4.3 Effect of metabolic inhibitors and hypoxia on ATP:ADP ratio 
3.4.3.1 Transfection of HEK293 cell with Perceval 
HEK293 cells expressing Perceval was initially used to examine whether 
Perceval fluorescence signal changes with glycolysis inhibition. Application of 5 mM 
2-DG caused a decrease in Perceval signal by 17.28±4.54% (Figure 3.27). Raising 
concentration of 2-DG from 5 mM to 50 mM caused further decrease in Perceval 
signal (n=2, data not shown). A preliminary study using HEK293 cells expressing 
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pHRed showed that application of 5 mM 2-DG did not change intracellular pH 
suggesting that observed reduction in Perceval signal was not due to acidification 
(data not shown). 
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Figure 3.27: The effect of 2-DG on Perceval signal. (A) Images of HEK293 cell 
expressing Perceval before (left) and after (right) application of 5 mM 2-DG. (B) 
Fractional fluorescence of the cell in (A) decreased with application of 5 mM 2-DG. 
(C) Mean±SEM of fractional fluorescence showing Perceval signal just before 
(control) and after the application of 5 mM 2-DG (P=0.084, n=3). 
 
3.4.3.2 Effect of glucose deprivation on ATP:ADP ratio in HCASMCs 
Perceval experiments were next carried out using HCASMCs. Removing 
glucose from extracellular solution resulted in a decrease in ATP:ADP signal by 
25.67±8.33% (Figure 3.28). This was not due to the loss of focus as the response 
was reversible (Figure 3.29). 
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Figure 3.28: Glucose removal caused a decrease in Perceval signal. (A) Images of 
HCASMC expressing Perceval under control condition (left) and after glucose 
removal (right). (B) Time course of fractional fluorescence change induced by 
glucose removal. (C) Mean±SEM of fractional fluorescence of Perceval just before 
(10 Glu) and after (0 Glu) glucose removal (n=6, including 3 cells from Figure 3.29).  
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Figure 3.29: Reduction in Perceval signal after glucose removal is reversible. (A) 
Images of HCASMC expressing Perceval under control condition (left), after 12 
minutes of glucose removal (middle), and after glucose re-administration (right). (B) 
Time course of fractional fluorescence caused by glucose removal and 
re-administration. (C) Mean±SEM of fractional fluorescence for control, 0 mM 
glucose and 10 mM glucose (n=3). 
 
3.4.3.3 Effect of metabolic inhibitors on ATP:ADP ratio in HCASMCs 
Continuous perfusion with PSS for about 40 minutes showed little change in 
Perceval fluorescence signal (Figure 3.30). When 5 mM 2-DG was substituted for 10 
mM glucose, Perceval fluorescence signal was reduced by 54.02±15.29% (Figure 
3.31). The effect of 2-DG was not reversible (data not shown). Experiments with 
cells expressing pHRed showed that 2-DG effect is unlikely to be caused by change 
in pH in bicarbonate buffered PSS as the brief change in the signal was transient 
(Figure 3.32). When HEPES buffered PSS was used, however, application of 2-DG 
caused a change in pHRed signal (Figure 3.33). Inhibiting ETC by application of 
antimycin decreased ATP:ADP ratio signal by ~45% (Figure 3.34). We also tested 
the effect of 20 mM NH4Cl on pHRed that produced predicted change in signal in a 
reversible manner (Figure 3.35).  
 
A 
B C 
121 
 
  
T im e  (m in )
F
/F
0
(
4
8
8
 n
m
)
0 1 0 2 0 3 0 4 0
0 .0
0 .5
1 .0
1 .5
P S S
 
Figure 3.30: Time control study with HCASMC expressing Perceval. Perfusion 
with PSS for a period of 40 minutes caused little change in Perceval fluorescence 
signal (n=1). 
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Figure 3.31: Application of 2-DG decreases Perceval signal. (A) Images of 
HCASMC expressing Perceval before (left) and after the application of 2-DG (right). 
(B) Time course of fractional fluorescence change caused by application of 2-DG. (C) 
Mean±SEM of fractional fluorescence of Perceval just before (control) and after 
administration of 2-DG (P=0.112, n=3).  
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Figure 3.32: The effect of 2-DG on pHRed signal in bicarbonate buffered PSS. 
(A) Images of HCASMC expressing pHRed before (left) and after application of 
2-DG (right). (B) Time course of fractional fluorescence during application of 2-DG. 
This experiment was repeated twice with a similar result. 
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Figure 3.33: The effect of 2-DG in HEPES buffered PSS. In HEPES buffered PSS, 
5 mM 2-DG caused a reduction in Perceval signal (A, n=1), as well as in pHRed 
signal (B, n=2). 
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Figure 3.34: Inhibiting ETC by antimycin causes a decrease in ATP:ADP ratio. 
Images of HCASMC expressing Perceval before (A) and after (B) application of 1 
µM antimycin. (C) Time course of fractional fluorescence showing ~ 45% decrease 
by antimycin (n=1).  
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Figure 3.35: pHRed reports changes in cellular pH. (A) A representative 
HCASMC transfected with pHRed before (left) and after (middle) application of 
NH4Cl. Right panel shows the image after washing of NH4Cl. (B) Time course of 
experiment shown in (A). (C) Average fractional fluorescence of pHRed at basal 
(measured just before the application of NH4Cl), 20 mM NH4Cl (measured at the end 
of NH4Cl application) and after wash (measured at the end of the experiment) (n=3). 
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3.4.3.4 Effect of hypoxia on intracellular ATP:ADP ratio. 
It is crucial to know the exact hypoxia level experienced by the cells. This is 
particularly important for acute experiments attempted in this thesis as the gas 
already dissolved in the experimental media may be slow to exchange with 
atmospheric gas where the O2 tension was manipulated. In addition, it is highly likely 
that the hypoxia effect on ATP:ADP ratio in resting HCASMCs, if any, will occur at 
a very low O2 tension, probably close to near anoxia [203]. The following 
experiments were carried out to address these issues.   
Manipulating O2 tension in the custom made micro-imaging chamber 
(atmospheric gas) was achieved by an O2 controller (# 0508.000, PeCon GmbH, 
Germany), which also allows the control of CO2/humidity/temperature. A fiber optic 
oxygen meter (PHIboard number: v1212143, PM number: 20060308, Serial number: 
TX3-AOT-03-0297, PeCon GmbH, Germany) was used to measure the dissolved O2 
level in the medium of the imaging dish. We first tested the dissolved O2 level in the 
cell culture medium when atmospheric O2 in the chamber was changed to 1%. When 
switched to hypoxia, O2 concentration in the chamber decreased from ~20% to 1% 
within 3 minutes. The O2 in cell culture medium also reached to near lowest level. 
However, the concentration of dissolved O2 in the medium (lowest at 2.87%) is not 
as low as that in the chamber (1%) as shown in Figure 3.36. In order to see whether 
O2 level changes during perfusion, dissolved O2 was examined while the cells were 
perfused with HCO3
-
-buffered PSS. In the hypoxic chamber (1% O2), reading of 
fiber optic oxygen meter showed exchange of O2 dissolved in PSS reached an 
equilibrium under perfusion followed by a continuous decrease by stopping 
perfusion (Figure 3.37). Therefore, we were unable to do hypoxia experiments with 
perfusion in this system as the dissolved O2 was still high during perfusion. One way 
to overcome this would be to have the perfusion solution gassed with nitrogen first to 
achieve hypoxia. 
In cell culture medium, hypoxia (1% O2) resulted in a decrease in ATP:ADP 
ratio signal by 10.99±2.13% (Figure 3.38). The change in Perceval signal caused 
by hypoxia was reversible (Figure 3.39). There was no change in Perceval signal 
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when mild hypoxia (10% and 5% O2) was tested (Figure 3.40). There was no change 
in intracellular pH after exposure to hypoxia as reported by pHRed (Figure 3.41). 
Ratiometric measurement (F543/F458) of pHRed signal from three HCASMCs also 
showed no change by hypoxia (Figure 3.42). 
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Figure 3.36: O2 concentration in the chamber and medium during hypoxia. (A) 
Dissolved O2 in the medium measured by fiber optic O2 meter. (B) O2 concentration 
in the medium converted into percentage (OxyMicro, filled circle) and O2 
concentration in the custom made micro-imaging chamber (atmospheric gas, Oxygen 
Control, filled square).  
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Figure 3.37: Measurement of dissolved O2 during perfusion. In the hypoxic 
imaging chamber (1% O2), perfusion brought dissolved O2 level in HCO3
-
-buffered 
PSS to a higher level near normoxia. When perfusion was stopped, the dissolved O2 
level in the solution continuously decreased. Note: The perfusion was started before 
equilibrium was reached the lowest level. 
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Figure 3.38: Effect of hypoxia (1% O2) on Perceval signal. (A) Images of 
HCASMC expressing Perceval under control condition (left) and hypoxia (right). (B) 
Time course of fractional fluorescence of the cell shown in (A). (C) Mean±SEM of 
fractional fluorescence of Perceval before and after hypoxia (n=8, including 5 cells 
from Figure 3.39). 
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Figure 3.39: Transient hypoxia caused a reversible change in ATP:ADP ratio 
signal. (A) Images of HCASMC expressing Perceval under control condition (left), 
after 10 minutes exposure to hypoxia (middle), and recovery after re-oxygenation 
(right). (B) Time course of fractional fluorescence of the cell shown in (A). (C) Mean
±SEM of fractional fluorescence of ATP:ADP ratio signal under control, hypoxia 
and O2 re-administration (n=5). 
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Figure 3.40: Effect of 10% and 5% O2 on Perceval signal. (A) Time course of 
fractional fluorescence of Perceval showed little change during exposure to 5% O2 
followed by a significant decrease under 1% O2. (B) Mean±SEM of fractional 
fluorescence of ATP:ADP ratio signal under normoxia, 5% O2 and 1% O2 (n=4). (C) 
Time course of fractional fluorescence of Perceval showed little change during 
exposure to 10% O2. (D) Mean±SEM of fractional fluorescence of ATP:ADP ratio 
signal under normoxia and 10% O2 (n=4). 
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Figure 3.41: Effect of hypoxia on pH. (A) Images of HCASMC expressing pHRed 
under control condition (left) and during exposure to 1% O2 (right). (B) Time course 
of fractional fluorescence of the cell showed little change with exposure to 1% O2. (C) 
Mean±SEM of fractional fluorescence of pHRed during control condition and 1% 
O2 (n=5). 
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Figure 3.42: Effect of hypoxia on pHRed ratio fluorescence. (A) 2D ratio of 543 
nm and 458 nm excitation from HCASMCs expressing pHRed before (left) and after 
(right) the exposure to 1% O2. Images are pseudo-coloured with ratio of 0-1. (B) 
Time course of the pHRed ratiometric signal (F543 nm/F458 nm) for individual cells.  
 
3.4.3.5 ATP:ADP ratio measurement with an improved biosensor, PercevalHR  
PercevalHR is an improved biosensor where ATP:ADP ratio detection range is 
more suitable to mammalian cells [186]. Therefore, PercevalHR was used in our 
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project after it became available. Vehicle control with DMSO showed PercevalHR 
signal was stable over 20 mins (Figure 3.43). In cell culture medium, metabolic 
inhibition of oxidative phosphorylation reduced ATP:ADP ratio signal by 22.58±
11.69% (1 µM rotenone), 17.69±6.67% (1 µM antimycin), 39.12±11.72% (6 µM 
oligomycin), 32.85±1.73% (1 µM CCCP, when measured at peak) and 9.49±4.10% 
(1 µM CCCP, when measured at steady state) (Figures 3.44, 3.45, 3.46 &3.47). 
Signal reduced by the application of rotenone was further decreased by application of 
antimycin (Figure 3.48A). On the other hand, rotenone had little effect in cells 
pre-treated with antimycin (Figure 3.48B). Transient hypoxia (1% O2) induced a 
decrease in PercevalHR signal by 17.49±7.22% in a reversible manner (Figure 
3.49). Hypoxia (1% O2) also decreased PercevalHR signal when cells were deprived 
of glucose or pre-treated with rotenone (Figure 3.49). 
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Figure 3.43: Vehicle control of PercevalHR fluorescence. (A) Images of 
PercevalHR transfected cell before (left) and after application of DMSO (right). (B) 
Time course of fractional fluorescence of PercevalHR during DMSO application at 
two regions of interest. (C) Mean±SEM of fractional fluorescence of PercevalHR 
before and after DMSO application (n=4). 
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Figure 3.44: Effect of rotenone on ATP:ADP ratio signal. (A) Images of 
HCASMC expressing PercevalHR before (left) and after (right) application of 1 µM 
rotenone. (B) Time course of fractional fluorescence during rotenone application. (C) 
Mean±SEM of fractional fluorescence of PercevalHR before and after 
administration of rotenone (P=0.111, n=3).  
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Figure 3.45: Effect of antimycin on ATP:ADP ratio signal. (A) Images of 
HCASMC expressing PercevalHR before (left) and after (right) application of 1 µM 
antimycin. (B) Time course of fractional fluorescence during antimycin application. 
(C) Mean±SEM of fractional fluorescence of PercevalHR before and after 
administration of antimycin (n=4). 
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Figure 3.46: Effect of oligomycin on ATP:ADP ratio signal. (A) Images of 
HCASMC expressing PercevalHR before (left) and after (right) application of 6 µM 
oligomycin. (B) Time course of fractional fluorescence of the cell shown in (A). (C) 
Mean±SEM of fractional fluorescence of PercevalHR before and after 
administration of oligomycin (P=0.085, n=3). 
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Figure 3.47: Effect of CCCP on ATP:ADP ratio signal. (A) Images of HCASMC 
before (left) and after (right) the application of 1 µM CCCP. (B) Time course of 
fractional fluorescence of the cell shown in (A). (C) Mean±SEM of fractional 
fluorescence before and after 15 mins administration of CCCP (n=3). 
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Figure 3.48: Effect of sequential application of rotenone and antimycin on 
ATP:ADP ratio signal. (A) Inhibiting complex I with rotenone then complex III 
with antimycin reduced the signal additively. This experiment was repeated twice 
(n=2). (B) The additive effect was not seen when the order was reversed. This 
experiment was repeated four times (n=4). 
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Figure 3.49: Effect of hypoxia on PercevalHR signal. Hypoxia decreased 
ATP:ADP ratio signal (A and B, n=4). The effect was reversible (C, n=3). Hypoxia 
(1% O2) also caused a decrease in PercevalHR signal with 0 glucose (D, n=1) or cell 
pre-treated with rotenone (E, n=1). 
 
3.4.4 Metabolic inhibition and mitochondrial membrane potential  
3.4.4.1 Mitochondria and mitochondrial membrane potential 
Mitochondria generate ATP by virtue of very negative mitochondrial inner 
membrane potential (~-200 mV). Thus, intervention that changes PercevalHR signal 
may do so by modulating mitochondrial membrane potential. Therefore, effect of 
hypoxia and metabolic inhibitors on mitochondrial membrane potential was 
investigated. First, the distribution pattern of mitochondria in HCASMCs was 
visualized using MitoTracker, a red-fluorescent dye that stains mitochondria in live 
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cells. Distribution of MitoTracker showed that HCASMCs are packed with 
mitochondria (Figure 3.50). As discussed earlier, ATP production by mitochondria is 
dependent on electrochemical motive force (ΔP). A compromised mitochondrial 
membrane potential will lead to the disruption of electron transport interrupting 
OXPHOS. Rhodamine123 was used to measure mitochondrial membrane potential. 
Rhodamine123 is a cell-permeant, cationic dye making it naturally accumulate in the 
mitochondria. Once accumulated, dye aggregation and quenching of the emission 
signal occurs. The release of the dye as a result of mitochondrial depolarization, on 
the other hand, results in unquenching and an increase in the fluorescence signal [195, 
204, 205] (Figure 3.51). Therefore, the distribution of rhodamine123 closely 
correlates with the changes of the mitochondrial membrane potential. Except Figure 
3.51, in which rhodamine123 signal in mitochondria and cytoplasm was measured 
separately, the changes of rhodamine123 signal in the rest of this chapter was 
measured by drawing a region of interest in the cells. Spontaneous oscillation of 
rhodamine123 signal in a very small number of HCASMCs was sometimes observed 
(data not shown). 
 
  
Figure 3.50: Staining mitochondrial with MitoTracker. (A) HCASMCs loaded 
with MitoTracker. (B) Brightfield. 
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Figure 3.51: Measurement of mitochondrial membrane potential. (A) Schematic 
illustration of rhodamine123 aggregation in the mitochondria and its release due to 
mitochondrial depolarization (modified from: www.biotec.com). (B) 1µM CCCP 
caused depolarization of mitochondrial membrane potential, resulting in release of 
the dye from mitochondrial matrix (left image) to cytosol (right image) with 
subsequent unquenching of the dye and an increase in the signal. (C) Time course of 
rhodamine123 fluorescence intensity in cytosol and mitochondria matrix of the cell 
shown in (B). 
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3.4.4.2 Metabolic inhibition and mitochondrial membrane potential measured in 
10 mM glucose PSS 
Metabolic inhibition and hypoxia caused changes in cellular ATP:ADP ratio, 
this may be due to their effect on mitochondrial membrane potential. Therefore, we 
examined mitochondrial membrane potential during metabolic inhibition and 
hypoxia in PSS containing 10 mM glucose. DMSO induced little change in 
mitochondrial membrane potential (Figure 3.52). Rotenone was expected to increase 
rhadamine123 signal due to its inhibitory effect on mitochondrial complex I. 
However, application of 1 µM rotenone caused a decrease in rhodamine123 signal by 
8.09±2.56% (Figure 3.53). This change was unexpected (see discussion).1 µM 
antimycin induced an increase in rhodamine123 signal by 66.52±16.57% (Figure 
3.54). 6 µM oligomycin increased rhodamine123 signal by 124.65±8.54% (Figure 
3.55). This unexpected change will be also discussed later. 1 µM CCCP increased 
signal by 176.76±13.28% (Figure 3.56). Hypoxia (1% O2) slightly increased 
rhodamine123 signal by 5.25±1.42% (Figure 3.57). When two inhibitors were 
applied sequentially, antimycin depolarized mitochondrial membrane potential in the 
presence of rotenone, and rotenone slightly decreased rhodamine123 signal in the 
presence of oligomycin. Both antimycin and CCCP caused further mitochondrial 
membrane depolarization in the presence of oligomycin (Figure 3.58). Hypoxia had 
no effect on rhodamine123 signal in the presence of oligomycin, but it reduced 
rhodamine123 signal of the cells pre-treated with CCCP and CCCP plus oligomycin 
(Figure 3.59). 
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Figure 3.52: Effect of DMSO on mitochondrial membrane potential of cells kept 
in 10 mM glucose PSS. (A) Images of rhodamine123 signal in HCASMCs before 
(left) and after (right) application of DMSO. (B) Time course of fractional 
fluorescence. (C) Mean±SEM of fractional fluorescence before and after 
administration of DMSO (n=17). 
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Figure 3.53: Effect of rotenone on mitochondrial membrane potential. (A) 
Images of rhomadine123 signal in HCASMCs before (left) and after (right) the 
application of rotenone. (B) Time course of fractional fluorescence of cells shown in 
(A). (C) Mean±SEM of fractional fluorescence of rhodamine123 before and after 
administration of rotenone (n=19). 
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Figure 3.54: Effect of antimycin on mitochondrial membrane potential. (A) 
Images of rhodamine123 signal in HCASMCs before (left) and after (right) 
application of antimycin. (B) Time course of fractional fluorescence of cells shown 
in (A). (C) Mean±SEM of fractional fluorescence before and after administration of 
antimycin (n=9). 
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Figure 3.55: Effect of oligomycin on mitochondrial membrane potential. (A) 
Images of HCASMCs before (left) and after (right) the application of oligomycin. (B) 
Time course of fractional fluorescence of cells shown in (A). (C) Mean±SEM of 
fractional fluorescence before and after administration of oligomycin (n=81). 
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Figure 3.56: Effect of CCCP on mitochondrial membrane potential. (A) Images 
of HCASMCs before (left) and after (right) the application of CCCP. (B) Time 
course of fractional fluorescence of cells shown in (A). (C) Mean±SEM of 
fractional fluorescence before and after administration of CCCP (n=92). 
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Figure 3.57: Effect of hypoxia on mitochondrial membrane potential. (A) Images 
of rhodamine123 signal in HCASMCs under control conditions (left) and exposure to 
hypoxia (right). (B) Time course of fractional fluorescence of cells shown in (A). (C) 
Mean±SEM of fractional fluorescence before and after hypoxia (P=0.109, n=103). 
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Figure 3.58: Effect of metabolic inhibitors on mitochondrial membrane 
potential. Application of antimycin in the presence of rotenone caused mitochondrial 
membrane potential depolarization (A, n=21). Effect of rotenone was inhibited in the 
presence of oligomycin (B, n=21). Antimycin and CCCP further depolarized 
mitochondrial membrane potential of the cells pre-treated with oligomycin (C and D, 
n=12 and 25 respectively). 
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Figure 3.59: Effect of hypoxia on mitochondrial membrane potential in the 
presence of metabolic inhibitors. Hypoxia had no effect on mitochondrial 
membrane potential of the cells pre-treated with oligomycin (A, n=18). Hypoxia 
significantly reduced the fractional fluorescence in the presence of CCCP (B, n=17) 
and in the combination of CCCP and oligomycin (C, n=21). 
 
3.4.4.2 Metabolic inhibition and mitochondrial membrane potential measured in 
60K
+
 PSS 
In the previous section, 1 µM rotenone and 6 µM oligomycin caused 
unexpected changes in rhodamine123 signal, and this may be due to an effect from 
plasma membrane potential. Previous studies have suggested that the uptake of 
mitochondrial membrane potential dyes including rhodamine123 is also dependent 
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on plasma membrane potential [206, 207]. If this is the case, then detected change in 
rhodamine123 signal may be due, in part, changes in plasma membrane potential. We 
therefore increased the extracellular K
+
 concentration to 60 mM in order to largely 
eliminate the effect of plasma membrane potential. When [K
+
]o is elevated from 5 
mM to 60 mM by replacing equimolar Na
+
, potassium equilibrium potential (EK) 
shifts from -88.7 mV to a more positive value of -21.1 mV. In 60 mM [K
+
]o there is 
little net flux of K
+
 across plasma membrane, eliminating possible influence of 
plasma membrane potential on rhodamine123 signal. Both time control and vehicle 
control showed no change in rhodamine123 signal in the presence of 60 mM K
+
 
(Figure 3.60 and 3.61). Rhodamine123 signal increased by 37.80±8.39% after 
application of 1µM rotenone (Figure 3.62), 90.18±13.05% after application of 1µM 
antimycin (Figure 3.63) and 108.29±18.63% at the peak after treatment with 1µM 
CCCP (Figure 3.65). 6 µM oligomycin caused a reduction in rhodamine123 signal 
by 11.81±4.44% (Figure 3.64). Hypoxia (1% O2) induced a negligible increase in 
rhodamine123 signal (~0.05%) in experiments from 4 dishes (Figure 3.66), but 
increased the signal from one dish by 17.99±2.34% (n=15, data not shown). 
Inhibition of complex I with rotenone followed by inhibition of complex III with 
antimycin caused additive increase in rhodamine123 signal. Inhibition of complex III 
with antimycin in the presence of oligomycin still increased rhodamine123 signal 
(Figure 3.67). Rhodamine123 signal increase due to application of oligomycin and 
antimycin was additive regardless of the order of applications (Figure 3.68). So, the 
distribution of rhodamine123 was also affected by plasma membrane potential, and 
this effect could be eliminated by elevating [K
+
]o to 60 mM. 
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Figure 3.60: Time control of mitochondrial membrane potential signal in 60K
+
 
PSS. Recording of 20 minutes showed no change in rhodamine123 signal (n=7). 
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Figure 3.61: Vehicle control of mitochondrial membrane potential signal in 
60K
+
 PSS. (A) Images of rhodamine123 signal in HCASMCs before (left) and after 
(right) the application of DMSO. (B) Time course of fractional fluorescence of the 
cells shown in (A). (C) Mean±SEM of fractional fluorescence of rhodamine123 
before and after administration of DMSO (n=11). 
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Figure 3.62: Effect of rotenone on mitochondrial membrane potential in 60K
+
 
PSS. (A) Images of rhodamine123 signal in HCASMCs before (left) and after (right) 
the application of rotenone. (B) Time course of fractional fluorescence of the cells 
shown in (A). (C) Mean±SEM of fractional fluorescence of rhodamine123 before 
and after administration of rotenone (n=33). 
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Figure 3.63: Effect of antimycin on mitochondrial membrane potential in 60K
+
 
PSS. (A) Images of rhodamine123 signal in HCASMCs before (left) and after (right) 
the application of antimycin. (B) Time course of fractional fluorescence of the cells 
shown in (A). (C) Mean±SEM of fractional fluorescence of rhodamine123 before 
and after administration of antimycin (n=30). 
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Figure 3.64: Effect of oligomycin on mitochondrial membrane potential in 60K
+
 
PSS. (A) Images of rhodamine123 signal in HCASMCs before (left) and after (right) 
the application of oligomycin. (B) Time course of fractional fluorescence of the cells 
shown in (A). (C) Mean±SEM of fractional fluorescence of rhodamine123 before 
and after administration of oligomycin (n=16). 
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Figure 3.65: Effect of CCCP on mitochondrial membrane potential in 60K
+
 PSS. 
(A) Images of rhodamine123 signal in HCASMCs before (left) and after (right) 
application of CCCP. (B) Time course of fractional fluorescence of the cells shown in 
(A). (C) Mean±SEM of fractional fluorescence of rhodamine123 before and at the 
peak after application of CCCP (n=17). 
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Figure 3.66: Effect of hypoxia on mitochondrial membrane potential in 60K
+
 
PSS. (A) Images of rhodamine123 signal in HCASMCs under control condition (left) 
and hypoxia (right). (B) Time course of fractional fluorescence of the cells shown in 
(A). (C) Mean±SEM of fractional fluorescence of rhodamine123 before and after 
hypoxia (n=29). 
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Figure 3.67: Effect of sequential application of metabolic inhibitors on 
mitochondrial membrane potential in 60K
+
 PSS. (A) Application of antimycin in 
the presence of rotenone caused a further increase in rhodamine123 signal (n=13). (B) 
In the cells pre-treated with oligomycin, antimycin increased the signal (n=18).   
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Figure 3.68: Effect of combined application of metabolic inhibitors on 
mitochondrial membrane potential signal in 60K
+
 PSS. Oligomycin caused an 
increase in mitochondrial membrane potential signal in the presence of antimycin (A, 
n=11). Rotenone (B, n=19), antimycin (C, n=14), CCCP (D, n=4) and hypoxia (E, 
n=17) caused an increase in rhodamine123 signal in the presence of oligomycin. 
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3.4.4.3 Metabolic inhibition and mitochondrial membrane potential measured in 
0 mM glucose PSS 
Removing glucose would reduce energy content of cells, so may unmask 
hypoxic/metabolic effects on mitochondrial membrane potential. Furthermore, 
hypoglycemia increases cardiovascular risks due to its effect on mitochondrial 
membrane potential and mitochondrial ROS production [208, 209]. We therefore 
characterized the effect of metabolic stress on mitochondrial membrane potential in 
the absence of extracellular glucose. Different from that in 10 mM glucose PSS, 1 
µM rotenone increased rhodamine123 signal by 35.03±6.35% (Figure 3.69).1 µM 
antimycin increased rhodamine123 signal by 83.40±5.54% (Figure 3.70). Different 
from the result using 10 mM glucose PSS, 6 µM oligomycin decreased 
rhodamine123 signal by 29.34±3.86% (Figure 3.71). 1 µM CCCP increased signal 
by 115.18±14.73% (Figure 3.72). Exposure to hypoxia (1% O2) for 10 minutes 
increased rhodamine123 signal from 106.22±1.68% to 110.25±3.38% (Figure 
3.73), suggesting an inhibition of electron transport chain. The data also showed that 
antimycin increased the signal in the presence of rotenone, and that hypoxia caused 
an increase and decrease in rhodamine123 signal in the presence of oligomycin and 
CCCP, respectively (Figure 3.74). All the results observed were as expected. The 
inconsistence of some effects from those in 10 mM glucose PSS could be explained 
by a glucose-dependent effect on the outside (plasma) membrane potential due to 
ATP depletion. These results also indirectly suggested HCASMCs used in the 
experiments rely largely on ATP generation through OXPHOS.  
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Figure 3.69: Depolarization of mitochondrial membrane potential by rotenone 
in 0 mM glucose PSS. (A) Images of HCASMCs before (left) and after (right) 
application of rotenone. (B) Time course of fractional fluorescence of cells shown in 
(A). (C) Mean±SEM of fractional fluorescence before and after rotenone (n=50). 
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Figure 3.70: Depolarization of mitochondrial membrane potential by antimycin 
in 0 mM glucose PSS. (A) Images of HCASMCs before (left) and after (right) 
application of antimycin. (B) Time course of fractional fluorescence of cells shown 
in (A). (C) Mean±SEM of fractional fluorescence before and after antimycin 
(n=48). 
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Figure 3.71: Hyperpolarization of mitochondrial membrane potential by 
oligomycin in 0 mM glucose PSS. (A) Images of HCASMCs before (left) and after 
(right) application of oligomycin. (B) Time course of fractional fluorescence of cells 
shown in (A). (C) Mean±SEM of fractional fluorescence before and after 
oligomycin (n=30). 
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Figure 3.72: Depolarization of mitochondrial membrane potential by CCCP in 0 
mM glucose PSS. (A) Images of HCASMCs before (left) and after (right) 
application of CCCP. (B) Time course of fractional fluorescence of cells shown in 
(A). (C) Mean±SEM of fractional fluorescence before and after CCCP (n=23). 
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Figure 3.73: Effect of hypoxia on mitochondrial membrane potential in 0 mM 
glucose PSS. (A) Images of HCASMCs before (left) and during hypoxia (right). (B) 
Time course of fractional fluorescence of cells shown in (A). (C) Mean±SEM of 
fractional fluorescence before and after hypoxia (n=25). 
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Figure 3.74: Effect of sequential application of metabolic inhibitors and hypoxia 
in 0 mM glucose PSS. (A) Antimycin caused an increase in rhodamine123 signal in 
the presence of rotenone (n=22). (B) Hypoxia increased rhodamine123 signal in the 
presence of oligomycin (n=40). (C) Hypoxia caused a decreased rhodamine123 
signal in the presence of CCCP (n=18). 
 
3.3.5 Microplate based ATP:ADP ratio measurement 
Transduction of HCASMCs with 3
rd
 generation lentivirus improved the 
efficiency to near 100% (see section 4.4.2) allowing ATP:ADP ratio to be measured 
on cell populations in multi-well plates. Hypoxia (1% O2) treatment induced an 
initial increase in ATP:ADP ratio signal by 10.89±0.29%, followed by a recovery to 
the original level (Figure 3.75). Inhibition of glycolysis or/and OXPHOS using 
metabolic inhibitors for 15 minutes caused a significant change in the 
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FUGW-PercevalHR signal (Figure 3.76). 
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Figure 3.75: Microplate based ATP:ADP ratio measurement under hypoxia. (A) 
Fluorescence recording by microplate based assay showed a transient increase in 
ATP:ADP ratio signal followed by a complete recovery under hypoxia. (B) Mean±
SEM of fractional fluorescence of FUGW-PercevalHR before and after 60 minutes 
exposure to hypoxia (n=29). 
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Figure3.76: Metabolic inhibitors cause a decrease ATP:ADP ratio signal 
measured in microplate. In the microplate based ATP:ADP ratio measurement, 
metabolic inhibitors caused a decrease in FUGW-PercevalHR signal (n=4). RFU: 
relative fluorescence units. 
 
3.4 Discussion 
Cytosolic ATP, the primary energy currency of living cells, plays an important 
role in the modulation of ion channels and signaling pathways. However, there are 
few studies about bioenergetics of VSMCs, especially in human coronary vasculature. 
Furthermore, there is an increasing realization that it is necessary to monitor 
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temporal and spatial changes of nucleotides within the microdomains of intracellular 
space. In this project, we examined the bioenergetic profile, ATP generation, and 
mitochondrial membrane potential of HCASMCs.  
Cells produce ATP through glycolysis and OXPHOS, the latter requiring 
energized mitochondria. Normally, cells generate ATP primarily and preferentially 
via OXPHOS. However, cancer cells rely almost exclusively on glycolysis for energy 
production known as Crabtree Effect [210]. Because O2 plays a vital role as the final 
electron acceptor in ETC, its levels in the vicinity of the cells can be used to evaluate 
the function of mitochondria. One of the classical methods is Clark type electrodes 
which measure O2 on a catalytic platinum surface with a net reaction as 
O2+4e
-
+2H2O4OH
-
 [211]. More recently, Seahorse XF analyzer has made it 
possible to allow simultaneous measurement of OCR and ECAR in multi-well plate 
based methods, offering convenience and improved levels of sensitivity [180, 181, 
183].         
In order to obtain best results from Seahorse, we optimized cell seeding density 
and doses of oligomycin and FCCP as these are important parameters. For example, 
the stimulation of OCR with FCCP displayed bell-shaped concentration dependency 
as previously reported [180, 183]. Therefore, concentrations of pharmacological 
inhibitors must be chosen with care to avoid over estimation or under estimation of 
effects. In order to make our results comparable between different experiments, the 
reading was normalized to cell number and total protein.  
In the mitochondrial stress test, addition of oligomycin induced a decrease in 
ATP synthase-linked oxygen consumption and ATP production from OXPHOS. 
When measured concurrently, ECAR and PPR increased immediately (Figure 3.15), 
suggesting that the rate of glycolysis increased above the baseline to maintain ATP 
production. On the other hand, increases in glycolysis resulted in a decrease in OCR 
(Figure 3.14). Therefore, glycolysis and OXPHOS are closely linked to each other to 
maintain the correct ATP production in HCASMCs. However, the ability of the cells 
to compensate for the reduction in ATP generation caused in one pathway by 
accelerating the other is not limitless, and spare capacities can be measured as 
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glycolysis reserve capacity and mitochondrial reserve capacity. Mitochondria have a 
spare capacity of ~2.49 fold of the ATP synthase-linked O2 consumption (Figure 2.4 
& 3.12). Inhibiting OXPHOS by oligomycin resulted in an increase by ~24% in the 
rate of glycolysis (Figure 2.5 & 3.14). High mitochondrial reserve capacity may play 
a crucial role in response to acute insults. However, if the cells are unable to increase 
the glycolysis sufficiently, or there is an excess demand of the energy when 
mitochondrial respiration is compromised, this will cause the cells to be more 
susceptible to various stresses [212]. In glucose free assay medium, adding 10 mM 
glucose decreased OCR from 76.89±3.32 pmol/min per 2x104 cells to 51.32±2.36 
pmol/min per 2x10
4
 cells and increased ECAR from 26.78±1.50 mpH/min per 
2x10
4
 cells to 85.27±3.22 mpH/min per 2x104 cells (n=8, Figure 3.14, OCR was 
not shown). In assay medium containing 25 mM glucose, cell OCR was 54.69±4.56 
pmol/min per 2x10
4
 cells and ECAR was 85.44±2.46 mpH/min per 2x104 cells (n=8, 
Figure 3.12, ECAR was not shown). These parallel studies indicated that assay 
medium containing 10 mM glucose is sufficient to support cellular metabolism, and 
an increase in glucose from 10 mM to 25 mM will not result in further effect on OCR, 
ECAR and ATP generation. A more detailed interpretation for mitochondrial 
bioenergetic profile was summarized by Hill et al [180] (Figure 3.77). 
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Figure 3.77: Summary of mitochondrial bioenergetic profile. In different cell 
types, the contribution of mitochondria to the ATP generation could be different, and 
the function of mitochondria can be assessed by sequentially adding pharmacological 
inhibitors (Modified from Hill et al., 2012 [180]). 
 
Are HCASMCs glycolytic or oxidative? In order to answer this question, ATP 
from both glycolysis and OXPHOS were calculated. In glycolysis, generation of two 
ATP from one molecular glucose releases 2 H
+
, so there is a 1:1 relationship between 
ATP and glycolytic PPR [201, 202], which is calculated in this study by subtracting 
non glycolytic PPR from PPR in glucose. Therefore, HCASMCs generate ATP at a 
rate of 115.87±3.33 pmol/min per 2x104 cells or 12.69±0.50 pmol/min per µg 
protein from glycolysis. HCASMCs generate ATP at a rate of 138.93±8.88 
pmol/min per 2x10
4
 cells or 15.04±0.59 pmol/min per µg protein from OXPHOS, 
166 
 
which is converted from ATP synthase-linked O2 consumption at a ratio of 2.31 [173] 
(Fig 3.15). So mitochondrial OXPHOS is responsible for ~54.53% of the total ATP 
production, and HCASMCs are therefore more oxidative, but they also rely 
substantially on glycolysis. By comparing different passages of the cells during 
culture, ATP synthase linked OCR decreased as well as mitochondrial reserve 
capacity as passage number increased (Figure 3.13). Thus, the later passage cells 
seem to rely more on glycolysis and more susceptible to acute insults.   
In addition to OCR and ECAR, Seahorse XF analyzer also allowed a broad 
investigation of the respiratory profile of HCASMCs, such as coupling efficiency, 
Stateapparent, RCRbasal, RCRmaximal. All of these are internally normalized parameters 
that provide more consistent information of cell bioenergetics [180]. Coupling 
efficiency is calculated as 100*(ATP linked respiration)/basal, it can be used to 
estimate the percentage of basal O2 consumption used to drive ATP synthesis. The 
coupling efficiency can also be presented as 1-(Proton leak+non-mitochondrial) 
respiration/basal respiration, it is therefore associated with proton leak related 
respiration. HCASMCs in culture had non-productive proton leak of about ~17% 
under physiological conditions (Figure 3.12). Others suggested that malfunction of 
OXPHOS will significantly increase proton leak [198]. HCASMCs have a relatively 
low leak when compared to approximately ~20% of proton leak reported for a range 
of vertebrate and invertebrate species [173]. Stateapparent helps to simplify the different 
parameters acting together to contribute to the overall flux through respiratory chain. 
The changes in the value could then indicate the changes in activation or the 
expression level of metabolic proteins controlling the processes [180], and further 
studies therefore could be carried out to determine these proteins. RCRbasal and 
RCRmaximal are both useful in evaluating the oligomycin sensitive respiration. It is 
more informative to report the ratio of oligomycin insensitive respiration to maximal 
respiration when ATP turnover rate is low. 
As discussed in section 2.5.3, outcome of Seahorse experiments can be 
classified into four bioenergetic phenotypes, aerobic, energetic, quiescent and 
glycolytic, by plotting OCR against ECAR. As shown in Figure 3.19, a change 
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caused by metabolic intervention can be displayed as a shift before and after the 
treatment. This simple analysis is useful in characterizing bioenergetics change not 
only as a result of metabolic insults, but also phenotype shift during cell proliferation 
and migration. The Seahorse results provided a clear overview of change in 
bioenergetics phenotype of HCASMCs caused by metabolic interventions, and 
detailed parameters including cellular ATP, ATP:ADP ratio and mitochondrial 
membrane potential can be investigated individually to further elucidate underlying 
mechanisms.  
Examination of ATP content in HCASMCs was carried out by luciferase-based 
CellTiter-Glo assay. We estimated a relatively high ATP level (~1.48x10
-14
 mole/cell) 
when compared to other somatic cell types (~10
-15
 mole/cell). We ascribe this to 
larger size of cells used. HCASMCs have an estimated cell volume of ~13.43 pL, 
more than 10 fold compared to that of single artery SMCs from rats [213]. Using this 
estimate, the ATP concentration in HCASMCs is calculated to be ~1.10 mM, a 
reasonable value expected in mammalian cells given the approximations involved in 
making this estimate. PDGF-BB and PGF2α did not cause any change in cellular 
ATP level when cells were kept in 10 mM glucose PSS. However, PGF2α caused a 
small decrease in ATP content of the cell in glucose free PSS (Figure 3.22). This 
may indicate that increase ATP utilization does not affect the cellular ATP 
concentration if there is enough extracellular substrate. Alternatively, the increased 
need in ATP generation could be met by the high reserve capacity (Figure 3.12). 
Blocking either glycolysis or oxidative phosphorylation decreased cellular ATP level, 
and a further effect was observed when inhibiting both pathways (Figure 3. 26). 
Measurement of ATP content under various conditions is useful. However, as 
the absolute amount of cellular ATP and ADP level might vary widely among 
individual HCASMCs, the ratio of ATP:ADP may be a more informative indicator. 
Additionally, some metabolic sensitive proteins including KATP channels are known 
to be regulated not only by ATP but also ADP. Such dual regulation relying on ATP 
and ADP presumably is useful as perhaps finer tuning can be achieved. 
Perceval/PercevalHR is one such ATP:ADP ratio biosensor with several advantages 
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[194]. First, unlike luciferase, Perceval/PercevalHR does not consume ATP during 
measurements. Second, it senses not the absolute ATP, but the ratio of ATP:ADP 
[185-187]. Third, using Perceval or PercevalHR allows investigation of cellular 
metabolism at individual single cell level, not cell population. Finally, PercevalHR is 
well tuned to the level of ATP:ADP ratio expected in mammalian cells, making it a 
suitable ATP:ADP ratio sensor for HCASMCs. 
When using fluorescent protein derived sensors, it is important to be aware that 
signal may also change in response to intracellular pH. We demonstrated that pHRed 
can be used with Perceval (Figure 3.9D). pHRed seems to be functioning correctly 
as it responded to 20 mM NH4Cl, producing expected intracellular pH changes in a 
reversible manner (Figure 3.35). Metabolic inhibition of HCASMCs with 5 mM 
2-DG or hypoxia induced no change in intracellular pH when measured in 
bicarbonate buffered PSS, and this is consistent with the results of other researchers 
[194]. Therefore, it seem safe to ascribe changes in Pervceval/PercevalHR signal to 
true changes in ATP:ADP. Indeed, intracellular pH of HCASMCs is rather well 
maintained as cells can handle pH changes via ion transporters on the cell membrane 
[214, 215] (Figure 3.78). There is, however, reports showing that pH can change 
with metabolic inhibition [194]. In response to 2-DG, Kiang et al. (1990) reported a ~ 
0.2 pH change in A-431 cells [216], and Brown et al. (1991) found the same degree 
of pH change in isolated epithelial cells [217]. It has been also reported that, in 
Neuro2A cells, metabolic inhibition by oligomycin and FCCP showed no effect on 
cytosol pH whilst complete withdrawal of glucose acidified the cytosol [197]. When 
estimated from ECAR change of our Seahorse result, application of 2-DG caused a 
decrease in ECAR by ~25.07 mpH/min, which may have an effect on extracellular 
and intracellular pH. Therefore, it is still important to monitor pH change in the cells 
while measuring ATP:ADP ratio changes in HCASMCs, and make adjustment if 
necessary.  
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Figure 3.78: pH regulation by ion transporters in SMC. (Modified from Madden 
et al., 2000 [214]) 
 
One of the key roles of the mitochondria is to generate ATP through OXPHOS, 
a malfunction of which could be potentially catastrophic to the cell. As the electrons 
pass from one carrier to the next, complex I, III and IV pump positively charged H
+
 
to the intermembrane space from matrix. Resultant PMF across the inner membrane 
is used by ATP synthase to generate ATP. O2 is the final electron acceptor, acting as a 
supplier of PMF and an indirect indicator of the process. Furthermore, ATP synthase 
can operate in reverse mode when ψm is depolarized where it consumes ATP. In this 
chapter, ψm was measured using rhodamine123. We observed spontaneous oscillation 
of rhodamine123 signal in several cells at rest or during pharmacological treatment 
(data not shown). Reason for this signal fluctuation is unknown. The majority of the 
cells did not oscillate and were used to study the effect of metabolic inhibitors and 
hypoxia on ψm. Metabolic inhibitors caused mitochondrial membrane potential 
depolarization by inhibition of ETC. CCCP induced mitochondrial membrane 
potential depolarization by dissipating H
+
 gradient across the inner mitochondrial 
membrane (Figures 3.56&3.72). Although oligomycin induced an unexpected effect 
(depolarization) in 10 glucose PSS, application of oligomycin caused 
hyperpolarization of ψm in 0 glucose and 60 K
+
 PSS. Oligomycin application is 
expected to cause mitochondrial membrane hyperpolarization due to blockade of 
proton re-entry into mitochondrial matrix that normally causes a small depolarization 
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(Figures 3.55&3.71). The fact that experiments using 60 K
+
 produced expected 
outcome suggests that plasma membrane potential change might have influenced 
rhodamine123 signal in PSS (see below). Hyperpolarizing effect of oligomycin was 
also observed in rat femoral arterial SMCs [218]. It was reported in cultured 
cerebellar granule cells, oligomycin caused a hyperpolarization of ~5-10 mV [219]. 
Hypoxia induced statistically non-significant increase in ψm in HCASMCs (Figures 
3.57&3.73). It was previously shown hypoxia did not cause ψm depolarization in rat 
femoral artery SMCs [203]. 
Albeit it has been shown that there is a linear relationship between 
rhodamine123 fluorescence signal and ψm in cuvette study of mitochondria [220], it 
is necessarily the same in live cell imaging in vivo. Since the distribution of 
rhodamine123 follows the Nernst equation, it would be expected that there is a 
non-linear relationship between the two, especially when at very negative potentials 
(Figure 3.51A). Many studies also suggested that uptake of rhodamine123 by 
mitochondria is strongly plasma membrane potential dependent [207, 221], and it is 
difficult to ascertain whether rhodamine123 binds to mitochondria in an energy 
dependent or independent way. These might explain why we observed an unexpected 
effect from rotenone (hyperpolarization) which was predicted to depolarize ψm and 
oligomycin (depolarization) which was predicted to hyperpolarize ψm in PSS 
containing 10 mM glucose. In order to eliminate the possible effect from plasma 
membrane potential change, further experiments were carried out in extracellular 
solution containing 60 mM K
+
. Under 60 mM K
+
, inhibitors of ETC (rotenone, 
antimycin) and CCCP depolarized ψm (Figure 3.62, 3.63&3.65), oligomycin 
hyperpolarized ψm (Figure 3.64), but hypoxia had little effect on ψm (Figure 3.66). 
Under some circumstances, for example dissipating ETC using CCCP, 
mitochondrial ATP synthase will work in a reverse mode in order to maintain the ψm 
at a cost of ATP consumption. Here, ATP synthase pumps out H
+
 from mitochondrial 
matrix using the energy from hydrolysis of ATP [179, 204, 222, 223]. The reverse 
mode of ATP synthase explains in some experiments we observed that mitochondria 
depolarization was transient and there was a partial repolarization of mitochondria 
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after depolarization by metabolic inhibitors, especially antimycin (Figure 3.70) and 
CCCP (Figure 3.65). When ATP synthase was blocked by oligomycin however, the 
repolarization was abolished. In the Seahorse experiments, oligomycin induced a 
decrease in ECAR after application of either R+A or FCCP, and this effect was 
diminished by the application of 2-DG before oligomycin, suggesting that ATP 
synthase was working in a reverse mode and caused a hydrolysis of ATP derived 
from glycolysis. 1% O2 caused little change in rhodamine123 signal no matter which 
extracellular solution. When the cells were pretreated with oligomycin, exposure to 
hypoxia resulted in significant changes in rhodamine123, indicating ψm 
depolarization.  
In summary, HCASMCs have a relative oxidative phenotype. When one energy 
production system is compromised, an alternative pathway can be called on to ensure 
continued supply of ATP. 
One major limitation of this chapter is that the transfection efficiency of 
HCASMCs was very low (<1%). The low level of transfection not only makes the 
experiments generally difficult, but also raises the question as to whether the 
minority of cells transfected would represent the majority of non-transfected cells. 
There is also a concern that the low rate of transfection could be a result of 
transfected cells dying before experiments. Therefore a better transfection method 
should be used to elucidate the cellular metabolism and O2 sensing of HCASMCs. 
This issue is addressed in Chapter 4. 
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Chapter 4 
Using Lentivirus Based 
Biosensors for Investigation of 
Cellular Metabolism of 
HCASMCs 
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4.1 Introduction 
Transfection, a widely used technique to introduce genetic product into cells, 
traditionally relies on lipid-based transfecting agents. The protocol is simple and 
straight forward, and the large number of commercially available transfection agents 
reflects the importance of this technique. However, such gene delivery methods 
including transient transfection with LP2000 and Fugene6 are not always very 
efficient. This is particularly problematic with primary cells such as HCASMCs. 
Furthermore, these methods do not provide a reliable means to control protein 
expression level, leading to under expression or over expression. Perhaps the biggest 
disadvantage of conventional transfection methods, however, is cytotoxicity where 
successful transfection could potentially make cells unhealthy. In order to transfect a 
high proportion of primary cells without detrimental effects, various methods such as 
non-viral custom vectors, adenovirus (Ad), adeno-associated viruses (AAV), 
retroviral packaging systems and lentiviral packaging systems have become a 
preferred choice of gene delivery. Each method is described in more detail below. 
 
4.1.1 PiggyBac
TM
 transposon vector system 
The PiggyBac (PB) DNA transposon technology, a method that utilizes custom 
vectors, has been successfully used in gene therapy, regenerative medicine, cell line 
engineering and animal model creation [224-226]. This system is supposed to be 
useful in altering the genomes of various animal species by simple transfection, 
reversing genomic modifications with footprint free transposon removal as well as 
helping to achieve highly efficient and cost-effective non-viral gene delivery. No 
cargo limit and reversible reactions are two unique features of the transposons. This 
means that re-transfection could be easily achieved with genomes containing an 
inserted PB vector using PB transposase expression vector. Moreover, the Super PB 
transposase expressing vector characterized by a strong cytomegalovirus (CMV) 
promoter offers very high level of expression of the transposase. With this system, 
high expression, stability and integration activity in many mammalian cells can be 
achieved by the optimized PB transposase coding sequence, a goal many researchers 
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wish to achieve. Figure 4.1 shows how PB system works. With the purpose to 
improve the transfection efficiency, this vector was tried in HCASMCs. 
 
 
Figure 4.1 PiggyBac
TM
 transposon vector systems. PB transposon is a mobile 
genetic element that efficiently transposes between vectors and chromosomes via a 
"cut and paste" mechanism. With this system, genes of interest between the two 
inverted terminal repeat sequences (ITRs) in the PB vector can be easily mobilized 
into target genomes. Moreover, transient re-transfection of genomes containing an 
inserted PB vector can be fulfilled with the PB transposase expression vector, in 
which transposons will be removed by transposase from the genome. (Reproduced 
from www.systembio.com/piggybac) 
 
4.1.2 Lentivirus-mediated gene delivery 
Although lentivirus remains less successful for gene therapy so far, some 
preclinical studies and clinical trials have demonstrated that lentivirus is emerging as 
a promising tool for a wide range of applications [227, 228]. A safe and stable 
lentiviral vector not only improves the efficiency of gene delivery, but also helps 
maintain normal tissue physiological function when compared to conventional ways 
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of gene delivery. 
Lentiviruses are a subset of retroviruses (Table 4.1) which can transduce both 
dividing and non-dividing cells with little immune response. Because lentivirus also 
integrates into host cell genome, the long term gene expression can be achieved 
where a transfected cell will produce two daughter cells with modified gene (Figure 
4.2). Due to these advantages, the 2
nd
 and 3
rd
 generation lentiviral systems (Figure 
4.3) became important and popular tools both in gene editing and gene therapy. A 
comparison of 2
nd
 and 3
rd
 generation lentiviral systems is shown in Table 4.2. 
The major aim of this chapter was to use lentivirus gene delivery system in 
order to bring reporter gene of interest to HCASMCs. Lentivirus transfection was 
more efficient and reliable and the changes of intracellular ATP:ADP ratio and pH 
were examined more successfully using lentivirus transfected HCASMCs.  
 
Table 4.1: Retroviridae family  
 
Adapted from Kantor et al., 2014 [229]. 
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Figure 4.2: Schematic representation of HIV-1 genome. The HIV-1 virus has three 
gene regions (gag, pol and env), the accessory proteins and the flanking Long 
Terminal Repeats (LTR) (Modified from Shaw et al., 2014 and Yasutsugu et al., 2011 
[230, 231]). 
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Figure 4.3: Schematic illustration of HIV-1 derived lentivirus. (A) First 
generation lentiviral vector: it is comprised of three separate plasmid DNAs encoding 
the vector genome, all HIV-1 gene except env, and Eve protein VSV-G. (B) Second 
generation lentiviral vector: this is also a three plasmids system, but with an 
improved safety by removing or mutating all accessory genes vif, vpr, vpu and nef 
from the packing plasmid. (C) The third generation lentiviral vector is designed to 
further reduce potential risk. It uses 4 plasmids instead of 3, and 5'LTR is partially 
deleted and fused to a heterologous enhancer/promoter such as CMV or RSV 
eliminating the requirement for Tat (Tat-independent). In addition, the 
enhancer/promoter is deleted from the U3 region of 3'LTR (ΔU3) in the transfer 
vector plasmid (self-inactivating (SIN) vector). (Adapted from Shaw et al., 2014 and 
Yasutsugu et al., 2011 [230, 231]) 
A 
B 
C 
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Table 4.2：Comparison of 2nd and 3rd generation lentiviral systems 
Feature 2
nd
 generation 3
rd
 generation 
Transfer 
Plasmid 
Can be packaged only by a second 
generation packaging system that includes 
TAT 
Can be packaged by both 2nd and 3rd 
generation packaging systems 
Packaging 
Plasmid 
All on one plasmid: Gag, Pol, Rev, Tat Two plasmids: one encoding Gag and Pol 
and another encoding Rev 
Envelope 
Plasmid 
Interchangeable: usually encodes for 
VSV-G 
Interchangeable: usually encodes for 
VSV-G 
Safety Safe. Replication incompetent: Uses 3 
separate plasmids encoding various HIV 
genes. 
Safer. Replication incompetent and always 
SIN: Uses 4 plasmids instead of 3 and 
eliminates the requirement for Tat. 
LTR Viral 
Promoter 
Wild type Hybrid: 5'LTR is partially deleted and 
fused to a heterologous enhancer/promoter 
such as CMV or RSV 
Taken from: https://www.addgene.org/viral-vectors/lentivirus/lenti-guide/  
 
4.1.3 Other alternatives  
In addition to lentivirus, the most commonly used viral vectors for gene editing 
and delivery are based on Ads, AAVs and retrovirus. Nanoparticles have also been 
utilized as an efficient vector. The basic characteristics of different vectors are 
summarized in Table 4.3.  
Ad is widely used for introduction of genetic material into host cells. It provides 
an efficient way to transduce mammalian cell types, both replicative and 
non-replicative. Viral DNA from Ad is maintained in episomal form in infected cells. 
Therefore it leads to transient transgene expression, and different from some other 
viral vectors capable of integrating into the host genome.  
AAV is a small helper dependent and non-pathogenic parvoviruses found as a 
contaminant during the preparation of simian Ad [232, 233]. The majority of 
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recombinant AAV vectors are based on AAV serotype 2. There are a number of 
features inherent to their viral biology, making AAV a widely used gene transfer 
vector. AAV has not been linked with disease, has a broad cell and tissue tropisms, 
and triggers limited viral host response. These features proved AAV to be a good 
gene delivery vector. 
A retrovirus is an enveloped, single-stranded RNA virus containing reverse 
transcriptase. As shown in Table 4.1, it comprises seven subfamilies. Generally, 
retrovirus vectors are replication-defective. Similar to AAV, retroviruses can provide 
long-term gene expression since it requires genome to be integrated in order to 
achieve gene expression. Amongst all viral vectors, oncoretroviruses were the first to 
be used as gene therapy vectors and subsequently contributed to many technical and 
conceptual advancements in the development of viral vectors.  
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Table 4.3: Basic properties of main viral vectors and non-viral vectors 
 Adenovirus AAV Retrovirus Lentivirus Non-viral Nanoparticle 
Family Adenovirus Parvoviridae Retrovirdae Retrovirdae - - 
Virion size 70-90 nm 18-26 nm 80-130 nm 80-130 nm - - 
Genome size 38-39 kb 4.7 kb 3-9 kb 3-9 kb - - 
Genome type dsDNA ssDNA ssRNA ssRNA RNA or DNA RNA or DNA 
Host genome 
integration 
No No Yes Yes No No 
Efficiency Low-high Moderate-high Moderate-high High Poor Poor-moderate 
Transgene 
expression 
Transient long-term long-term long-term Transient Variable 
Immunogenicity High Low Low Low Low Low-high 
Infection/tropism Dividing cells Dividing and 
non-dividing 
Dividing cells Dividing and 
non-dividing 
Dividing and 
non-dividing 
Dividing and 
non-dividing 
Packaging 
capacity 
≤7.5 kb ≤1.8 kb ≤8 kb ≤8 kb No limitation No limitation 
Modified from Mohan et al., 2013 [234]. 
 
4.2 Aims 
The purpose of this chapter was to produce high yields of primary HCASMCs 
expressing the reporter genes PercevalHR and pHRed. As described previously, 
PercevalHR reports the cellular ATP:ADP ratio while pHRed reports pH. 
Furthermore, it is possible that KATP channels are regulated by the change of 
ATP:ADP ratio near plasma membrane microdomains. It follows that signal from 
PercevalHR diffused throughout the cytosol reporting the global change in the ratio 
may not be a good indicator. Thus, we also targeted PercevalHR to the lipid rafts of 
the cell membrane by adding a membrane targeting sequence derived from Lyn 
kinase. 
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4.3 Methods 
4.3.1 Plasmid production, amplification and isolation 
A conventional 3
rd
 generation HIV-based lentivirus packaging system was used 
in this work. The plasmids (RRE, REV, VSVG) required for the production of 
lenti-psuedoviral particles carrying the expression construct were used to transduce 
competent E.Coli cells. A 3
rd
 generation lentivirus vector with a conditional 
packaging system was used [235]. This system requires an envelope plasmid for the 
viral envelope, two packaging plasmids to produce the viral packaging proteins, and 
a transfer plasmid containing the gene of interest (Figure 4.3). 
All plasmids contained an ampicillin resistance gene for selection of 
transformed E.Coli. Transformation of E.Coli was performed following the 
manufacturer’s protocol involving heat shock. Growth of transformed cells and 
plasmid isolation were performed according to manufacturers’ protocols (growth in 
LB broth containing ampicillin and plasmid isolation with commercially available 
mini-prep preparation of plasmid DNA). Successful transformation was confirmed 
by both restriction analysis and automated sequencing. 
 
4.3.2 Production of lenti-psuedoviral particles 
The purified plasmids were prepared with maxi-prep, then transfected 
transiently into the packaging cell line HEK293T cells, either by calcium 
precipitation or by using commercially available transfection reagents. The resulting 
lenti-psuedoviral particles were secreted into culture media and collected. 
Lenti-psuedoviral particles were frozen and stored in -80°C freezer or used 
immediately (Figure 4.4). 
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Figure 4.4: Production of lentivirus. Lentivirus were produced by introducing 
transfer plasmid, packaging plasmids and envelope plasmid into HEK293T cells 
transiently using calcium phosphate or transfection reagents. Maximal lentivirus 
generation usually occurred after 48-72 hours of transfection at which point viral 
particles were collected and clarified from cell debris. Vector particles can be further 
purified, concentrated and titrated before stored at -80℃. (Modified from Shaw et al., 
2014 [230]) 
 
4.3.3 Transduction 
The lenti-pseudoviral particles were used to transduce HCASMCs. Transduction 
was carried out following the protocols used by Kutner et al. (2009) and Li et al. 
(2012) with modifications [236, 237]. Transduction was performed on cells cultured 
for 3-21 DIV (days in vitro). The vector was added and incubated with the cells for 
16-24 hours, then the media was completely removed, and fresh media was added. If 
treated with DNase, it can help to remove any remaining cDNA. The transduced cells 
will express the fluorescent reporter protein as a result of viral integration into the 
host genome, but incapable of generating new viral particles and infecting other cells 
as the envelope and packaging genes are no longer present. The cells were imaged at 
day 3 onwards after transduction by a confocal laser microscope located in the 
Center for Cell Imaging suite (CCI). 
 
4.3.4 Cell permeabilisation 
 It is of high importance that the signals from biosensors are calibrated in vivo. In 
particular, although Perceval and PercevalHR are supposed to detect ATP:ADP ratio, 
Plasmid mixture Transient transfection of HEK293T cells Virus collection 
183 
 
it has been also reported that their signals are independent of ADP [196]. Thus, 
attempts were made to calibrate the PercevalHR using standard solutions containing 
known concentration of ATP and ADP. To achieve this, HCASMCs have to be 
permeabilised in such a way that hydrophilic nucleotides can be introduced into the 
cells without loss of biosensor. Here permeabilisation with ESCIN or α-toxin was 
carried out for PercevalHR in vivo calibration. 
  
4.3.4.1 Permeabilisation with ESCIN 
Escin, a natural mixture of triterpenoid saponins isolated from horse chestnut 
(Aesculus hippocastanum) seeds, was first used to permeabilise HCASMCs. 
Cells expressing PercevalHR were incubated with 20 µM ESCIN (Sigma, 
E1378) in calibration solution containing [mM]: 140 KCl, 10 NaCl, 10 HEPES, 2 
EGTA and 0.05 EDTA. After cells had been permeabilised, and the fluorescence of 
PercevalHR reached a steady state, cells were then perfused with calibration solution 
with different concentrations of ATP containing a free Mg
2+
 of 0.5 mM. Images were 
taken using LSM510 high speed confocal laser scanning microscope with a regular 
interval. 
 
4.3.4.2 Permeabilisation with α-toxin 
PercevalHR transfected cells were washed with PercevalHR calibration solution 
A then B (see below), then permeabilised with 200 µl PercevalHR calibration 
solution B containing 200 µg/ml α-toxin for ~1 hour. Cells were then washed with 
PercevalHR calibration solution B and replaced with PercevalHR calibration solution 
B containing required concentrations of nucleotides while keeping free Mg
2+
 
constant at 0.5 mM (see the columns below. All calculations were done using 
MAXCHELATOR: http://maxchelator.stanford.edu/). Images were taken using 
LSM510 high speed multiphoton confocal laser scanning microscope. 
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PercevalHR calibration solution A 
(pH 7.2) 
NaCl 
NaOH 
KCl 
HEPES 
EGTA 
EDTA 
110 mM 
30 mM 
10 mM 
10 mM 
10 mM 
0.05 mM 
 
PercevalHR calibration solution B 
(pH 7.2) 
KCl 
NaCl 
HEPES  
EGTA 
EDTA 
140 mM 
10 mM 
10 mM 
2 mM 
0.05 mM 
 
 
ATP (mM) ADP (mM) ATP:ADP MgCl2 (mM) 
1  0.1  10 3.6  
1  1  1 4.5  
0  0 - 2.5 
1  0 - 3.5 
3 0 - 5.5 
10 0 - 12.5 
 
4.3.5 Making FUGW-pHRed and Lyn-FUGW-PercevalHR 
 FUGW-pHRed was constructed by inserting pHRed into the lentiviral vector 
from FUGW-PercevalHR. Lyn-FUGW-PercevalHR was made by inserting a 5’ 
myristoylation and palmitoylation lipid modification sequence (GCIKSKRKDK) into 
FUGW-PercevalHR. 
 
4.3.6 Analysis of cell morphology using Fiji 
 In order to characterize the morphology of the cells, images taken using 
LSM510 or LSM510 multiphoton confocal microscope were analyzed by the 
following parameters (Taken from Fiji manual): 
Area Area of selection in square pixels or in calibrated square units (e.g., mm
2
, µm
2
, 
etc.) if Analyze >Set Scale. . . was used to spatially calibrate the image. 
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Major and Minor Primary (the longest) and secondary (the shortest) axis of the best 
fitting ellipse. 
Shape descriptors Calculates and displays the following:  
Circularity 4π × [Area]/ [Perimeter] 2 with a value of 1.0 indicating a perfect 
circle. As the value approaches 0.0, it indicates an increasingly elongated shape. 
Values may not be valid for very small particles. Uses the heading Circ.  
Aspect ratio The aspect ratio of the particle’s fitted ellipse, i.e., [Major 
Axis]/[Minor Axis]. Uses the heading AR.  
Roundness 4×[Area] /(π×[Major axis])2 or the inverse of Aspect Ratio. Uses the 
heading Round.  
Solidity [Area]/[Convex area]. 
A representative analysis is shown in Figure 4.5. Dead cells and the cells those 
are cut off by the edge of the field are excluded.  
 
  
Figure 4.5: Analysis of cell morphology using Fiji. Cells were measured by 
drawing lines around the cell boundaries (left). All defined measurements are shown 
in the result table (right). 
 
4.3.7 Cell volume measurement using Fiji 
HCASMCs expressing Lyn-FUGW-PercevlHR were lifted with trypsin and 
suspended in cell culture medium. Images of the cells were taken using LSM510 
multiphoton confocal microscope (examples: see Figure 4.60 & 4.61). After the 
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length of major and minor axis have been reported (see 4.3.6), cell volume was 
estimated and calculated as: V= (4/3)×π×((major axis/2+minor axis/2)/2)3. 
 
4.3.8 Ratiometric image analysis using Fiji 
Ratiometric analysis of confocal images was performed with Fiji software 
(Figure 4.6). Background was taken from the cell-free area and was subtracted from 
each channel before the image was processed. Ratio images for PercevalHR were 
obtained from pixel-by-pixel division of 488 nm excitation images with 458 nm 
excitation images, and ratio images of pHRed were produced from pixel-by-pixel 
division of 561 nm excitation images with 458 nm excitation images. A region of 
interest was drawn to analyze the changes of the ratio before and after treatment.  
 
           
Figure 4.6: Modal for ratiometric image analysis of a cell expressing 
PercevalHR or pHRed. On the left are the pixelated cartoons of a fluorescent cell 
showing uneven distribution of fluorescence from two different excitation 
wavelengths indicated on top left (green) and bottom left (blue). Pixel-by-pixel 
division of the left two images results in a ratio image on the right (red). In this way, 
the image is normalized for biosensor concentration in the cell, and thus the final 
reading is independent of protein concentration (Modified from Tantama et al., 2014 
[187]). 
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4.4 Results 
4.4.1 PiggyBac
TM
 transposon vector system 
We first tried PiggyBac
TM
 transposon vector system using vector (System 
Biosciences, Cat no. PB533A-2) containing anterior gradient protein 2 (AGR2) 
provided by Christopher Clarke (University of Liverpool). HCASMCs were labelled 
with anti-AGR2 primary antibody (Abcam, Cat no. ab56703) and visualized with 
AF488-conjugated goat anti-mouse secondary antibody (Molecular Probes, Cat no. 
A-11011). Overview of transfection images were taken by EVOS FL cell imaging 
system (Life Technologies). Although HCASMCs were transfected with PB vector, 
the efficiency was still very low and the fluorescent signal was weak (Figure 4.7). 
Therefore, we did not apply this vector for PercevalHR. 
 
 
Figure 4.7: Transfection of PB vector containing AGR2. (A) Bright field. (B) 
Staining of AGR2. (C) DAPI staining of the nucleus. (D) Overlay of the channels. 
Scale bar is 100 μm. 
 
4.4.2 Transfection of HCASMCs with FUGW-PercevalHR 
Figure 4.8 shows HCASMCs transfected with FUGW-PercevalHR using 3
rd
 
A B 
C D 
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generation lentivirus system viewed with EVOS FL cell imaging. Compared to 
transient transfection using reagents, infection with lentivirus brought the 
transfection efficiency to almost 100% where most of the cells were green. 
For the rest of experiments, cells were plated into 35 mm glass-bottom dishes 
for confocal microscopy imaging. 
 
 
Figure4.8: FUGW-PercevalHR transfected HCASMCs. (A) Green channel and (B) 
bright field images of negative control. (C) Green channel and (D) bright field 
images of HCASMCs transfected with FUGW-PercevalHR. Scale bar is 400 μm. 
 
4.4.3 Morphological comparison between transfection with lentivirus and 
transfection reagents 
It is commonly known that most of the transfection reagents are toxic to the 
cells to some extent. Detrimental effect is often indicated by changes in cell 
morphology as well as compromised function. Here we compared the cell 
morphology of transfected cells using reagents and lentivirus (Figure 4.9). 
A 
B 
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HCASMCs transfected using reagents had a shorter minor axis of 19.28±1.86 µm, a 
major axis of 68.56±3.73 µm, and an area of 988.46±88.10 µm2 respectively 
(n=20), compared to 36.99±2.94 µm, 144.17±11.11 µm and 4356.67±503.19 µm2 
of the cells infected with lentivirus (n=33) (Figure 4.10; P<0.001 for all parameters). 
By comparing shape descriptors between the two groups (Figure 4.11; Group A: 
Transfection reagent, n=20; Group B: Lentivirus, n=33), there was no significant 
difference in Circ (A:B: 0.40±0.04 vs 0.37±0.03), AR (A:B: 4.61±0.71 vs 4.58±
0.49), Round (A:B: 0.31±0.04 vs 0.30±0.03 ) and Solidity (A:B: 0.81±0.03 vs 
0.78±0.03 ). The size of lentivirus transduced cells was closer to that of 
non-transfected cells (see section 6.3.1) while that of transfected cells using reagents 
was much smaller in both major and minor axis indicating an unhealthy state. 
 
 
Figure 4.9: Cell transfection using different methods. (A) Cell transfected with 
Perceval using Fugene6. (B) Cell expressing FUGW-PercevalHR and FUGW-pHRed 
using 3
rd
 generation lentivirus. 
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Figure 4.10: Comparison of cell size between different transfection methods 
with Fiji. Cells transfected using transfection reagents are smaller in size in terms of 
major axis, minor axis and area when compared to the cells infected with lentivirus.  
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Figure 4.11: Comparison of cell morphology between different transfection 
methods using Fiji. Analysis of the shape descriptors showed that there is no 
significant difference in Circ, AR, Round and Solidity of cells using different 
transfection methods. 
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4.4.4 Intracellular calibration of FUGW-PercevalHR  
4.4.4.1 Cell permeabilisation using ESCIN  
In the first instance, ESCIN was applied to permeabilise HCASMCs expressing 
PercevalHR (Figure 4.12). Application of 20 µM ESCIN caused an immediate 
decrease in PercevalHR fluorescence. This could be due to the decrease in 
intracellular ATP by diffusion. However, PercevalHR signal did not recover when 
ATP concentration was raised to 10 mM. Likely explanation for this is that there was 
an escape of PercevalHR from HCASMCs following permeabilisation.  
 
 
 
Figure 4.12: Cell permeabilisation with ESCIN. (A) HCASMC expressing 
PecevalHR. (B) Permeabilising with 20 µM ESCIN resulted in a decrease in 
PercevalHR signal. (C) PercevalHR fluorescence did not recover after 10 mM ATP 
was applied. 
  
4.4.4.2 Cell permeabilisation using α-toxin  
As shown above, permeabilisation with ESCIN appeared to be too harsh for in 
vivo calibration as membrane became too leaky so that not only ATP but also 
biosensor moved across the cell membrane. To circumvent this problem, 
α-Hemolysin from staphylococcus aureus (α-toxin, Sigma, Cat no. H9395) was used 
to permeabilise FUGW-PercevalHR transfected cells. Alpha toxin has previously 
been used in the Perceval calibration in MIN6 beta cells [196]. However, after 
incubation HCASMCs with α-toxin, the majority of the cells contracted, causing 
detachment of HCASMCs from the dish. This meant that cells were washed away 
A 
ESCIN (+10mM ATP)  (+) ESCIN (-) ESCIN 
B C 
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when solutions were exchanged (Figure 4.13). The contraction occurred even when 
the calcium was chelated using 10 mM EGTA. In order to minimize cell contraction 
and detachment, 35 mm glass-bottom dishes were coated with poly D-Lysine before 
the cells were seeded. This facilitated the attachment of cells. To prevent cell 
contraction, 10 µM wortmannin (Sigma, Cat no. W1628) was added to PercevalHR 
calibration solution A (Figure 4.14). Wortmannin, a chemical primarily known as a 
phosphoinositide 3-kinases (PI3Ks) inhibitor, is also a potent inhibitor of smooth 
muscle MLCK [238]. Thus, wortmannin is routinely used for smooth muscle 
confocal imaging where movement of cells needs to be prevented. Surprisingly, 
wortmannin only slowed and did not completely prevent cell contraction. The reason 
for this is unknown, but wortmannin is a ‘dirty’ compound with multiple targets. 
Nonetheless, cell contraction and detachment was sufficiently less problematic in the 
presence of wortmannin, and in vivo calibration was possible. 
   
 
Figure 4.13: α-toxin causes SMC contraction. Time course of pictures taken by 
CMEX microscope (Euromex) showed that incubating the cells with α-toxin caused 
extensive HCASMCs contraction. 
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Figure 4.14: Poly D-Lysine coating helps cells adhere to the glass. (A) HCASMCs 
expressing PercevalHR after 1 hour permeabilisation with α-toxin. (B) Treating the 
glass bottom dishes with Poly D-Lysine helped cells to stick better. Note thread like 
structure of cells. 
 
4.4.4.3 Cell permeabilisation for in vivo calibration 
Permeabilised cells were washed with PercevalHR calibration solution B 
followed by PercevalHR calibration solution B containing 10 mM ATP (Sigma, Cat 
no. A2383). Images were taken with LSM510 multiphoton confocal microscope. 
After switching to PercevalHR calibration solution B containing 0 mM ATP, 
PercevalHR fluorescence decreased to its minimum. The signal remained stable and 
can be reversed between 10 ATP and 0 ATP for a relatively long period (Figure 
4.15).  
 
4.4.4.4 PercevalHR detects millimolar concentrations of ATP 
In order to further investigate ATP sensitivity of PercevalHR, a 
concentration-response curve was constructed. Cells were imaged first with 10 and 0 
mM MgATP. Next, cells were treated again with calibration solution B containing 10 
mM ATP, and the extracellular solution was replaced with calibration solution B 
containing 3 mM ATP, 1 mM ATP and 0 mM ATP (Figure 4.16). PercevalHR 
fluorescence showed a concentration dependent decrease and recovered to original 
level when 10 mM ATP was re-administrated at the end of the experiment (Figure 
B A 
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4.16A). Plot of fractional fluorescence against time and curve fitting (hyperbolic 
function) showed a half maximal effect occurring at ~3.29 mM (Figure 4.16B). 
 
4.4.4.5 PercevalHR detects intracellular ATP:ADP ratio 
PercevalHR has been reported to be more sensitive to ATP:ADP ratio rather 
than ATP level alone. Moreover, it could be argued that ATP:ADP ratio is 
functionally more relevant parameter than absolute amount of ATP. However, it has 
been also reported that Perceval signal was not dependent on the level of ADP [196]. 
We therefore studied the influence of ADP on PercevalHR fluorescence using 
permeabilised HCASMCs (Figure 4.17). 
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Figure 4.15: PercevalHR signal measured using α-toxin permeabilised 
HCASMCs. (A) Confocal microscopy recording of PercevalHR fluorescence from a 
single HCASMC permeabilised with α-toxin. PercevalHR fluorescence decreased 
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when MgATP was removed, and recovered after re-administration of MgATP. Stable 
and predictable signal change indicates that in vivo calibration can be conducted over 
a long period of time. Confocal images of an individual HCASMC at three points of 
the study are shown. Scale bar is 50 µm. (B) Mean±SEM of PercevalHR 
fluorescence at 10 mM, 0 mM, and 10 mM of ATP (n=4). 
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Figure 4.16: Dose-response curve of PercevlHR fluorescence as a function of 
ATP concentrations. (A) PercevalHR fluorescence determined over physiological 
range of ATP concentrations with corresponding confocal images of HCASMC. 
Scale bar is 50 µm. (B) Dose-response relationship between ATP concentration and 
FUGW-PercevalHR fluorescence (FUGW-PercevalHR fluorescence at 0 mM ATP 
was set as 0 here). Curve fitting of the data (hyperbolic function) shows a half 
maximal effect at ~3.29 mM ATP (n=4). 
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Figure 4.17: Effect of ADP on PercevalHR fluorescence. (A) Effect of ADP on 
PercevalHR signal in a single α-toxin permeabilised HCASMC. Confocal images of 
HCASMC with 0.1 (left) or 1.0 mM (right) ADP while ATP concentration was kept 
as 1.0 mM. Scale bar is 50 µm. (B) Mean±SEM of PercevalHR fluorescence when 
α-toxin permeabilised cells were exposed to either 0.1 or 1 mM ADP when ATP was 
constant (1.0 mM) (n=5). 
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4.4.5 Metabolic inhibitors and intracellular ATP:ADP ratio 
As mentioned earlier, chemical transfection efficiency with HCASMCs was 
very low. More importantly, the process seems to have detrimental effect on 
HCASMCs. This means that the effect of metabolic inhibitors and hypoxia evaluated 
with chemically transfected cells may not be reliable as metabolic state of the cells 
may not be physiological. Here, in order to overcome these problems, we repeated 
experiments using HCASMCs expressing PercevalHR by lentivirus transduction. In 
this part, the experiments with 2-DG and glucose deprivation were carried out with 
perfusion while test chemicals were added directly to the dish without perfusion for 
all other experiments. 
 
4.4.5.1 Glycolytic inhibition with 2-DG 
First, we examined the effect of glycolytic inhibitor, 2-DG, on PercevalHR 
signal. Cells were exposed to 5 mM 2-DG instead of 10 mM glucose. Upon 
application of 2-DG, PercevalHR fluorescence signal decreased by 42.37±4.11% 
after 10 mins (Figure 4.18). There was no recovery in PercevalHR signal when 5 
mM 2-DG was replaced by 10 mM glucose for 5 mins (data not shown). 
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Figure 4.18: 2-DG caused decrease in PervcevalHR signal. (A) Images of 
HCASMCs expressing PercevalHR before (left) and after (right) application of 5 
mM 2-DG. (B) Time course of fractional fluorescence of cells shown in (A). (C) 
Mean±SEM of fractional fluorescence of PercevalHR before and after 5 mM 2-DG 
(n=18). 
 
4.4.5.2 Effect of glucose removal on PercevalHR signal 
Transient removal of glucose from extracellular solution caused about ~10% 
decrease in PercevalHR signal in 12 minutes, and it was reversed after glucose 
re-administration (Figure 4.19). 
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Figure 4.19: Transient glucose removal caused a transient decrease in 
PercevalHR signal. (A) Images of HCASMCs expressing PercevalHR under control 
condition (left), after 12 minutes of glucose removal (middle), and after glucose 
re-administration (right). (B) Time course of fractional fluorescence of the cells 
showed a ~10% decrease by glucose removal. Fluorescent signal recovered by 
glucose re-administration. (C) Mean±SEM of fractional fluorescence of PercevalHR 
measured with 10, 0 and 10 mM glucose (n=4, during this experiment several cells 
moved and contracted were excluded). 
 
4.4.5.3 Time control and vehicle control of PercevalHR fluorescence 
Prior to examining effect of metabolic inhibitors, control experiments were 
conducted to evaluate the possible bleaching of the fluorescence and drift in focal 
plane (time control, Figure 4.20) and the effect of DMSO on PercevalHR signal 
(vehicle control, Figure 4.21). 
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Figure 4.20: Time control of PercevalHR fluorescence. (A) Images of HCASMCs 
expressing PercevalHR at 5 min (left) and 20 min (right). (B) Time course of 
fractional fluorescence of the cells in (A). (C) Mean±SEM of fractional 
fluorescence of PercevalHR at 5 min and 20 min (n=63). 
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Figure 4.21: Vehicle control of PercevalHR fluorescence. (A) Images of 
HCASMCs expressing PercevalHR under control condition (left) and after 15 
minutes application of DMSO (right). (B) Time course of fractional fluorescence of 
the cells in (A). (C) Mean±SEM of fractional fluorescence of PercevalHR before 
and after administration of DMSO (n=32). 
 
4.4.5.4 Effects of inhibitors of oxidative phosphorylation on PercevalHR signal 
Metabolic inhibition by blocking mitochondrial respiratory chain caused a 
significant decrease in the fractional fluorescence signal. Application of 1 µM 
rotenone that blocks mitochondrial complex I caused a reduction by16.36±2.32% 
(Figure 4.22, n=58). Inhibiting mitochondrial complex III with 1 µM antimycin 
reduced PercevalHR fluorescence by 53.92±2.38% (Figure 4.23, n=41). An ATP 
synthase inhibitor, oligomycin (6 µM), caused a decrease in PercevalHR signal by 
37.97±2.17% (Figure 4.24, n=71). 1 µM CCCP, a proton ionophore, reduced 
PercevalHR signal by 33.14±2.76% (Figure 4.25, n=54). However, hypoxia 
induced little change in PercevalHR fluorescence (Figure 4.26, n=5).  
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Figure 4.22: Metabolic inhibition of mitochondrial complex I caused a decrease 
in PercevalHR signal. (A) Images of HCASMCs expressing PercevalHR before 
(left) and after 15 minutes application of 1 µM rotenone (right). (B) Time course of 
fractional fluorescence of the cells shown in (A). (C) Mean±SEM of fractional 
fluorescence of PercevalHR before and after administration of rotenone (n=58). 
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Figure 4.23: Metabolic inhibition of mitochondrial complex III caused a 
decrease in PercevalHR signal. (A) Images of HCASMCs expressing PercevalHR 
under control condition (left) and after 10 minutess application of 1 µM antimycin 
(right). (B) Time course of fractional fluorescence of the cells shown in (A). (C) 
Mean±SEM of fractional fluorescence of PercevalHR before and after 
administration of 1 µM antimycin (n=41). 
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Figure 4.24: Blocking ATP synthase caused a decrease in PercevalHR signal. (A) 
Images of HCASMCs expressing PercevalHR under control condition (left) and after 
15 minutes application of 6 µM oligomycin (right). (B) Time course of fractional 
fluorescence of the cells shown in (A). (C) Mean±SEM of fractional fluorescence of 
PercevalHR before and after administration of 6 µM oligomycin (n=71).  
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Figure 4.25: Application of proton ionophore resulted in a reduction in 
PercevalHR signal. (A) Images of HCASMCs expressing PercevalHR under control 
condition (left) and after 15 minutes application of 1 µM CCCP (right). (B) Time 
course of fractional fluorescence of the cells shown in (A). (C) Mean±SEM of 
fractional fluorescence of PercevalHR before and after administration of 1 µM CCCP 
(n=54). 
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Figure 4.26: Effect of hypoxia on PercevalHR signal. (A) Images of HCASMCs 
expressing PercevalHR under control condition (left) and after 15 minutes exposure 
to 1% O2 (right). (B) Time course of fractional fluorescence of the cells showed 
hypoxia caused little change in PercevalHR fluorescence. (C) Mean±SEM of 
fractional fluorescence of PercevalHR before and after exposure to hypoxia (n=5). 
 
4.4.5.5 Interrelationship of the components in mitochondrial respiratory chain 
The process taking place in mitochondria to generate ATP is complex. In order 
to further understand individual steps, metabolic inhibitors were sequentially applied 
to the cells. In order to test relationship between complex I and complex III, 
HCASMCs were first incubated with 1 µM rotenone for 10 mins, then 1 µM 
antimycin was applied. Antimycin caused a further decrease in PercevalHR 
fluorescence (Figure 4.27) indicating that blocking complex I did not abolish the 
effect of inhibiting downstream electron transport. We also tested the relationship 
between electron transport chain and ATP synthase by inhibiting ATP synthase with 6 
µM oligomycin in the presence of 1 µM antimycin. 6 µM oligomycin had no 
additional effect on PercevalHR fluorescence in the cells pre-treated with 1 µM 
antimycin (Figure 4.28). Thus, ATP synthase appears to be tightly coupled with the 
mitochondrial inner membrane potential in HCASMCs.  
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Figure 4.27: Interrelationship of mitochondrial complex I and complex III. (A) 
Time course of fractional fluorescence of the cells treated with 1 µM antimycin in 
the presence of 1 µM rotenone. Antimycin decreased PercevalHR fluorescence of the 
cells pre-treated with rotenone. (B) Mean±SEM of fractional fluorescence of 
PercevalHR before and after the application of 1 µM antimycin in the presence of 
rotenone. (n=11) 
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Figure 4.28: Interrelationship of ETC and ATP synthase. (A) Time course of 
fractional fluorescence of the cells treated with 1 μM antimycin followed by 6 μM 
oligomycin. (B) Mean±SEM of fractional fluorescence of PercevalHR at basal state 
and after application of 1 µM antimycin, then 6 µM oligomycin in the continued 
presence of antimycin (n=22). 
 
4.4.5.6 Ratiometric measurement of PercevalHR signal  
PercevalHR appeared to show non-uniform distribution in HCASMCs (e.g. 
Figure 4.26). This could be due to a true reflection of ATP:ADP gradient within a 
cell. However, this may be also due to the uneven distribution of the biosensor itself 
influenced by cell thickness and internal structure such as nucleus and sarcoplasmic 
reticulum [187]. PercevalHR can be used as a ratiometric biosensor, meaning the 
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intensity of the signal could be made concentration independent [186, 187]. This 
could be done as Fhigh/Flow (F500/F420) or as Fhigh/Fiso (F500/F455) using an isosbestic 
point at ~455 nm (Figure 4.29) [186]. Due to a lack of the exact wavelengths 
available, F488/F458 was used instead of F500/F455 in the experiment. A pixel-to-pixel 
ratiometric image showed that PercevalHR was unevenly distributed in HCASMCs 
with signal higher at peripheral region than inside the cell (Figure 4.30A, 4.31A & 
4.32A). Changes in PercevalHR fluorescence were analyzed by drawing a region of 
interest inside the cell, and there was no obvious change in F488/F458 signal of both 
time control and vehicle control (Figure 4.30 & 4.31). Figure 4.32 shows the effect 
of rotenone on F488/F458 ratio signal. The ratiometric 2D images before (left) and after 
(right) application of 1 μM rotenone showed that signal decrease occurred 
throughout the cell even though the biosensor distribution was uneven (Figure 
4.32A). The time course of ratiometric measurement (Figure 4.32B, left panel) was 
essentially identical to that of 488 nm (Figure 4.32B, right top panel). Time course 
of 458 nm signal was not completely flat, perhaps reflecting it is not the true 
isosbestic point (Figure 4.32B, right bottom panel). Therefore, we feel safe that 
PercevalHR signal measured at 488 nm is reliable in reporting ATP:ADP changes. 
 
 
Figure 4.29: HCASMCs expressing FUGW-PercevalHR. (A) Cells excited at near 
isosbestic point of 458 nm. (B) Cells excited at 488 nm. (C) Brightfield image. (D) 
Overlay image. 
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Figure 4.30: Time control of ratiometric imaging. (A) A pixel-to-pixel ratio of 488 
nm excitation image divided with 458 nm excitation image from a single HCASMC 
at time 5 min (left) and 20 min (right) respectively. Images are pseudo-coloured with 
ratio of 0-5. (B) Time course of F488 nm/F458 nm from a region of interest of the cell 
shown in (A).  
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Figure 4.31: Vehicle control of ratiometric imaging. (A) A pixel-to-pixel ratio of 
488 nm excitation image divided with 458 nm excitation image from an individual 
HCASMC before (left) and after application of DMSO (right). Images are 
pseudo-coloured with ratio of 0-5. (B) Time course of F488 nm/F458 nm from a region of 
interest of the cell shown in (A). 
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Figure 4.32: Effect of rotenone on PercevalHR ratiometric signal. (A) A 
pixel-to-pixel ratio of 488 nm excitation image divided with 458 nm excitation image 
from a single HCASMC during control condition (left) and after application of 1 µM 
rotenone (right). Images are pseudo-coloured with ratio of 0-5. (B) Time course of 
F488 nm/F458 nm ratio showed a ~23% decrease after 10 minutes when compared to the 
time point just before the application of 1 µM rotenone. The right panels give the 
individual time course of 488 nm (top panel) and 458 nm (bottom panel) signals 
where the latter is near isosbestic point. 
 
4.4.6 Constructing FUGW-pHRed 
Lentivirus induction dramatically increased the transfection efficiency of 
PercevalHR while keeping HCASMCs in a better condition. Following this 
improvement, we constructed a lentivirus based FUGW-pHRed by inserting pHRed 
into the lentivirus vector made from FUGW-PercevalHR (Figure 4.33). The ligation 
product was verified by restriction analysis on an agarose gel (Figure 4.34) and DNA 
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sequencing.  
     
 
Figure 4.33: Schematic diagram of constructing FUGW-pHRed. Restriction 
digest was performed on both GW1-pHRed and FUGW-PercevalHR using XbaI and 
EcoRI. An agarose gel was run with the restriction mixture, and the insert and vector 
of interest were then isolated by gel extraction and purification. T4 ligation was 
performed in the end in order to ligate the insert with the vector. 
 
 
Figure 4.34: Agarose gel verification of FUGW-pHRed. Product of FUGW-pHRed 
digested with XbaI and EcoRI-HF was run on a 1% agarose gel. The DNA size 
marker is a commercial 1 kb gene ruler. The position of the wells and direction of 
DNA migration is noted. 
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4.4.7 Transfection of HCASMCs with FUGW-pHRed 
HCASMCs transduced with FUGW-pHRed were checked after day 3 using 
EVOS FL cell imaging system (Figure 4.35). 
 
 
Figure 4.35: HCASMCs expressing FUGW-pHRed. (A) Negative control of the 
transfection. (B) HCASMCs infected with FUGW-pHRed. Scale bar is 400 μm. 
 
4.4.8 Effect of metabolic inhibitors on intracellular pH 
Time control and vehicle control were carried out first to ensure that 
FUGW-pHRed signal was stable during the course of experiments (Figures 4.36 & 
4.37). We next tested the effects of metabolic inhibitors on pHRed signal. 1 µM 
rotenone or 6 µM oligomycin caused little change (Figures 4.38 & 4.39). 1 µM 
antimycin in the presence of 1 µM rotenone had little effect on pHRed signal (Figure 
4.40). Because a sequential application of metabolic inhibitors was used in previous 
experiments with Perceval HR (e.g. Figure 4.27), we also examined effect of 
metabolic inhibitors on pH when applied sequentially. Application of 1 µM CCCP to 
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the cells pre-incubated with 6 µM oligomycin also showed little change in pHRed 
signal (Figure 4.41). These manipulations indicated that the changes in ATP:ADP 
signal recorded using PercevalHR were not caused by a change in cellular pH. Note 
that the positive control for pHRed using NH4Cl was already provided (see Figure 
3.35).  
 
  
T im e  (m in )
F
/F
0
 (
4
5
8
 n
m
)
0 5 10 15 20
0 .0
0 .5
1 .0
1 .5
 
F
/F
0
 (
4
5
8
 n
m
)
3  m in 1 8  m in
0 .0
0 .5
1 .0
1 .5
 
Figure 4.36: Time control of FUGW-pHRed fluorescence. (A) Images of 
FUGW-pHRed transfected cells at 3 min (left) and 18 min (right). (B) Time course of 
fractional fluorescence of the cells during a period of 18 mins. (C) Mean±SEM of 
fractional fluorescence of pHRed at 3 min and 18 min (n=35). 
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Figure 4.37: Vehicle control of FUGW-pHRed fluorescence signal. (A) Images of 
FUGW-pHRed transfected cells before (left) and after (right) application of DMSO. 
(B)Treating the cells with DMSO for 15 mins had little effect on pHRed fluorescence. 
(C) Mean±SEM of fractional fluorescence of pHRed before and after DMSO 
application (n=23). 
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Figure 4.38: Effect of rotenone on pHRed signal. (A) Images of FUGW-pHRed 
transfected cells before (left) and after (right) application of 1 µM rotenone. (B) 
pHRed reported little change after the application of 1 µM rotenone. (C) Mean±
SEM of fractional fluorescence of pHRed before and after 1 µM rotenone application 
(n=5). 
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Figure 4.39: Effect of oligomycin on pHRed signal. (A) Images of FUGW-pHRed 
transfected cells before (left) and after (right) application of 6 µM oligomycin. (B) 
There was little change in pHRed signal after the application of 6 µM oliomycin. (C) 
Mean±SEM of fractional fluorescence of pHRed before and after application of 6 
µM oligomycin (n=4). 
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Figure 4.40: Effect of antimycin on cellular pH in the presence of rotenone. (A) 
Images of FUGW-pHRed transfected cells treated with 1 µM rotenone (left) and after 
subsequent application of 1 µM antimycin in the continued presence of rotenone 
(right). (B) 1 µM antimycin induced no change in pHRed signal in the presence of 1 
µM rotenone. (C) Mean±SEM of fractional fluorescence of pHRed before and after 
application of 1 µM antimycin of the cells pre-treated with rotenone (n=5). 
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Figure 4.41: Effect of CCCP on pHRed signal in the presence of oligomycin. (A) 
Images of FUGW-pHRed transfected cells treated with 6 µM oliogomycin (left) and 
after application of 1 µM CCCP in the continued presence of oligomycin (right). (B) 
Exposure to 1 µM CCCP to cells pre-incubated with 6 µM oligomycin showed little 
change in pHRed signal. (C) Mean±SEM for fractional fluorescence of pHRed 
before and after application of 1 µM CCCP in the presence of oligomycin (n=4).   
 
4.4.9 Ratiometric measurement of intracellular pH 
Like PercevalHR, pHRed can also be used for ratiometric imaging where signal 
can be made protein concentration independent. It exhibits dual excitation peaks at 
440 and 585 nm, and emission peak at 610 nm [197]. Further experiments were 
carried out to measure intracellular pH ratiometrically. Cells expressing pHRed were 
excited at 458 and 561 nm, the closest wavelength options of LSM510 multiphoton 
confocal microscope (Figure 4.42). Blocking mitochondrial respiratory chain with a 
single inhibitor exerted little effect on intracellular pHRed signal (Figures 4.43, 4.44, 
4.45, 4.46, 4.47 & 4.48). Application of 1 µM CCCP in the presence of 1 µM 
antimycin also showed little change in pHRed signal (Figure 4.49).    
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Figure 4.42: HCASMCs expressing FUGW-pHRed. (A) Cells expressing pHRed 
excited at 458 nm. (B) Cells expressing pHRed excited at 561 nm. (C) Brightfield 
image. (D) Overlay image. 
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Figure 4.43: Time control of FUGW-pHRed fluorescence. (A) A pixel-to-pixel 
ratio of 561 nm excitation image divided by excitation image of 458 nm from 
HCASMCs expressing pHRed at 3 min and 18 min, respectively. Images are 
pseudo-coloured with ratio of 0-5. (B) Time course of F561 nm/F458 nm ratio showed no 
change during 18 mins period. (C) Mean±SEM of ratio fluorescence of pHRed at 
time point 3 min and 18 min (n=54). 
A B 
C D 
A 
B C 
222 
 
 
 
T im e  (m in )
F
5
6
1
/F
4
5
8
0 5 10 15 20
0 .0
0 .5
1 .0
1 .5
2 .0
D M S O
 
F
5
6
1
/F
4
5
8
C o ntro l D M S O
0 .0
0 .5
1 .0
1 .5
2 .0
 
Figure 4.44: Vehicle control of FUGW-pHRed fluorescence. (A) A pixel-to-pixel 
ratio of 561 nm excitation image divided by excitation image of 458 nm from 
HCASMCs expressing pHRed before (left) and after (right) the application of DMSO. 
Images are pseudo-coloured with ratio of 0-5. (B) Time course of F561 nm/F458 nm ratio 
showed no change after the application of DMSO. (C) Mean±SEM of ratio 
fluorescence of pHRed during control condition and after adding DMSO (n=11). 
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Figure 4.45: Effect of rotenone on FUGW-pHRed ratio fluorescence. (A) A 
pixel-to-pixel ratio of 561 nm excitation image divided by excitation image of 458 
nm from HCASMCs expressing pHRed before (left) and after (right) the application 
of 1 µM rotenone. Images are pseudo-coloured with ratio of 0-5. (B) Time course of 
F561 nm/F458 nm showed little change in the fluorescence ratio after application of 1 µM 
rotenone. (C) Mean±SEM of ratio fluorescence of pHRed during control condition 
and after adding 1 µM rotenone (n=13). 
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Figure 4.46: Effect of antimycin on FUGW-pHRed ratio fluorescence. (A) A 
pixel-to-pixel ratio of 561 nm excitation image divided by excitation image of 458 
nm from HCASMCs expressing pHRed before (left) and after (right) the application 
of 1 µM anitimycin. Images are pseudo-coloured with ratio of 0-5. (B) Time course 
of F561 nm/F458 nm showed little change in the fluorescence ratio after application of 1 
µM antimycin. (C) Mean±SEM of ratio fluorescence of pHRed during control 
condition and after adding 1 µM antimycin (n=16). 
 
 
 
 
 
 
 
A 
B C 
225 
 
 
T im e  (m in )
F
5
6
1
/F
4
5
8
0 5 1 0 1 5
0 .0
0 .5
1 .0
1 .5 6   O lig o
 
F
5
6
1
/F
4
5
8
C o ntro l O ligo
0 .0
0 .5
1 .0
1 .5
 
Figure 4.47: Effect of oligomycin on FUGW-pHRed ratio fluorescence. (A) A 
pixel-to-pixel ratio of 561 nm excitation image divided by excitation image of 458 
nm from HCASMCs expressing pHRed before (left) and after (right) the application 
of 6 µM oligomycin. Images are pseudo-coloured with ratio of 0-5. (B) Time course 
of F561 nm/F458 nm showed no change in the fluorescence ratio after application of 6 
µM oligomycin. (C) Mean±SEM of ratio fluorescence of pHRed during control 
condition and after adding 6 µM oligimycin (n=4). 
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Figure 4.48: Effect of CCCP on FUGW-pHRed ratio fluorescence. (A) A 
pixel-to-pixel ratio of 561 nm excitation image divided by excitation image of 458 
nm from HCASMCs expressing pHRed before (left) and after (right) the application 
of 1 µM CCCP. Images are pseudo-coloured with ratio of 0-5. (B) Time course of 
F561 nm/F458 nm showed no change in the fluorescence ratio after application of 1 µM 
CCCP. (C) Mean±SEM for the ratio fluorescence of pHRed during control 
condition and after adding 1 µM CCCP (n=5). 
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Figure 4.49: FUGW-pHRed ratio fluorescence in response to antimycin and 
subsequent application of CCCP. (A) A pixel-to-pixel ratio of 561 nm excitation 
image divided by excitation image of 458 nm from HCASMCs expressing pHRed 
under control condition (left), and after application of 1 µM antimycin (middle) 
followed by application of 1 µM CCCP (right). Images are pseudo-coloured with 
ratio of 0-5. (B) Time course of F561 nm/F458 nm where neither 1 µM antimycin nor 1 
µM CCCP affected cytosolic pH. (C) Mean±SEM of ratio fluorescence of pHRed 
during control condition and subsequent application of 1 µM antimycin and 1 µM 
CCCP (n=13) 
 
4.4.10 Simultaneous imaging of intracellular ATP:ADP ratio and pH 
So far, ATP:ADP ratio and pH signal were measured separately. Although it 
seems reasonable to suggest that changes seen in ATP:ADP ratio were real and not 
secondary to change in pH from those experiment (see Sections 4.4.8 & 4.4.9), 
ideally, it is better to conduct simultaneous measurement of intracellular ATP:ADP 
ratio and pH. In order to achieve this goal, we co-transfected HCASMCs with 
PercevalHR and pHRed. 
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4.4.10.1 Co-transfection of HCASMCs with FUGW-PercevalHR and 
FUGW-pHRed 
HCASMCs co-transfected with FUGW-PercevalHR and FUGW-pHRed were 
checked after day 3 using EVOS FL cell imaging system, and well transfected cells 
were used for further experiments. Figure 4.50 shows images of HCASMCs 
expressing both FUGW-PercevalHR and FUGW-pHRed. 
 
 
Figure 4.50: HCASMCs expressing both PercevalHR and pHRed. (A) 
PercevalHR fluorescence (488 nm excitation). (B) pHRed fluorescence (458 nm 
excitation). (C) Bright-field image. (D) Overlay image. Scale bar is 400 µm. 
 
4.4.10.2 Simultaneous measurements of ATP:ADP ratio and pH using 
co-transfected HCASMCs 
Metabolic inhibitors of mitochondrial respiratory chain reduced intracellular 
ATP:ADP ratio (Figure 4.51, green). There was little change in pH in most of the 
experiments, as assessed by concurrent measurement with pHRed (Figure 4.51 A-E, 
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red), but application of CCCP showed change in pH (Figure 4.51 F). Thus, the 
PercevalHR signal change caused by all metabolic inhibitors except CCCP is not 
secondary to intracellular pH change. Furthermore, time courses of PercevalHR and 
pHRed signal decrease caused by application of CCCP was not identical, suggesting 
that PercevalHR seems to report, at least in part, change in ATP:ADP ratio (Figure 
4.51F).   
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Figure 4.51: Concurrent measurement of intracellular ATP:ADP ratio and pH. 
Green squares and red circles show time course of PercevalHR and pHRed 
measurements for following conditions. (A) Time control (n=70). (B) Vehicle control 
(n=32). (C) 1 µM rotenone (n=12). (D) 1 µM antimycin (n=24). (E) 6 µM 
oligomycin (n=17). (F) 1 µM CCCP (n=27). 
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4.4.11 PercevalHR fluorescence and mitochondria 
It has previously been reported that, although oligomycin and FCCP caused no 
change in cytosol pH, they caused acidification of mitochondrial matrix [197]. In 
order to elucidate the possibility if PercevalHR signal may be influenced by pH of 
mitochondrial matrix, MitoTracker was used to visualize mitochondria in cells 
expressing PercevalHR. Our results showed that there was no or little co-localization 
of the two signals as PercevalHR (green) did not overlap with pHRed (red) as shown 
the lack of yellow area (Figure 4.52). This indicates that PercevalHR signals do not 
originate from mitochondria matrix, and is therefore unlikely to be influenced by 
mitochondrial pH change.  
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Figure 4.52: Distribution of PercevalHR and MitoTracker. (A) 2D images of 
PercevalHR (green) and MitoTracker (red) signal in HCASMC. Scale bar is 50 µm. 
(B) 3D reconstruction of the cell showing distribution of PercevalHR and 
MitoTracker. Both 2D and 3D images showed no co-localization of PercevalHR and 
MitoTracker. 
 
4.4.12 Membrane targeting PercevalHR/Lyn-FUGW-PercevalHR 
In later experiments, we observed membrane potential hyperpolarization with 
hypoxia, and this might be an effect through the activation of KATP channels in the 
cells membrane (see Section 5.3.2.4). However, hypoxia did not cause significant 
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change in intracellular ATP:ADP ratio when measured using FUGW-PercevalHR 
(Figure 4.26). The lack of effect, however, could be explained if FUGW-PercevalHR, 
which senses global ATP:ADP ratio, remains constant cannot detect change in near 
membrane ATP:ADP ratio. It is conceivable that KATP channels are regulated by 
ATP:ADP ratio in the plasma membrane micro-domains, not by change in bulk 
ATP:ADP ratio. With the purpose of addressing this problem, we next looked at the 
ATP:ADP ratio near the cell membrane in the following two ways: (i) Targeting 
FUGW-PercevalHR to the lipid rafts of cell membrane; (ii) TIRF imaging. 
  
4.4.12.1 Designing of Lyn-FUGW-PercevalHR: Sub-cloning 
A 5’ myristoylation and palmitoylation lipid modification sequence 
(GCIKSKRKDK) derived from Lyn kinase has been previously applied to target 
proteins of interest to membrane lipid rafts [188]. Therefore, we next applied this 
sequence to FUGW-PercevalHR.  
We first tried to introduce the targeting sequence into FUGW-PercevalHR with 
traditional PCR cloning without success (Figure 4.53). We then tried In-Fusion 
cloning method, and it proved to be successful (Figure 4.54). The cloning product 
was verified by restriction analysis (Figure4.55) and DNA sequencing. 
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Figure4.53: Designing of Lyn-FUGW-PercevalHR by PCR cloning. (A) 
Schematic instruction of Lyn- FUGW-PercevalHR biosensor. (B) Targeting sequence 
was designed in the forward primer and cloned into PercevalHR by PCR with two 
blunt ends of XbaI and EcoRI. T4 ligation was performed with PCR product and 
lentiviral vector to produce Lyn-FUGW-PercevalHR. 
 
 
Figure4.54: Designing of Lyn-FUGW-PercevalHR by In-Fusion cloning. 
Linearized vector was first generated using restriction enzyme XbaI. Targeting 
sequencing (blue) was designed with bases of sequence homology at both 5’ and 3’ 
ends (yellow and red). In-Fusion cloning reaction was set according to 
manufacturer’s protocol. 
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Figure 4.55: Agarose gel verification of Lyn-FUGW-PercevalHR. Product of 
Lyn-FUGW-PercevalHR digested with XbaI and EcoRI-HF was run on a 1% agarose 
gel. The DNA size marker is a commercial 1kb gene ladder. The position of the wells 
and direction of DNA migration is noted.  
 
4.4.12.2 Cell transfection with Lyn-FUGW-PercevalHR 
Lyn-FUGW-PercevalHR was tested first in HEK293 cells (Figure 4.56). The 
images from z-stacks taken by LSM510 multiphoton high speed laser scanning 
confocal microscope were reconstructed in order to show the cells expressing Lyn- 
FUGW-PercevalHR in a 3D manner (Figure 4.57). Both 2D and 3D reconstruction 
images showed Lyn-FUGW-PercevalHR fluorescence was localized in the cell 
membrane. 
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Figure 4.56: HEK293 cells transfected with Lyn-FUGW-PercevalHR. LSM510 
multiphoton high speed laser scanning confocal microscope was used to collect Lyn- 
FUGW-PercevalHR signal at a signal z-plane. 
 
 
Figure 4.57: 3D reconstruction of HEK293 cells transfected with 
Lyn-FUGW-PercevalHR. Images from z-stacks taken by LSM510 multiphoton high 
speed laser scanning confocal microscope were reconstructed. Reconstructed images 
were shown with different angles. Scale bar is 30 µm. 
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4.4.12.3 HCASMC transfection with Lyn-FUGW-PercevalHR 
We then moved to transfect HCASMCs with Lyn-FUGW-PercevalHR. 
Compared to global transfection with non-targeted PercevalHR, cell transfected with 
targeted PercevalHR showed higher expression and distribution of the fluorescent 
protein in the plasma membrane region (Figure 4.58). Because cultured HCASMCs 
are spread and thin, it was easier to observe the transfected cells by lifting them with 
trypsin where cells become spherical. Confocal images of lifted HCASMC 
expressing Lyn-FUGW-PercevalHR showed higher fluorescence in the cell 
membrane area (Figure 4.59). 
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Figure 4.58: HCASMC transfected with Lyn-FUGW-PercevalHR. Compared to 
global transfection (A), cell transfected with membrane targeted PercevalHR showed 
higher expression of fluorescent protein in the cell plasma membrane (B). 
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Figure 4.59: Lifted HCASMC expressing Lyn-FUGW-PercevalHR. Compared to 
global transfection (A), cell transfected with targeted PercevalHR showed higher 
expression of fluorescent protein in the cell plasma membrane (B). 
 
4.4.12.4 Using Lyn-FUGW-PercevalHR to report ATP:ADP ratio in the plasma 
membrane microdomains 
Using membrane targeted Lyn-FUGW-PercevalHR, changes of ATP:ADP ratio 
by a metabolic inhibitor was tested. Application of CCCP produced a decrease in 
Lyn-FUGW-PercevalHR emission fluorescence (Figure 4.60). Thus, although not 
tested in the current study, membrane targeted PercevalHR may be a useful tool in 
examining whether hypoxia can modify ATP:ADP ratio in near membrane area. 
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Figure 4.60: Metabolic inhibition lead to a change in Lyn-FUGW-PercevalHR 
signal. Images of Lyn-FUGW-PercevalHR in a single lifted HCASMC under control 
condition (A, top) and after application of 1 µM CCCP (B, top). Plot profile by 
drawing a line across the cell showed 1 µM CCCP decreased ATP:ADP ratio both in 
the membrane lipid raft microdomains and intracellular space. 
 
4.4.13 TIRF imaging of FUGW-PercevalHR 
Without targeting the plasmid to the membrane, TIRF analysis offers a direct 
way to look at the fluorescent molecules in the cell membrane and 
sub-plasmalemmal region (Figure 4.61) [190, 239]. Due to its advantages (i.e. 
spatial restriction and high signal-to-noise ratio of the excitation field), TIRF has 
been widely applied to study cell biological applications, especially spatial-temporal 
dynamics of molecules at or near the cell surface [190, 239]. In this study, we used 
TIRF technique to image HCASMCs expressing PercevalHR and pHRed (Figure 
4.62). Real time imaging of FUGW-pHRed showed dynamic movement of the red 
fluorescence in the cell membrane area (data not shown). Preliminary studies 
indicated that application of metabolic inhibitor (1 µM antimycin) resulted in a 
decrease in FUGW-PercevalHR and Lyn-FUGW-PercevalHR signal in the near 
membrane area (Figure 4.63). Therefore TIRF imaging has the unique property to 
A B 
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directly look at fluorescent signals and their changes in the cell membrane area. 
 
 
 
Figure 4.61: Diagram of TIRF imaging. (A) In epifluorescence, the excitation 
beam goes through directly and stimulates all fluorophores in the entire sample. (B) 
In TIRF imaging, the excitation beam enters the cover-slip-sample interface at an 
incidence angle greater than the critical angle (θc), and an evanescent field is 
generated when excitation light is internally reflected at the interface. The light in the 
evanescent filed (evanescent wave) decays exponentially as the distance from the 
interface increases, so only the fluorophores and fluorescent-tagged proteins in close 
proximity to the coverslip are selectively excited. (Modified from Mattheyes et al., 
2010 [191]). 
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Epifluorescence TIRF 
  
  
  
 
Figure 4.62: Images obtained using epifluorescence and TIRF. (A) HCASMC 
expressing FUGW-PercevalHR. (B) HCASMC expressing FUGW-pHRed. (C) 
HCASMC expressing Lyn-FUGW-PercevalHR. The microscope was focused at the 
adherent plasma membrane of HCASMC and the images were acquired with 
epifluorescence and TIRF, the latter clearly showed the detailed fluorescence signal 
at membrane area. Scale bar is 20 µm. 
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Before antimycin After antimycin 
  
  
Figure 4.63: TIRF imaging of the effect of 1 µM antimycin on cellular 
metabolism. (A) Images of HCASMCs expressing FUGW-PercevalHR before (left) 
and after (right) the application of 1 µM antimycin. (B) Images of HCASMCs 
expressing Lyn-FUGW-PercevalHR before (left) and after (right) the application of 1 
µM antimycin. Scale bar is 20 µm. 
 
4.5 Discussion 
4.5.1 Lentivirus transduction and other alternatives 
Gene delivery vectors can be generally categorized into non-viral based vectors, 
viral vectors and combined hybrid systems (Figures 4.64 & 4.65). Non-viral systems 
can be further divided into two groups according to the way of preparation: chemical 
(synthetic vector-based gene delivery) and physical (carrier-free gene delivery) 
approaches. In terms of viral vectors, Ads, AAVs, retroviruses and lentiviruses are 
commonly used with different characteristics (Table 4.4) [240]. A lot of work has 
been focused on the development of vectors with improved efficiency, specificity and 
A 
B 
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safety. The modifications were made mainly with transfer vector by engineering a 
SIN lentiviral transfer vector or non-integrating lentivirus vectors (Figure 4.3), and 
other lentiviral components were also modified (Table 4.5). 
Because of the low transfection efficiency of HCASMCs using non-viral 
vectors (see section 3.3.2), in this chapter we applied 3
rd
 generation lentiviral gene 
delivery system which dramatically increased the efficiency to almost 100% for both 
PercevalHR and pHRed. The co-transfection, successfully achieved using lentivirus 
technique, was practically impossible with lipid-based transfection. One limitation 
that could affect the efficiency of transfection is that we did not titrate the virus. 
Therefore viral concentration in some batches could be lower than others, and this 
explains why transfection efficiency was not as consistent as it should have been. 
When lower concentration of virus was suspected, a second transfection was 
conducted, particularly for pHRed. By comparing cell morphology from non-viral 
and viral vectors transfected cells, we found that the latter maintained a significantly 
larger size, closer to the shape of normal cultured HCASMCs (Figure 4.10 & 6.2). 
We therefore conclude that HCASMC transfection using lentivirus maintained a 
better morphology and thus perhaps more physiological function. It should be noted 
that hypoxia caused a decrease in intracellular ATP:ADP ratio in HCASMCs 
transfected using the reagents (see Section 3.4.3.4) while there was no change in 
lentivirus transduced cells (Figure 4.26). The discrepancy could be due to the fact 
that condition of cells was compromised after transient transfection using reagents. 
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Figure 4.64: Representative components of a gene delivery vector. Expression of 
a gene of interest is driven by an upstream promoter. Inclusion of an intron into the 
expression cassette assures higher transcription level. The internal ribosome entry 
site (IRES) permits co-transcription of two genes from the same transcript in a 
bicistronic manner. A further enhancement of gene expression can be achieved by 
using the Woodchuck Hepatitis Virus Post-transcriptional Regulatory Element 
(WPRE) to increase the level and stability of the nuclear transcripts. The expression 
of a therapeutic gene can be spatially limited to a specific cell type by inclusion of a 
miR recognition sequence at the 3′ end, which is recognized by its cognate miR 
transcript. The polyadenylation signal ensures properly sized transcripts. An optional 
element which can be included in the vector backbone is the scaffold 
matrix-associated region (S/MAR) which permits episomal replication and vector 
dilution in successive cell generations. An alternative to obtain stable and long term 
expression can be achieved by using transposon sequences for integration of the 
vector into the host genome. (Modified from Sergiu et al., 2015 [241]) 
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Figure 4.65: Schematic illustration of viral and non-viral delivery systems for 
gene delivery. Gene of interest can be delivered by a DNA vector or viral vector. 
(Modified from Nayerossadat et al., 2012 [242]) 
 
Table 4.4: Advantages and disadvantages of different gene delivery systems 
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Table 4.5: Development of improved recombinant lentivectors 
 
Taken from Escor et al., 2010 [240]. 
 
4.5.2 Reporting intracellular ATP:ADP ratio using FUGW-PercevalHR 
Compared to total ATP level, ATP:ADP ratio is arguably a more important 
element in cellular energy status. Perceval is originally constructed to monitor the 
changes in cellular ATP:ADP ratio [185, 196]. Although F488/F405 or F488/F435 
ratiometric change in the excitation spectrum makes Perceval an ideal sensor, it 
saturates at low ATP:ADP ratio (ATP:ADP <5) and therefore was basically tuned to 
extreme metabolic inhibition [185]. However, mammalian ATP:ADP ratios are 
estimated to range from 1 to 100 in healthy conditions [243, 244]. The improved 
sensor PercevalHR meets the requirements to measure ATP:ADP ratio expected in 
mammalian cells [186, 187]. As it was shown in the previous chapter (section 3.3.2), 
the transient transfection efficiency of HCASMCs with PercevalHR was very low 
(<1%). Use of FUGW-PercevalHR, a lentivirus version of PercevalHR, increased the 
transfection efficiency to nearly 100% allowing previously difficult experiments to 
be carried out. For instance, in vivo calibration would not have been attempted due to 
the high wastage of cells during the course of experiments (and cost of α-toxin). One 
surprising problem was that, although, α-toxin has been successfully used for 
Perceval calibration with islet beta cells [196], it caused smooth muscle cell 
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contraction and cell detachment during treatment (Figure 4.13). By improving the 
efficiency of transfection, lentivirus transduction made the calibration of PercevalHR 
possible (Figure 4.14). Results showed that EC50 of PercevalHR is suited to measure 
realistic ATP concentration in mammalian cells (Figure 4.16) and that PercevalHR 
signal is dependent not only ATP but also ADP (Figure 4.17). Taken together, 
PercevalHR is an excellent tool to explore changes in nucleotide concentrations in 
HCASMCs. 
We then assessed the effect of metabolic inhibitors and hypoxia on intracellular 
ATP:ADP ratio. Both blocking glycolysis and mitochondrial respiratory chain caused 
a reduction in intracellular ATP:ADP ratio (Figure 4.18 & 4.22-4.25). Removal of 
glucose from extracellular solution lead to a small and reversible decrease in 
ATP:ADP ratio (Figure 4.19). These results were consistent with the effects 
observed from the transiently transfected cells (see section 3.4.3). However, hypoxia 
induced no change in cellular ATP:ADP ratio (Figure 4.26), in disagreement with the 
results from transiently transfected cells (see Figure 3.38). We deduce that the 
following two possible reasons might have contributed to this inconformity. First, the 
cells infected with lentivirus maintained a better physiological condition. Second, O2 
level used in the studies were not low enough to cause a change in intracellular 
energy in lentivirus infected cells. Further experiments will be required to address 
this issue in the future. 
Vastly improved transfection made co-transfection of FUGW-pHRed and 
FUGW-PercevalHR possible. Generally, metabolic inhibitors and hypoxia had little 
effect in intracellular pH measured by FUGW-pHRed. Therefore, it is likely that 
observed changes in the ATP:ADP ratio reported with PercevalHR is not secondary 
to pH-induced changes. The exception to this was CCCP (Figure 4.51) that caused 
change in pHRed signal. Even in this experiment, however, it is highly unlikely that 
the observed change in PercevalHR was entirely due to pH as the time course of two 
biosensor signals were quite different (Figure 4.51). Mathew et al. showed in 
Neuro2A cells oligomycin and FCCP caused no change in intracellular pH, but when 
pHRed was targeted to the mitochondrial matrix by COX8, it was reported an 
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acidification of the mitochondrial matrix after the application of FCCP [197]. We 
have shown that there is no co-localization of PercevalHR and MitoTracker (Figure 
4.52), suggesting that mitochondrial pH change is unlikely to influence the reading 
of PercevalHR. Simultaneous measurement of intracellular ATP:ADP ratio and pH 
will help to correct any changes in ATP:ADP ratio signal that may occur as a result of 
pH change [186, 197]. 
 
4.5.3 Investigation of cellular metabolism in plasma membrane microdomains  
One of the major objectives of the project was to look at the role of KATP 
channels in hypoxic vasodilation. An exciting aspect is that live cell imaging can be 
combined with other techniques such as electrophysiology techniques. KATP channels 
have been found in the lipid rafts and caveolae of plasma membrane in the 
cardiovascular system although some suggest that they also exist in mitochondria 
[157, 164, 245, 246]. After having achieved targeting PercevalHR to lipid rafts of 
cell membrane, we could investigate the KATP channel physiology with further great 
detail in intact cells. As an alternative to membrane targeting, TIRF imaging system 
also opened the door for looking at the signal near the cell membrane with high 
resolution. Both a single- molecule TIRF analysis (e.g. dynamic movement of ion 
channels) and two single-molecule TIRF/FRET analysis (e.g. identification of 
molecules that interact with ion channels) have been described [190]. However TIRF 
imaging could not directly distinguish the signal from different compartments of the 
membrane if not using reporters containing specialized targeting sequence (e.g. lipid 
rafts and non-lipid rafts). In conclusion, membrane targeted PercevalHR and TIRF 
offer more spatially detailed information regarding ATP:ADP ratio change. Although 
the effect of hypoxia was not tested in the current study, these new tools offer an 
exciting opportunity for the future investigations. 
 
4.5.4 Gene delivery in cardiovascular system 
Gene delivery using viral vectors has been widely used in the labs and clinical 
trials, and using both viral and non-viral vectors have also become one of the most 
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promising fields for developing new treatments. The first gene therapy clinical trial 
was carried out in 1989 in patients with advanced melanoma, using tumor infiltrating 
lymphocytes modified by retroviral transduction [247]. Since then, more clinical 
trials were carried out, including viral vector application in cardiovascular system 
[227, 248, 249]. Figure4 .66 shows the year for different gene delivery methods used 
in heart research and the trend in the total number of publications. Even though the 
therapeutic efficacy of gene delivery to date is not as good as originally hoped, 
further investigations are being carried out and may offer new area of treatments in 
the future. 
 
 
Figure 4.66: The evolution of heart gene delivery research. The number of 
publications is plotted against the year. A great increase in the number of heart gene 
delivery papers is noticed after AAV vector is introduced, which was first used in the 
clinical trial for advanced heart failure initiated in 2007. (Reproduced from Nalinda 
et al., 2011[227]) 
 
4.6 Conclusion  
In conclusion, we successfully employed a 3
rd
 generation lentiviral vector 
system. With this method, we were able to investigate intracellular ATP:ADP ratio 
and pH changes under desired environment. Targeting PercevalHR to lipid rafts of 
the cell membrane will further address the relationship between cellular ATP:ADP 
ratio and KATP channel activity under hypoxia in the future. 
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Chapter 5  
Effect of Hypoxia and K+ Channel 
Modulators on Ca2+ Homeostasis 
and Membrane Potential of 
HCASMCs 
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5.1 Introduction 
In order for coronary hypoxic vasodilation to be physiological useful, several 
criteria have to be met. First, it must be sensitive to O2 levels that occur during 
vasodilation in the intact heart [2]. Second, it must be a local event that does not 
require neuronal/circulating hormonal inputs. Third, it must respond to change in O2 
tension in a dynamic and timely manner so that the artery can respond promptly to 
the increased metabolic needs where supply can be matched to the demand. Finally, 
it must lead to lowering of [Ca
2+
]i as this is the pre-requisite for vasorelaxation. 
We hypothesize that hypoxia may regulate [Ca
2+
]i by either directly modulating 
Ca
2+
 homeostasis or indirectly regulating K
+
 channels and membrane potential. In 
order to evaluate the effect of hypoxia on Ca
2+
 homeostasis, it was necessary to 
elevate [Ca
2+
]i. The reduction in [Ca
2+
]i will be more readily detected when [Ca
2+
]i 
was increased, and arguably hypoxic vasodilation occurs when artery is already 
somewhat contracted and [Ca
2+
]i elevated. PDGF-BB, an α1-adrenergic agonist 
phenylephrine (PE), prostaglandin F2α (PGF2α) and thromboxane A2 receptor 
(prostanoid TP receptor) agonist (U46619) are known vasoconstrictors which cause 
increases in [Ca
2+
]i and smooth muscle contraction via the activation of second 
messenger signaling cascade [92, 112]. An increase in [K+]o also results in 
increases in [Ca
2+
]i due to membrane depolarization and opening of VDCCs without 
receptor activation. In this chapter, changes in [Ca
2+
]i were reported using membrane 
permeable Ca
2+ 
sensitive dyes, Fluo-4 AM and Fura-Red AM. A fluorescent 
membrane potential dependent dye, DiBAC4(3), was used to monitor changes in 
membrane potential [250]. Membrane hyperpolarization caused by activation of K
+
 
channels should be diminished when [K
+
]o is elevated. The role of specific K
+
 
channel subtypes involved can be elucidated using specific pharmacological 
inhibitors. For instance, KATP channels are inhibited by the glibenclamide, BKCa 
channels are inhibited by penitrem A and iberitoxin, IKCa and SKCa channels are 
inhibited by tram34 and apamin, respectively, whilst Kir channels are inhibited by 
low concentration of Ba
2+
 [251, 252]. Ultimately, the identity of K
+
 channels 
involved in hypoxia, if any, could be examined using patch clamp technique [99, 203, 
251 
 
252].  
 
5.2 Aims 
The aim of this chapter is to evaluate the effect of hypoxia on [Ca
2+
]i and 
membrane potential. Roles of different types of K
+
 channels in setting HCASMC 
membrane potential were also investigated. 
 
5.3 Results  
5.3.1 Effect of hypoxia on Ca
2+
 homeostasis in single HCASMCs 
5.3.1.1 Imaging with Ca
2+
 reporting fluorescent indicators 
Fluo-4 AM and Fura-Red AM are both membrane permeable dyes which 
become Ca
2+
 sensitive when de-esterified and trapped within the cells. Binding to 
Ca
2+
 increases Fluo-4 fluorescence signal and decreases that of Fura-Red. Figure 5.1 
shows that application of 20 ng/ml PDGF-BB increased Ca
2+
 concentration in both 
cytosolic and nuclear region. Some cells showed spontaneous Ca
2+
 oscillations 
without vasoconstrictors. Representative Ca
2+
 oscillations occurring spontaneously 
or induced by vasoconstrictors are shown in Figure 5.2. Application of 
vasoconstrictors increased frequency of Ca
2+
 oscillations in the cells with 
spontaneous oscillations at rest and triggered Ca
2+
 oscillations in quiescent cells 
(Figure 5.2A and 5.2B). Increasing [K
+
]o from 5 mM to 80 mM not only triggered 
Ca
2+
 oscillations in the cells, but also caused gradual elevation in the basal [Ca
2+
]i 
(Figure 5.2C). These results suggest that Ca
2+
 homeostasis can be investigated using 
HCASMCs.  
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Figure 5.1: Ca
2+
 measurement with Fluo-4. (A) Images of HCASMCs loaded with 
Fluo-4 before (upper panel) and after (lower panel) treatment with 20 ng/ml 
PDGF-BB. (B) Time course of cytoplasmic (upper panel) and nuclear (lower panel) 
Ca
2+
 signal changes. 
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Figure 5.2: Ca
2+
 oscillations. (A) 20 ng/ml PDGF-BB increased Ca
2+
 oscillation 
frequency reported by Fluo-4. (B) 20 ng/ml PDGF-BB triggered Ca
2+
 oscillations in 
cell without spontaneous oscillations at rest. (C) Ca
2+
 oscillations and gradual [Ca
2+
]i 
increase induced by 80 mM K
+
 reported by Fura-Red fluorescence. Note that 
Fura-Red signal decreases when [Ca
2+
]i rises. 
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5.3.1.2 Analysis of Ca
2+
 measurements 
In order to quantify Ca
2+
 oscillations, four basic parameters, amplitude (A), 
frequency (F), amplitude multiple frequency (AxF) and area under curve (AUC) 
were analyzed. Amplitude was corrected and calculated as (Fp-F0)/F0, where Fp is 
the measurement at the peak and F0 is the nearest baseline measurement. Frequency 
was presented as the number of oscillations per hour (/hr), and AxF is the product of 
amplitude and frequency. AUC of Ca
2+
 oscillations was determined with Matalab 
software. After fractional fluorescence of Fluo-4 counts (F/F0) was corrected for the 
drift in basal line, AUC of each oscillation was calculated by a trapezoid integration 
method. A representative analysis is shown in Figure 5.3.   
 
 
Figure 5.3: Analysis of Ca
2+
 oscillations with Matalab. Fractional fluorescence of 
Fluo-4 (blue) was corrected using the regression of basal line (dark green). The AUC 
of each oscillation was calculated with trapezoid integration method from the 
corrected curve (red) with horizontal new baseline (light green) and reported by the 
software (blue cross, right panel). 
 
5.3.1.3 Effect of vasoconstrictors on [Ca
2+
]i 
In order to study the effect of hypoxia on [Ca
2+
]i, we first aimed to elevate 
[Ca
2+
]i using various vasoconstricting agents. Culturing of SMCs is known to change 
the phenotype including loss of receptors/signal transduction cascade that normally 
trigger elevation in [Ca
2+
]i [253, 254]. A23187, a Ca
2+
 ionophore, was used first as 
positive control. Application of A23187 increased [Ca
2+
]i immediately with the peak 
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reaching approximately 5 fold, and this is likely to be maximum fractional increase 
in single HCASMCs under our experimental condition (Figure 5.4). Next 
receptor-mediated vasoconstrictors, PDGF-BB, PE, PGF2α and U46619, as well as 
high K
+
, were tested (Figure 5.5-5.9). PE had no effect on most of the cells. In cells 
that responded to PE (8 out of 34 cells), PE induced an increase in amplitude from 
0.26±0.17 to 2.29±0.74, frequency from 4.64±3.05 to 11.75±2.75, AxF from 
4.80±3.15 to 19.83±4.63; AUC from 0.13±0.08 to 1.44±0.36, washing with PSS 
reduced amplitude to 1.25±0.80, frequency to 7.00±2.67, AxF to 9.30±4.70 and 
AUC to 0.53±0.28 respectively (Figure 5.6). The effects of other vasoconstrictors 
and high K
+
 were summarized in Table 5.1. 
 
Table 5.1 The effects of vasoconstrictors and high K
+ 
on [Ca
2+
]i 
 Amplitude  
(A) 
Frequency  
(/hr, F) 
AxF Area under curve 
(AUC) 
 - + - + - + - + 
PDGF 
(n=18) 
0.86 
±0.35  
2.39** 
±0.31 
2.58 
±0.95 
10.40*** 
±1.03 
6.89 
±2.95 
23.33** 
±3.56 
0.49 
±0.22 
1.74*** 
±0.23 
PGF2α 
(n=10) 
0 2.48 
±0.45 
0 14.80 
±1.44 
0 38.62 
±10.19 
0 1.30 
±0.27 
U46619 
(n=11) 
0.21 
±0.10 
1.69*** 
±0.29 
4.73 
±2.36 
10.36 
±2.54 
2.34 
±1.06 
12.22*** 
±1.27 
0.10 
±0.05 
0.94* 
±0.16 
80 K
+
 
(n=9) 
0.22 
±0.12 
0.67* 
±0.08 
4.44 
±2.42 
16.40** 
±2.11 
2.81 
±1.49 
11.16** 
±2.21 
0.12 
±0.06 
0.30* 
±0.03 
*For PE data, refer to the text. 
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Figure 5.4: Effect of A23187 on intracellular Ca
2+
. Application of 10 μM A23187 
increased fractional fluorescence (F/F0) of Fluo-4 (n=3). 
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Figure 5.5: Effect of PDGF-BB on intracellular Ca
2+
. Parameters of Ca
2+
 
oscillations. Corrected amplitude (A), frequency (B), AxF (C) and AUC (D) under 
unstimulated (basal) conditions, following application of 20 ng/ml PDGF-BB and 
after wash with PSS (n=18, including 6 cells with spontaneous oscillations). 
A B 
C D 
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Figure 5.6: Effect of PE on intracellular Ca
2+
. Parameters of Ca
2+
 oscillations. 
Corrected amplitude (A), frequency (B), AxF (C) and AUC (D) under unstimulated 
(basal) conditions, following application of 10 μM PE and after wash with PSS (n=8, 
including 2 cells with spontaneous oscillations).  
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Figure 5.7: Effect of PGF2α on intracellular Ca2+. Parameters of Ca2+ oscillations. 
Corrected amplitude (A), frequency (B), AxF (C) and AUC (D) under unstimulated 
(basal) conditions, following application of 10 μM PGF2α and after wash with PSS 
(n=10, all the cells without spontaneous oscillations). 
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Figure 5.8: Effect of U46619 on intracellular Ca
2+
. Parameters of Ca
2+
 oscillations. 
Corrected amplitude (A), frequency (B), AxF (C) and AUC (D) under unstimulated 
(basal) conditions, following application of 1 μM U46619 and after wash with PSS 
(n=11, including 4 cells with spontaneous oscillations). 
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Figure 5.9: Effect of high K
+
 on intracellular Ca
2+
. Elevation of extracellular K
+
 
from 5 mM to 80 mM increased Ca
2+
 oscillations, indicated by corrected amplitude 
(A), frequency (B), AxF (C) and AUC (D) (n=9, including 3 cells with spontaneous 
oscillations). 
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5.3.1.4 Effect of hypoxia on intracellular Ca
2+
 
Vasoconstrictors either triggered or enhanced Ca
2+
 oscillations in single 
HCASMCs suggesting that at least some of the Ca
2+
 handling mechanisms are still 
intact in those cells. Next, the effect of hypoxia was examined. Figure 5.10A shows 
that Ca
2+
 oscillations induced by application of 20 ng/ml PDGF-BB is stable 
although there was a small decrease in frequency and/or amplitude in some cells. 
Exposure to hypoxia caused a decrease in Ca
2+
 oscillations, and a representative 
example is shown in Figure 5.10B. In the presence of 20 ng/ml PDGF-BB, Ca
2+
 
oscillations were observed with an amplitude of 1.34±0.23, a frequency (/hr) of 
22.86±2.86, AxF of 31.20±4.90, and AUC of 0.53±0.08. Exposure to hypoxia 
(1% O2) for 10 minutes caused decreases in amplitude to 0.78±0.16, frequency (/hr) 
to 17.14±2.76, AxF to 12.47±2.96, AUC to 0.46±0.11 (Figure 5.11). Exposure to 
hypoxia for 30 minutes decreased 10 μM PGF2α induced Ca2+ oscillations with 
amplitude from 1.99±0.49 to 1.37±0.53, frequency (/hr) from 15.56±2.22 to 17.67
±3.40, AxF from 29.31±6.40 to 17.83±2.44, and AUC from 0.76±0.22 to 0.47±
0.40 (Figure 5.12). Exposure to hypoxia for 25-30 minutes also decreased 1 μM 
U46619 induced Ca
2+
 oscillations with amplitude from 0.83±0.28 to 0.65±0.13, 
frequency (/hr) from 25.89±2.58 to 16.68±3.25, AxF from 33.74±12.40 to 13.98
±5.02, and AUC from 0.43±0.08 to 0.21±0.05 (Figure 5.13). Acute hypoxia had a 
minimum effect on basal Ca
2+
 of the cells without oscillations, but reduced Ca
2+
 
oscillations of single HCASMC with spontaneous oscillations (Figure 5.14). Taken 
together, hypoxia significantly reduced amplitude/amplitude and frequency of Ca
2+
 
oscillations in HCASMCs. Note that in some cells with spontaneous oscillations 
hypoxia not only reduced Ca
2+
 oscillations but also seemed to decrease basal Ca
2+
 
(e.g. Figure 5.14). 
In order to examine the role of VDCCs in Ca
2+
 responses, a dihydropyridine 
calcium channel blocker nimodipine was applied. When cells were preincubated with 
a KATP channel opener, pinacidil (10 µM) for 10 mins, 20 ng/ml PDGF-BB still 
caused a transient rise in intracellular Ca
2+
 (Figure 5.15). Blocking VDCCs by 
nimodipine (10 µM) for 10 minutes caused variable response. Application of 
260 
 
nimodipine induced no change or little change in basal Ca
2+
 or spontaneous Ca
2+
 
oscillations in some cells (Figure 5.16). In another experiment, a decrease of 13.03
±2.05% in the basal fluorescence was observed in response to nimodipine (n=7, 
p=0.001). Hypoxia caused a decrease in high K
+
 induced Ca
2+
 oscillations, but not 
significantly, indicating an effect, at least in part, independent of VDCCs (Figure 
5.17). It should be emphasized that these experiments are preliminary, and more 
work is required to examine the role of VDCCs in hypoxia properly. 
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Figure 5.10: Effect of hypoxia on Ca
2+
 oscillations. (A) Ca
2+
 oscillations induced 
by 20 ng/ml PDGF-BB. (B) Hypoxia caused attenuation of Ca
2+
 oscillations induced 
by 10 μM PGF2α. 
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Figure 5.11: Effect of hypoxia on PDGF-BB induced Ca
2+
 oscillations. Effect of 
hypoxia (1% O2) on amplitude (A), frequency (B), AxF (C), and AUC (D) of Ca
2+
 
oscillations induced by PDGF-BB (n=7).   
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Figure 5.12: Effect of hypoxia on PGF2α induced Ca2+ oscillations. Effect of 
hypoxia (1% O2) on amplitude (A), frequency (B), AxF (C), and AUC (D) of Ca
2+
 
oscillations induced by PGF2α (n=6). 
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Figure 5.13: Effect of hypoxia on U46619 induced Ca
2+
 oscillations. Effect of 
hypoxia (1% O2) on amplitude (A), frequency (B), AxF (C), and AUC (D) of Ca
2+
 
oscillations induced by U46619 (n=17). 
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Figure 5.14: Effect of hypoxia on basal and spontaneous Ca
2+
 oscillations. (A) 
Exposure to hypoxia for 10 mins had little effect on basal Ca
2+
 of the cells without 
spontaneous oscillations (n=21). (B) Hypoxia reduced spontaneous Ca
2+
 oscillations 
of single HCASMCs (n=25). 
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Figure 5.15: Effect of PDGF-BB on intracellular Ca
2+
 in the presence of 
pinacidil. Pinacidil (10 µM) was applied for 10 minutes before, and throughout 
application of PDGF-BB. 
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Figure 5.16: Effect of nimodipine on basal Ca
2+
 and spontaneous Ca
2+
 
oscillations. (A) 10 µM nimodipine induced no change in basal Ca
2+
 level for a 10 
mins period. (B) Spontaneous Ca
2+
 oscillations were not inhibited by 10 µM 
nimodipine for a 10 mins period.  
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Figure 5.17: Effect of hypoxia on high K
+
 induced Ca
2+
 oscillations. Exposure to 
hypoxia for 15 minutes caused a non-significant decrease in Ca
2+
 oscillations 
induced by high K
+
. The cells in this experiment were loaded with Fura-Red (n=3). 
 
5.3.2 Effect of hypoxia on membrane potential of single HCASMCs 
Hypoxia caused significant reduction in Ca
2+
 oscillations induced by 
vasoconstrictors. However, the inconsistency in cell response including presence or 
absence of spontaneous Ca
2+
 oscillations at rest made interpretation of the results 
difficult. Crucially, lack of nimodipine effect on Ca
2+
 oscillations strongly suggests 
that cyclic fluctuation in [Ca
2+
]i may be explained by Ca
2+
 release from, and 
sequestration to, SR (Figure 5.16). It follows that the mechanisms by which hypoxia 
causes reduction in Ca
2+
 oscillations may be largely independent of membrane 
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hyperpolarization. That said, K
+
 channels seem important in HCASMCs as elevation 
of [K
+
]o not only induced Ca
2+
 oscillations but also gradual increase in basal [Ca
2+
]i 
(Figure 5.2C). To further investigate the role of K
+
 channels in HCASMCs, 
experiments were carried out to measure changes in membrane potential. Using a 
membrane potential-sensitive dye DiBAC4(3), we addressed the following questions: 
(i) Which K
+
 channel(s) play a major role in setting resting membrane potential of 
HCASMCs? (ii) What are the effects of metabolic inhibitors/hypoxia on membrane 
potential? (iii) Which K
+
 channels are involved in changes caused by metabolic 
inhibitors/hypoxia? 
 
5.3.2.1 Measurement of membrane potential with DiBAC4(3) 
DiBAC4(3) is a slow-response potential-sensitive fluorescent probe (Figure 
5.18 A). It is an appropriate reporter of membrane potential change in HCASMCs 
where depolarization and hyperpolarization are expected to be slow and steady. It is 
permeable to plasma membrane, accumulating in the cytoplasm following a Nernst 
equilibrium distribution [255]. The anionic dye in the cell binds to intracellular 
proteins or membrane resulting in an enhanced fluorescence and also a red spectral 
shift [256, 257]. Depolarization of membrane potential causes additional entry of the 
anionic dye into the cell, increasing the fluorescence signal. Hyperpolarization, on 
the other hand, results in a decrease in the signal (Figure 5.18 B). Compared to 
cationic carbocyanines, DiBAC4(3) and related dyes are largely excluded from 
mitochondria due to their overall negative charge, making them primarily sensitive to 
plasma membrane potential. Initial experiments (n=3) characterized the correlation 
of the changes in the fluorescence (F/F0) with the millivolt (mV) change in K
+
 
equilibrium potential, calculated with Nernst equation using various concentrations 
of [K
+
]o (5, 30, and 80 mM). A representative characterization experiment is shown 
in Figure 5.19.  
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Figure 5.18: Distribution of DiBAC4(3) according to membrane potential. (A) 
Chemical structure of DiBAC4(3). (B) DiBAC4(3) molecules accumulate in cells 
following Nernst equilibrium distribution. Depolarization results in an additional 
accumulation of the dye and therefore an increase in fluorescence; conversely 
hyperpolarization causes a decrease in the fluorescence. 
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Figure 5.19: Characterization of DiBAC4(3) fluorescence. (A) Images of 
DiBAC4(3) loaded cells at 5 mM, 30 mM and 80 mM [K
+
]o. (B) DiBAC4(3) 
fluorescence changes upon increasing concentrations of [K
+
]o. (C) Relationship 
between changes in DiBAC4(3) fluorescence and EK, calculated by Nernst equation. 
The slope of the regression line is ~2.13%/mV (n=3, cells contracted or moved were 
excluded). 
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5.3.2.2 Identification of K
+
 channels involved in resting membrane potential 
Preliminary experiments using DiBAC4(3) clearly indicated that HCASMCs 
depolarize in a [K
+
]o dependent manner, and therefore K
+
 channels are important in 
setting resting membrane potential. Next, a series of K
+
 channel inhibitors were 
applied to dissect which K
+
 channels are involved. Glibenclamide, penitrem A, 
tram34, apamin, BaCl2 and XE991 are inhibitors of KATP, BKCa, IKCa, SKCa, Kir and 
Kv7 channels. 
There was no change in DiBAC4(3) fluorescence in control studies where 
nothing, DMSO, or water was applied (Figure 5.20), suggesting membrane potential 
is stable. Application of K
+
 channel inhibitors for 10-15 minutes changed the 
fractional fluorescence of DiBAC4(3) by 54.94±8.18% (10 µM glibenclamide, 
n=37, p=0.000), 1.10±2.69% (200 nM penitrem A, n=18), -2.50±2.08 (1 µM 
tram34, n=13), 0.08±0.48% (200 nM apamin, n=32), 69.95±7.46% (25 µM BaCl2, 
n=26, p=0.000), and 3.87±1.40% (10 µM XE991, n=14) respectively (Figure 5.21). 
Changes caused by glibenclamide and BaCl2 are highly significant, suggesting that 
among all the K
+
 channels examined, KATP and Kir channels play important roles in 
setting resting membrane potential of HCASMCs. BaCl2 also caused an increase in 
the fluorescence in the presence of 10 µM glibenclamide (data not shown). At the 
concentration used, BaCl2 should act as a specific blocker of Kir channels [43, 252], 
and additive effect of glibenclamde and BaCl2 further support the hypothesis that 
both KATP channels and Kir channels regulate resting membrane potential in 
HCASMCs. 
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Figure 5.20: Changes of DiBAC4(3) fluorescence in control studies. (A) Imaging 
the cells for a period of 20 minutes had no effect on DiBAC4(3) fluorescence (n=42). 
(B) Application of DMSO for 10 minutes had no effect on DiBAC4(3) fluorescence 
(n=51). (C) Application of H2O for 10 minutes had no effect on DiBAC4(3) 
fluorescence (n=17). Mean±SEM of DiBAC4(3) fluorescence just before the 
treatment and at the end point was shown in right panels. 
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Figure 5.21: Effects of K
+
 channels in regulating resting membrane potential of 
HCASMCs. (A) The effect of 10 µM glibenclamide. (B) The effect of 200 nM 
penitrem A. (C) The effect of 1 µM tram34. (D) The effect of 200 nM apamin. (E) 
The effect of 25 µM BaCl2. (F) The effect of 10 µM XE991. (G) A summary of 
percent fold change of fractional fluorescence of DiBAC4(3) after application of K
+
 
channel inhibitors. 
 
A 
C 
E 
G 
F 
B 
D 
271 
 
5.3.2.3 Pharmacological modulation of K
+
 channels 
Response and sensitivity of K
+
 channels to pharmacological modulators can be 
different due to the origin of the artery. For example, the majority of HCASMC BKCa 
channels contain β1 subunit that is reported to have a high sensitivity to Ca2+ and 
little sensitivity to IbTX and penitrem A [258-261]. Thus, the changes in membrane 
potential of HCASMCs were further characterized in response to a variety of K
+
 
channel agonists and antagonists. 10 µM adenosine, a physiological vasodilator 
thought to be important in coronary circulation, caused a reduction in DiBAC4(3) 
fluorescence by 30.88±3.25% (Figure 5.22). KATP channel opener, pinacidil (10 µM) 
decreased DiBAC4(3) fluorescence by 31.62±4.02% (n=14), and subsequent 
application of glibenclamide (10 µM) fully reversed the change (n=10). Note that 
higher signal after application of glibenclamide above base line indicates that KATP 
channels are open at rest (see Figure 5.21). Pinacidil was ineffective when cells were 
pre-incubated with 10 µM glibenclamide (n=17) (Figure 5.23). NS1619 (10 µM) 
caused a reduction in DiBAC4(3) fluorescence by 41.54±2.01% (n=95). However, 
application of 200 nM penitrem A (n=68) or 100 nM IbTX (n=25) did not block 
NS1619 induced hyperpolarization. Pre-treating the cells with 100 nM IbTX for 10 
mins also had no influence on the effect induced by NS1619 (n=18) (Figure 5.24). 1 
µM NS11021, a potent BKCa channel activator, induced a decrease in DiBAC4(3) 
signal by 26.17±7.16% (n=6). Higher concentration of NS11021 (10 µM) caused a 
larger effect on membrane potential, however this effect was also unaffected by 100 
nM IbTX (64.74±1.81% vs 66.47±1.82%, NS11021 and NS11021 plus IbTX 
respectively, n=36) (Figure 5.25). Application of 1 µM SKA31, an activator of 
IKCa/SKCa, decreased DiBAC4(3) fluorescence by 30.46±4.08% (n=31), and 10 µM 
SKA31 by 51.21±1.55% (n=14).The effect from 1 µM SKA31 was not inhibited by 
200 nM apamin alone (n=11), but by a combination of 200 nM apamin and 1 µM 
tram34 (n=15) (Figure 5.26). 
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Figure 5.22: Effect of adenosine on plasma membrane potential. (A) Time course 
of fractional fluorescence of cells treated with 10 μM adenosine. (B) Mean±SEM of 
DiBAC4(3) fluorescence during control condition (at 5 min) and after (at 15 min) 
application of 10 µM adenosine (n=21). 
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Figure 5.23: Effect of KATP channel modulators on membrane potential. (A) 
Application of 10 µM pinacidil caused hyperpolarization of plasma membrane 
(n=14). (B) Subsequent addition of 10 µM glibenclamide increased the signal above 
the basal level significantly (n=10). (C) 10 µM glibenclamide caused an increase in 
DiBAC4(3) signal, and subsequent addition of 10 µM pinacidil had no effect (n=17). 
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Figure 5.24: Effect of NS1619 on membrane potential. (A) Application of 10 µM 
NS1619 caused a rapid and sustained hyperpolarization (n=95). (B) Subsequent 
application of 200 nM penitrem A (n=68) or, (C) 100 nM IbTX after NS1619 (n=25) 
or, (D) pre-incubation with 100 nM IbTX for 10 mins did not alter the effect of 
NS1619 (n=18). 
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Figure 5.25: Effect of NS11021 on membrane potential. (A) Application of 1 µM 
NS11021 resulted in a decrease in fractional fluorescence of DiBAC4(3) (n=6). (B) 
The response of membrane potential to application of 10 µM NS11021 followed by 
100 nM IbTX. 10 μM NS11021 caused a highly significant decrease in fluorescence, 
and the effect was not affected by application of 100 nM IbTX (n=36). 
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Figure 5.26: Effect of IKCa and SKCa channel modulators on membrane 
potential. (A) 1 µM and (B) 10 µM SKA31 (n= 31&14 respectively) caused a 
reduction in the fractional fluorescence of DiBAC4(3). (C) The effect of 1 µM 
SKA31 was not inhibited by 200 nM apamin (n=11), but by 200 nM apamin plus 1 
µM tram34 (D, n=5). 
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5.3.2.4 Effect of metabolic inhibitors/hypoxia on membrane potential 
In the previous chapters, we have reported the effect of metabolic inhibitors and 
hypoxia on cellular ATP and ATP:ADP ratio of HCASMCs. Here experiments were 
repeated to investigate the effects of metabolic inhibitors and hypoxia on membrane 
potential.  
Application of 1 µM rotenone decreased DiBAC4(3) fluorescence signal by 
34.44±1.29% (n=91), and this effect was inhibited by high [K+]o (n=4) (Figure 
5.27), suggesting hyperpolarization depends on the opening of K
+
 channels. 
Inhibiting mitochondrial complex III by 1 µM antimycin induced a decrease by 
40.16±2.72% in DiBAC4(3) fluorescence (n=25), which could be blocked by 10 
µM glibenclamide or 60 K
+
 (Figure 5.28), an indication that KATP channels may be 
involved. 6 µM oligomycin also caused a reduction in fluorescence signal by 41.67
±3.05% (n=10) (Figure 5.29A). However, addition of 1 µM CCCP caused a rise in 
DiBAC4(3) fluorescence (n=23) (Figure 5.29B). The possible explanation for this 
could be that application of CCCP resulted in an increase in DiBAC4(3) dye uptake 
by the cells [262].  
Hypoxia (1% O2) induced a decrease in DiBAC4(3) fluorescence by 12.37±
1.31% (n=72). The effect caused by hypoxia is reversible after re-administration of 
O2 (n=7), and was blocked by 60 K
+
 (n=11) (Figure 5.30), suggesting the 
involvement of K
+
 channels. Exposure to hypoxia resulted in a decrease in 
DiBAC4(3) fluorescence by 13.74±3.12% in the presence of 10 µM of pinacidil 
(n=5), by 11.21±1.43% in the presence of 10 µM of glibenclamide (n=36), by 17.08
±2.44% in the presence of 25 µM BaCl2 (n=14), by 11.70±2.14% in the presence 
of 10 µM glibenclamide and 25 µM BaCl2 (n=25), by 16.07±2.92% in the presence 
of 100 nM IbTX (n=17), by 17.28±2.40% in the presence of 200 nM penitrem 
(n=14) (Figure 5.31). These results indicate that K
+
 channels are likely to be 
involved in hypoxia-induced membrane hyperpolarization reported by DiBAC4(3), 
but classic K
+
 channel inhibitors, when applied singly, failed to block the effect of 
hypoxia. 
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Figure 5.27: Effect of rotenone on membrane potential. (A) Application of 1 µM 
rotenone caused a decrease in DiBAC4(3) fluorescence (n=91). (B) Increasing K
+
 
concentration of extracellular solution from 5 mM to 60 mM abolished the effect of 
rotenone (n=4). 
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Figure 5.28: Effect of antimycin on membrane potential. (A) 1 µM antimycin 
caused membrane potential hyperpolarization (n=25). (B) 10 µM glibenclamide 
inhibited the effect of antimycin (n=22). (C) The effect of antimycin was inhibited by 
60 K
+ 
(n=6). 
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Figure 5.29: Effect of oligomycin and CCCP on membrane potential. (A) 
Application of 6 µM oligomycin induced a decrease in fractional fluorescence of 
DiBAC4(3) (n=10). (B) 1 µM CCCP caused an increase in DiBAC4(3) fluorescence 
(n=23). 
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Figure 5.30: Effect of hypoxia on membrane potential. (A) Exposing the cells to 
hypoxia decreased fractional fluorescence of DiBAC4(3) (n=72). (B) Recovery of 
HCASMCs from hypoxia caused membrane potential depolarization (n=7). (C) The 
effect of hypoxia was inhibited by 60 K
+ 
(n=11). 
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Figure 5.31: Role of K
+
 channels in hypoxia induced hyperpolarization. The 
effect of hypoxia on membrane potential in the presence of 10 µM pinacidil (A, n=5), 
A 
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D 
E 
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10 µM glibenclamide (B, n=36), 25 µM BaCl2 (C, n=14), 10 µM glibenclamide plus 
25 µM BaCl2 (D, n=25), 100 nM IbTX (E, n=17), 200 nM penitrem A (F, n=14). 
 
5.4 Discussion 
Many studies suggested that hypoxia causes vasodilation by decreasing [Ca
2+
]i. 
Some investigations indicated that hypoxia has a direct effect on Ca
2+
 channels while 
others have shown that hypoxia causes membrane potential hyperpolarization and a 
closure of VDCCs [33, 34, 44, 45]. The observation that hypoxia inhibited Ca
2+
 
oscillations in the presence of vasoconstrictors (Figures 5.11, 5.12&5.13) fits to the 
hypothesis that hypoxia causes coronary artery dilation by reducing [Ca
2+
]i. However, 
the application of nimodipine did not modify the Ca
2+
 oscillations, suggesting Ca
2+
 
oscillations are largely independent of VDCCs (Figure 5.16). In the present study, 
however, the effect of nimodipine was not tested under hypoxic condition, and 
therefore we do not know whether nimodipine antagonizes inhibitory effect of 
hypoxia on Ca
2+
 oscillations. At this preliminary stage, we are far from providing 
cellular events underpinning the inhibition of Ca
2+
 oscillations by hypoxia, but it will 
be interesting to see whether hypoxia reduces SR Ca
2+
 content.   
Even though results of Ca
2+
 measurements in the current work are very limited 
and Ca
2+
 handling of HCASMCs is far from clear, it seems useful to discuss Ca
2+
 
homeostasis based on its central role in many type of cells. Ca
2+
 is a ubiquitous 
second messenger and the concentration difference between extracellular (in mM 
range) and intracellular spaces (in sub μM range) is the largest for Ca2+. This allows 
Ca
2+
 to play spatially and temporally important roles in signal transduction cascade. 
As discussed above, the absolute value of [Ca
2+
]i is important, but in some cases, 
activation of events may occur as a form of Ca
2+
 oscillations where the frequency, 
not just amplitude, may be an important form of signaling. This is an interesting form 
of carrying information as prolonged increase in [Ca
2+
]i is generally harmful to the 
cells.   
The phenomenon of Ca
2+
 oscillations was first observed in hepatocytes [263]. In 
HCASMCs, some cells were quiescent at rest while others exhibited spontaneous 
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Ca
2+
 oscillations. The selective α1-adrenergic receptor agonist, PE, had no effect on 
most of the cells. This is likely to be due to loss of the receptors or a decrease in the 
sensitivity of the receptors. However, PDGF-BB, PGF2α, U46619 and 80 mM K+ all 
increased Ca
2+
 oscillations in the majority of HCASMCs. Combined with the results 
that hypoxia reliably inhibited Ca
2+
 oscillations, HCASMCs seem a good model to 
study Ca
2+
 handling and the effect of hypoxia in future. 
Although not examined in the current study, the possibility that hypoxia may 
cause coronary artery relaxation independent of [Ca
2+
]i should be also considered in 
the future. A basic model of receptor mediated increase in [Ca
2+
]i and Ca
2+
 
sensitization in HCASMCs is shown in Figure 5.32, both of them are possible 
controlling points for hypoxia. Hypoxia not only directly decreases [Ca
2+
]i, but also 
can cause Ca
2+ 
desensitization in which way it induces vasodilation without a 
decrease in [Ca
2+
]i [264, 265]. Furthermore, other studies provided the evidence that 
hypoxia directly modulates Ca
2+
 channels showing a reduction in O2 rapidly 
inhibited ICa, and this effect was reversible [45, 266]. Further support for hypothesis 
that hypoxia directly modulates VDCC comes from the study where pretreating 
aortic rings with L-type VDCC blockers abolished hypoxia induced dilation [267]. In 
the current study, we also showed that hypoxia seem to decrease Ca
2+
 oscillations in 
the presence of high K
+
 (60 mM), but the effect was not significant (Figure 5.17). 
However, this set of experiment consists of 3 cells, a number too small to be 
statistically reliable. Had a larger number of cells tested, it is conceivable that there 
was a statistically significant difference. If so, our result would have been consistent 
with the work of Smani et al. (2002), in which they demonstrated in isolated human 
and porcine myocytes, low O2 tension decreased L-type Ca
2+
 current and reduced 
cytosolic [Ca
2+
] and this effect was independent of K
+
 channel activation [77]. 
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Figure 5.32 Mechanisms of VSMC contraction. AA, arachidonic acid; G, 
guanosine-5’-triphosphate-binding protein; IP3R, inositol trisphosphate receptor; 
MLC20, regulatory light chain of myosin (20 kDa); MLCK, myosin light chain kinase; 
MYPT, myosin phosphatase target subunit; SR, sarcoplasmic reticulum. (Modified 
from Akata, 2007 [92]) 
 
It is important to note that Ca
2+
 signaling in SMC is crucial not only for 
contraction but other functions including proliferation and bioenergetics. In this 
context, spatial compartmentalization of Ca
2+
 may play an important role. Apart from 
SR, nucleus and mitochondria are thought to be Ca
2+
 storage sites, and these 
organelles are often found to be close to each other. In Ca
2+
 oscillations of 
HCASMCs, we observed intracellular Ca
2+
 increase was always accompanied by an 
increase in nuclear Ca
2+
 (Figure 5.1). It has been suggested that the inner surface of 
nuclear envelop membrane of VSMCs contain IP3 receptors [268, 269]. Changes in 
nuclear Ca
2+
 concentration may play a vital role in gene regulation, expression, and 
modulate transcription factors such as cAMP response element-binding protein 
(CREB) and nuclear factor of activated T-cells (NFAT) [270, 271]. However, there 
are very limited studies in this, and the mechanisms involved are controversial and 
still poorly understood. 
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Mitochondria have been suggested as a Ca
2+
 storage site in a wide range of cell 
types [272]. It is generally recognized that SERCA, sarcolemmal NCX and 
plasmalemmal Ca
2+
 ATPase are the main routes for cytosolic Ca
2+
 removal, and 
mitochondria Ca
2+
 uptake seems to account for a small proportion when compare 
with them [272]. It has been shown that mitochondrial Ca
2+
 plays an important role 
in many cell types including VSMCs, especially in local Ca
2+
 buffering and ATP 
synthesis [218, 273-275]. The latter may be particularly important in contracting 
SMCs where increase in mitochondrial Ca
2+
 affects enzymes involved in oxidative 
ATP production (i.e. PDH, G3PDH) [275]. Moreover, it has also been shown in rat 
aortic SMCs that there is a close relationship between mitochondria and SR, and 
application of FCCP completely abolished the large, transient mitochondrial Ca
2+
 
increase induced by agonists [276]. 
K
+
 channels are clearly involved in setting resting membrane potential in 
HCASMCs, as application of 10 µM glibenclamide and 25 µM BaCl2 caused 
significant increase in DiBAC4(3) signal (Figure 5.21). 25 µM BaCl2 also caused 
membrane potential depolarization in the presence of 10 µM glibenclamide. 
Therefore, we conclude both KATP and Kir contribute to resting membrane potential 
of HCASMCs. Further characterization of K
+
 channels using selective activators and 
inhibitors showed that HCASMCs functionally express KATP, BKCa, IKCa/SKCa 
channels (Figures 5.23, 5.24, 5.25&5.26). In HCASMCs, changes in membrane 
potential caused by 10 µM NS1619 and 10 µM NS11021, activators of BKCa, were 
not inhibited by IbTX, and this could be due to the specific β subunit in human 
coronary BKCa channels. A total of four types of modulatory β subunits have been 
identified, and in HCASMCs the majority of BKCa channels contain β1 subunit 
(KCNMB1) [258], which has higher sensitivity to Ca
2+
 and a lower sensitivity to 
IbTX [259].   
Most puzzling results regarding hypoxia effects on membrane potential was that 
none of the traditional K
+
 channel inhibitors eliminated the reduction in signal 
caused by hypoxia, although the effect of hypoxia was absent in high [K
+
]o (Figures 
5.30 & 5.31). Even if direct membrane potential measurement using current patch 
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clamp is preferable to DiBAC4(3) experiments, the fact that hypoxia reduced signal, 
and high [K
+
]o prevented this effect strongly suggest hypoxia activates K
+
 channels. 
The lack of effect of traditional K
+
 channel inhibitors when applied singly may be 
explained by the hypothesis that more than one K
+
 channels are involved, and so 
combination of antagonists are required to block hypoxia effect or K2P channels are 
important in hypoxic hyperpolarization studying of which is difficult due to a lack in 
specific channel inhibitors. These unresolved questions ultimately require current 
clamp experiments to be answered. 
In conclusion, HCASMCs retaining functional Ca
2+
 handling mechanisms and 
K
+
 channels that respond to hypoxia may be a useful model to examine further 
mechanisms by which [Ca
2+
]i may be lowered when PO2 is reduced. However, more 
work need to be done, ideally including patch clamp techniques. 
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Chapter 6     
Effect of Hypoxia and K+ Channel 
Modulators on HCASMCs 
Proliferation and Migration 
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6.1 Introduction 
HCASMCs obtained from Promocell originate from human coronary artery 
tunica media of RCA and LCA (LAD and LCX branches). Though cultured VSMCs 
are initially contractile phenotype, they undergo profound and reversible changes 
during cell culture as discussed earlier. This is because VSMCs maintain functional 
plasticity [277] and become synthetic phenotype triggered by local environmental 
stimuli [23, 278]. For example, physiological hypoxia induces erythropoiesis and 
angiogenesis, events useful in adaptive response for athletes [279-282]. More 
importantly in relation to this thesis, hypoxia results in contractile SMC 
dedifferentiation, migration and proliferation by re-entering cell cycle. This can be a 
pathological hypoxic response, causing atherosclerosis or vascular injury that may 
lead to cardiovascular malfunction and life-threatening outcomes [23, 24, 283]. 
Cell replication is a process highly energy dependent [284]. Hypoxia could 
regulate VSMC growth directly and indirectly via VSMC mitogens produced by ECs 
[285, 286]. Moreover, K
+
 and Ca
2+
 channels, typically known for regulation of 
vascular tone [1, 92, 112, 287], are upregulated/downregulated during phenotype 
switching in VSMC including HCASMCs [288-291]. Evidence suggests K
+
 channel 
activity is required in the initiation of G1 progression [291-293]. An increase in 
[Ca
2+
]i was reported to be required in G0/G1 transition by regulating transcription of 
some early genes [294-298]. Although many hypotheses have been suggested, the 
mechanisms underlying hypoxic phenotype changes in VSMCs still remain obscure. 
Because of the cell plasticity, it is necessary and important to characterize 
HCASMCs over passages to evaluate phenotype change that may occur during 
culture as this may have an unexpected influence on the results. Promocell suggests a 
maximum of 15 population doublings with monitoring of cell phenotype. We 
characterized HCASMCs at different passage points using WB and ICC with 
antibodies against three SMC specific markers: smooth muscle α-actin (α-SMC), an 
early-stage marker; calponin, a mid-stage marker; and smooth muscle myosin heavy 
chain (MHC), a late-stage marker [299, 300]. Multi-well plate based assays have 
been performed to evaluate cell proliferation and migration. Cell proliferation was 
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examined using MTT assay while cell migration was assessed using scratch wound 
assay and transwell assay. FACS analysis offers detailed information about the 
changes in cell cycle [301]. Pharmacological tools were used to address the potential 
roles of ion channels in phenotype change. 
 
6.2 Aims 
The time dependent changes in specific SMC markers in primary cultured 
HCASMCs were characterized in this chapter. The effect of hypoxia on HCASMC 
proliferation and migration and the possible roles of K
+
 channels were investigated. 
 
6.3 Results 
6.3.1 Cell growth and morphology 
First, basic features of HCASMCs were characterized at different points of cell 
culture including cell growth rate and morphology. Bright field images of the cells 
were captured using a DC5000 CMEX microscope camera (Euromex) at x10 
magnification. Figure 6.1A shows HCASMCs at P7, 10, 13 and 16 showing a 
stellate or spindle shape. In order to characterize the cell growth rate, the time taken 
for each passage to reach confluence was plotted (Figure 6.1B). The cell 
morphology measurement was carried out at confluence of ~50-60%. Albeit the size 
(minor axis, major axis and area) of HCASMCs increased during culture (Figure 
6.2), there was no statistical difference in cell Circ, AR, Round and Solidity (see 
Section 4.3.6 for details) (Figure 6.3). Analysis of these parameters indicates 
HCASMCs maintain an elongated spindle shaped morphology, typical for a 
differentiated phenotype, during the period passage used in this thesis. 
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Figure 6.1: Morphology of HCASMCs. (A) Pictures of cultured HCASMCs 
between P7 and P16. (B) As cell passage number increased, the time for cells to 
reach confluence increased. Linear regression (red dotted line) of early passages 
(P7-P12) divergent from old passages (≥P13). 
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Figure 6.2: Comparison of cell size between different passages. The size of major 
axis, minor axis and area (calculated from major and minor axis) increased as the cell 
passage number increased during culture. 
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Figure 6.3: Comparison of cell morphology between different passages. Analysis 
of shape descriptors (Circ, AR, Round and Solidity) indicates there is no significant 
difference between different passages of cultured HCASMCs. 
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6.3.2 Coomassie blue staining 
WB is an important procedure to detect specific proteins using antibodies [302]. 
In coomassie staining, the dye binds to all proteins, and its non-specific binding 
makes it a convenient and widely used overview of general protein expression. 
Coomassie staining can be used as loading control in WB analysis [303]. Therefore 
this procedure was used to compare the general distribution of proteins in HCASMC 
lysates across cell passages. Protein lysates from P7-P13 showed comparable 
distribution (Figure 6.4). 
 
 
Figure 6.4: Coomassie blue staining of electrophoretically separated protein 
sample from P7-P13. 
 
6.3.3 WB and ICC 
In order to further characterize specific SMC proteins, Western blotting was 
applied [302]. α-SMA with a molecular weight of 42 kDa was identified as a single 
band in lysates from P7 to P13 (Figure 6.5A). Calponin, which has a molecular 
weight of 34 kDa, was also identified throughout the passages (Figure 6.5B). When 
compared to α-SMA, calponin was less specific, indicated by a larger size band in 
both SMC and EC lysates (Figure 6.5B). Re-blotting of actin showed a single band 
at 42 kDa (Figure 6.5C). In ICC, HCASMCs were labelled with anti-α-SMA, 
anti-calponin and anti-MHC antibodies, and visualized by AF488-conjugated 
secondary antibodies (Figure 6.6). EC markers CD31 and vWF were used as 
negative controls in ICC, and these EC markers were absent from HCASMCs (data 
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not shown). Taken together, WB and ICC results show that there is little change in 
the expression pattern of signature SMC proteins with few, if any, contaminating ECs. 
Although this still does not guarantee there are no functional changes during cell 
culture, it seems that later passage HCASMCs used in this thesis still retain at least 
some property of early passage cells. 
  
A α-actin 
 
 
B Calponin 
 
 
C Actin 
 
 
 
Figure 6.5: WB of α-SMA and calponin in HCASMCs. (A) α-SMA in HCASMC 
lysate from P7-P13, single band at 42 kDa, 20 minutes exposure. (B) Calponin in 
HCASMC lysate from P7-P13, with a primary band at 34 kDa, 20 minutes exposure. 
(C) Actin (re-blotting) in HCASMC lysate from P7-P13, single band at 42 kDa, 15 
minutes exposure. All primary and secondary antibodies were diluted in TBST 
containing 5% non-fat powdered milk (Section 2.1.2). EC lysate was used as 
negative control. 
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Figure 6.6: ICC of α-SMA, calponin and MHC expression. Confocal images of 
HCASMCs labelled with primary antibodies (anti-α-SMA, anti-calponin and 
anti-MHC) and AF488-conjugated secondary antibodies. Scale bar is 50 µm. 
 
6.3.4 Effect of hypoxia on cell number determined by cell counting 
In order to assess the effect of hypoxia on cell growth, changes in cell number 
were first examined. HCASMCs were plated into 6-well or 24-well plate and 
incubated overnight. On the following day, cells were serum ‘starved’ with smooth 
muscle cell growth medium 2 containing 0.1% supplement (this low serum medium 
is indicated as SF medium in this chapter). Starved cells were then cultured using 
fully supplemented media under desired conditions. At the end of the experiment, 
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cells were lifted with trypsin and counted with Z1 Coulter particle counter. Serum 
deprivation halted the growth of HCASMCs, indicated by a smaller cell number in 
SF group (Figure 6.7). Inhibiting OXPHOS of HCASMCs with 6 µM oligomycin 
significantly reduced cell number after 6 hours, and the effect increased in a time 
dependent manner (Figure 6.8). Exposure to hypoxia (1% O2) for 24 hours caused 
little change in cell number in medium containing supplement (FS medium) (Figure 
6.9A). Treatment with high glucose (25 mM) for 48 hours in SF medium caused an 
increase in cell number (Figure 6.9B). Exposure to hypoxia for 48 hours in SF 
medium seemed to cause an increase in cell number, but the change is not significant. 
These preliminary results showed that adding high glucose to SF medium will 
increase cell number and inhibiting oxidative pathway in FS medium will decrease 
cell number. Exposure to hypoxia for a short term had no effect on cell number in 
both FS and SF medium, but hypoxia may require longer exposure time to be 
effective, and this will be addressed later in this chapter.  
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Figure 6.7: Effect of serum deprivation on cell number after 48 hours. 1.25x10
5
 
HCASMCs (initial count) were seeded into each well of 6-well plate (n=3). Number 
(x80) in the outline of Y axis indicates the diluting factor of cell suspension for 
counting purpose. 
 
297 
 
C
e
ll
 n
u
m
b
e
r 
p
e
r 
w
e
ll
 (
x
4
0
)
6  hr 2 4  hr 4 8  hr
0
500
1000
1500
F S
F S + D M S O
F S + O lig o
* * * P < 0 .0 01
* * * P < 0 .0 01
* * P < 0 .0 1
* * P < 0 .0 1
* * P < 0 .0 1
* * P < 0 .0 1
 
Figure 6.8: Effect of 6 µM oligomycin on cell number. HCASMCs were seeded 
into 24-well plate at the density of 3x10
4
 (initial count) (n=4). 
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Figure 6.9: Effect of hypoxia and high glucose on cell number. (A) Cells were 
seeded into 6-well plate at a density of 1.0 x10
5
 cells per well (n=6). (B) Cells were 
seeded into 6-well plate at a density of 1.25 x10
5
 cells per well (n=3). 
 
6.3.5 Assessing HCASMC proliferation with MTT assay 
6.3.5.1 Overview 
MTT assay, a colormetric quantitative assay, is widely used to measure 
cytotoxicity [304] and proliferation of cells [305-307]. Its main advantages are 
rapidity, precision, convenience and safety [308]. The principle behind this method is 
that yellow MTT is reduced by active mitochondria dehydrogenases (i.e. living cells) 
by cleaving the tetrazolium ring, producing a purple product called formazan [307]. 
The formation of the colored product is proportional to mitochondrial activity, and 
therefore makes it ideal for measuring metabolically active cells. The reaction of 
MTT is shown in Figure 6.10. The plot showing background corrected absorbance 
(570 nm) as a function of the number of the cells yields a linear relationship, but the 
A B 
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signal saturates when there are too many cells (Figure 6.11A). Digitonin (200 µg/ml) 
and 35% ethanol (EtOH), both killing the cells, were used as negative controls 
(Figure 6.11B). Deprivation of serum slowed HCASMC growth significantly, 
indicated by a reduction in MTT absorbance at 570 nm to 85.26±3.57% after 48 
hours (Figure 6.11C, n=6). 
 
Figure 6.10: Colormetric change of MTT in reaction. Yellow MTT is reduced by 
mitochondria to produce a purple product, formazan. 
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Figure 6.11: Cell number and 570 nm absorbance of MTT assay. (A) Background 
corrected absorbance at 570 nm against cell number (n=6). (B) Negative control for 
MTT assay in normoxia and hypoxia (n=6). (C) Deprivation of serum slowed cell 
growth (n=6). The absorbance at 570 nm was corrected for background. 
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6.3.5.2 Effect of PDGF-BB and high glucose on HCASMC proliferation 
In FS medium, application of 20 ng/ml PDGF-BB seemed to increase MTT 
signal, but the effect was not significant (100.36±3.22% after 24 hours and 106.94
±5.25% after 48 hours) (Figure 6.12A). In SF medium, the change in MTT signal 
was statistically significant after the application of PDGF-BB (119.80±6.65% after 
24 hours and 118.77±6.42% after 48 hours) (Figure 6.12B). Compared to basal 
medium containing 5.55 mM glucose, high glucose (25 mM) induced significant 
changes in MTT signal in cell culture medium with and without supplement (122.89
±6.24% in FS medium, 127.97±6.74% in SF medium) (Figure 6.13).   
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Figure 6.12: Effect of PDGF-BB on HCASMC proliferation. (A) Effect of 
PDGF-BB on HCASMC proliferation in FS medium (n=6). (B) Effect of PDGF-BB 
on HCASMC proliferation in SF medium (n=6). 
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Figure 6.13: Effect of high glucose on HCASMC proliferation. (A) Effect of high 
glucose on cell proliferation in FS medium (n=6). (B) Effect of high glucose on cell 
proliferation in SF medium (n=6). Cells in this experiment were treated with high 
glucose for 48 hours without prior serum starving. 
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6.3.5.3 Effect of hypoxia on HCASMC proliferation 
Next, experiments were carried out to examine whether hypoxia causes a 
change in HCASMC growth. We measured MTT signal from cells exposed to 
different concentrations of O2 (normoxia, 5% and 1%). MTT absorbance signals 
were 114.79±3.96% in 5% O2 and 93.54±5.28% in 1% O2 after 2 days; to 150.41
±1.29 % in 5% O2 (p<0.01) and 119.77±8.07 % in 1% O2 after 4 days; 165.35±
5.36% in 5% O2 (p<0.001) and 123.84±2.18% in 1% O2 (p<0.01) after 6 days in 
cell culture medium (Figure 6.14). These results suggest that exposure HCASMCs to 
both mild (5% O2) and severe hypoxia (1% O2) caused HCASMC proliferation. The 
cell number between 5% O2 group and 1% O2 group is highly significant after 6 days, 
this may be due to the fact that cell proliferation is energy dependent and the cells 
experience more severe energy crisis under 1% O2 than in 5% O2, thus severe 
hypoxia partially reversing the enhancing effect of mild hypoxia on cell proliferation. 
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Figure 6.14: Effect of hypoxia on HCASMC proliferation. Exposure to hypoxia, 
both 5% and 1% O2 induced HCASMC proliferation in FS medium (n=6). D: day. 
 
6.3.5.4 Effect of K
+
 channel modulators on cell proliferation 
In order to investigate whether K
+
 channels play a role in HCASMC 
proliferation, a wide range of K
+
 channel modulators were applied. KATP channel 
activator 10 µM pinacidil had no effect on MTT absorbance (102.12±2.02% after 
24 hours and 99.63±2.52% after 48 hours). Inhibition of KATP channels by 10 µM 
glibenclamide changed MTT absorbance to 91.01±1.97% (p<0.05) after 48 hours 
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(Figure 6.15A). In SF medium, application of 10 µM glibenclamide for 48 hours had 
little effect on cell proliferation, and this may not be surprising since cells are not 
growing (Figure 6.15B). In SF medium, BKCa channel opener (10 µM NS1619) and 
antagonist (100 nM IbTX) had little effect on MTT signals (Figure 6.16A and B). 
BKCa channel inhibitors, 100 nM IbTX and 200 nM penitrem A had no effects on 
MTT signals in FS medium (Figure 6.16C and D). In FS medium, IKCa/SKCa 
activator and inhibitors had no effect on cell proliferation (Figure 6.17A and B). 
Inhibiting Kir channel (25 µM BaCl2) for 48 hours caused little change in both FS 
and SF medium (Figure 6.18). Application of Kv channel inhibitor XE991 (10 µM) 
had no effect on MTT absorbance (Figure 6.19). These results are preliminary but 
suggest that KATP channels that are open at rest may regulate cell proliferation. 
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Figure 6.15: Effect of KATP channel modulators on HCASMC proliferation. (A) 
Effect of pinacidil and glibenclamide on HCASMC proliferation (n=6). Only the 
significance against the control was shown in the graph. (B) Effect of glibenclamide 
on HCASMC proliferation after 48 hours in SF medium (n=6). 
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Figure 6.16: Effect of BKCa channel modulators on HCASMC proliferation. (A) 
Effect of NS1619 on cell proliferation in SF medium (n=4). (B) Effect of IbTX on 
cell proliferation in SF medium (n=6). (C) Effect of IbTX on cell proliferation in FS 
medium (n=6). (D) Effect of penitrem A on cell proliferation in FS medium (n=4). 
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Figure 6.17: Effect of IKCa/ SKCa channel modulators on HCASMC 
proliferation. (A) Effect of SKA31 and apamin on HCASMC proliferation (n=6). (B) 
Effect of Tram34 on HCASMC proliferation after 48 hours (n=4). 
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Figure 6.18: Effect of Kir channel inhibitors on HCASMC proliferation. (A) 
Effect of BaCl2 on HCASMC proliferation after 48 hours (n=6). (B) Effect of BaCl2 
on HCASMC proliferation in SF medium after 48 hours (n=6). 
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Figure 6.19: Effect of Kv channel inhibitor on HCASMC proliferation. XE991 
had little effect on HCASMC proliferation for a period of 24 hours and 48 hours 
(n=4).  
 
6.3.5.5 Effect of ion channel inhibitors on hypoxia induced HCASMC 
proliferation 
Hypoxia caused HCASMCs proliferation, and ion channels maybe involved in 
this process. In this part, we further examined whether hypoxic proliferation is 
through, at least in part, an increase in K
+
 channel activity by using K
+
 channel 
inhibitors. In Figure 6.14 we have shown that the effect of 1% O2 on HCASMCs 
proliferation is time dependent. To see a maximal effect of K
+
 channel inhibitors, we 
chose to look at the effect 6 days after application of inhibitors. Hypoxia (1% O2) 
induced increase in MTT absorbance was significantly reduced by 10 µM 
glibenclamide (p<0.001) and 10 µM XE991 (p<0.05). 100 nM IbTX, 1 µM tram 34, 
A B 
304 
 
200 nM apamin, 25 µM BaCl2 and 10 µM nimodipine had little effect on cell 
proliferation (Figure 6.20). These results indicate that KATP and KV7 channels maybe 
involved in hypoxia induced HCASMC proliferation. 
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Figure 6.20: Effect of ion channel inhibitors on hypoxia induced HCASMC 
proliferation. The effect of glibenclamide (A, n=6), IbTX (B, n=6), tram34 and 
apamin (C, n=6), XE991 (D, n=6), BaCl2 (E, n=6), nimodipine (F, n=6) on hypoxia 
induced HCASMC proliferation after 6 days. 
 
6.3.6 Effect of hypoxia on HCASMC migration 
We next studied the effect of hypoxia on cell migration by scratch wound assay 
and transwell migration assay. In scratch wound assay, the effect of 20 ng/ml 
PDGF-BB on HCASMC migration was assessed every 2 hours. Application of 20 
ng/ml PDGF-BB seemed to cause cell migration, but the changes were not 
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significant within 10 hours. The changes may become greater if the time course was 
increased, but the limitation of this method did not allow us to examine the migration 
for a longer time because the wounds were closed after 12 hours (Figure 6.21). The 
difference in migration rate between groups with different O2 levels was significant 
after 12 hours (normoxia vs 5% O2 vs 1% O2, 29.32±1.34% vs 39.83±1.94% vs 
40.91±3.52%, P<0.05) and 24 hours (normoxia vs 5% O2 vs 1% O2, 71.46±4.44% 
vs 87.18±2.24% vs 87.48±3.09%, P<0.05) (Figure 6.22). These results indicate 
that hypoxia, both mild and severe, causes HCASMC migration.  
In the transwell migration assay, cell seeding number was optimized first and a 
density of 2x10
4
 cells/well was chosen (data not shown). Hypoxia caused an increase 
in the number of migrated HCASMCs after 8 hours (normoxia vs 8% O2 vs 1% O2, 
19.33±0.88 vs 23.44±1.70 vs 27.11±1.16, P<0.01) (Figure 6.23). These 
observations further support the results from scratch would assay by showing 
HCASMC migration increased under mild (8% O2) and severe (1% O2) hypoxia. 
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Figure 6.21: The effect of PDGF-BB on HCASMC migration. (A) Images of 
control and experimental groups before and after 10 hours of migration. (B) The 
migration rate of HCASMCs was assessed every 2 hours during cell migration (n=4). 
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Figure 6.22: The effect of hypoxia on HCASMC migration. Migration rate of 
HCASMCs was assessed after 4 hours, 12 hours and 24 hours exposure to hypoxia 
(n=3). * indicates the significance against control (normoxia). 
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Figure 6.23: Hypoxia induces HCASMC migration in transwell assay. Mean±
SEM for the average of migrated cells over 8 hours exposure to different O2 levels 
(n=9). 
 
6.3.7 Effect of metabolic inhibitors and hypoxia on HCASM cell cycle  
Cell proliferation is a process that produces two identical daughter cells from a 
mother cell, which generally comprises cell growth and cell division, and the latter 
requires a series of successful events during cell cycle. Figure 6.24 gives an example 
of HCASMCs at different stages. Nowadays, revolutionary techniques employing 
flow cytometry and related software allow us to quantify and evaluate cell cycle 
processes and cell growth [301, 309]. 
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Figure 6.24: Staining of HCASMCs with Reastain Diff kit. (A) A typical cultured 
HCASMC. (B) HCASMC with two nuclei during cytokinesis. 
 
6.3.7.1 Cell cycle analysis of HCASMCs using FACS 
Cell cycle has two distinct processes, named interphase and mitotic phase (M), 
the former consists of Gap 1 (G1), synthesis (S), and Gap 2 (G2) (Figure 6.25). In 
this project, the distribution of these phases of HCASMCs was obtained by 
examining the intensity of DAPI incorporation using FACS [301]. With non-stained 
HCASMCs set as a negative control (Figure 6.26), a typical plot is shown in Figure 
6.27, in which cell size is shown in forward scatter (FSC) and granularity in side 
scatter (SSC). The markers for each phase were added to cell cycle profile graph 
manually. The polygon drawn around the dot plot shows the cells considered for 
analysis, which defines the gate. Cells at different cell cycle phases have different 
amount of DNA copies, and the latter is directly related to DAPI intensity detected 
by FACS. Therefore, relative percentage of HCASMCs at each stage can be 
calculated from frequency histograms (Figure 6.27C). Cell cycle was synchronized 
before each treatment by deprivation of serum from cell culture medium. Cells serum 
free for 48 hours showed a larger proportion at G0/G1 phase (P<0.001) and G2/M 
phase (P<0.05), and smaller proportion at sub-G0/G1 phase (P<0.001), than those for 
24 hours. Therefore, the following experiments were done with the cells serum free 
for 48 hours prior to treatments (Figure 6.28). 
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Figure 6.25: Schematic presentation of cell division cycle. A complete cell cycle is 
comprised of four distinct phases that are characterized by their different DNA 
content. Once the cell passes restriction point (R point), it progresses to gap phase 1 
(G1) and begins DNA synthesis in S phase. Cells prepare to divide in gap phase 2 
(G2) and then enter M phase, in which they divided into two daughter cells through 
mitosis and cytokinesis.  
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Figure 6.26: Negative control with unstained HCASMCs. (A) Scatter graph 
showing the size and granularity of HCASMCs. (B) Dot plot of background 
fluorescence of non-stained HCASMCs. (C) Profile graph of non-stained 
HCASMCs. 
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Figure 6.27: Cell cycle analysis. (A) Scatter graph showing the size and granularity 
of HCASMCs. (B) Dot plot of fluorescence signals of DAPI stained HCASMCs 
(fluorescence gate). (C) Cell cycle graph showing different phases of cell cycle stage. 
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Figure 6.28: Effect of serum deprivation on HCASMC cell cycle. HCASMCs 
were synchronized before each experiment to induce quiescence (n=4). 
 
6.3.7.2 Effect of hypoxia on HCASMCs cell cycle 
To determine whether hypoxia induced HCASMC proliferation is through a 
general effect on cell cycle phase, DNA content was quantified. After exposure of 
HCASMCs to different levels of O2, we found that the percentage of cells at 
sub-G0/G1 phase decreased and cell proportion at G0/G1 phase increased with a 
reduction in O2 concentration (Figure 6.29 & 6.30). This suggests that hypoxia 
induced cell number increase is more likely due to decreased cell death rather than 
cell cycle arrest. Application of 10 µM glibenclamide showed little effect on cell 
cycle profile in normoxia and severe hypoxia, but resulted in a cell cycle profile with 
a smaller proportion of cells at sub-G0/G1 phase and a larger proportion at G0/G1 
phase when compared to 5% O2. These preliminary data suggests that a possible 
explanation for glibenclamide inhibition of hypoxia induced HCASMC proliferation, 
if cell cycle related, could be slowing the cell cycle. The experiments are preliminary, 
and further experiments are needed to provide solid evidence for the role of K
+
 
channels in hypoxia induced cell proliferation. 
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Figure 6.29 Cell cycle profiles of HCASMCs in hypoxia. (A) A representative cell 
cycle profile showing the percentage of cells at each cell cycle phase after exposure 
to various O2 concentrations for 2D, 4D and 6D. (B) Mean±SEM for the average 
percentage of cells at each cell cycle phase after 6D exposure to normoxia, 5% and 
1% O2 (n=4). * indicates the statistics against normoxia, and # indicated the statistics 
between 5% and 1% O2. 
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Figure 6.30 Effect of glibenclamide on HCASMCs cell cycle. HCASMCs were 
incubated in normoxia or hypoxia for 6D, and treated with 10 µM glibenclamide. 
(n=4). Statistics was carried out as Normoxia vs Gliben, 5% vs 5%+Gliben and 1% 
vs 1%+Gliben. 
B 
A 
313 
 
6.4 Discussion 
VSMC differentiation is essential during vascular development. It is well known 
that VSMCs can switch among a spectrum of phenotypes from a quiescent 
‘contractile’ phenotype state to an active ‘synthetic’ state, in which SMCs can 
migrate from media to intima where the cells start to become more proliferative [23, 
277, 310]. Therefore, a series of methods were used to characterize HCASMC 
phenotype throughout culture, and identify phenotype changes during treatments 
such as hypoxia. 
As HCASMC passage increased, they became larger in size and slowed down in 
growth rate. There seems to be an increase in cell major axis and we observed a 
significant increase in cell minor axis during culture (Figure 6.2), but these are 
within the normal range suggested by Promocell (approximately ~120-240 µm in 
length including extensions and ~15-45 µm in width). There was no difference in cell 
shape parameters (Circ, AR, Round and Solidity) from P7 to P13. HCASMCs 
maintained an elongated spindle shaped morphology throughout culture, which is 
typical for differentiated SMCs [311]. Coomassie blue staining of electrophoretically 
separated total protein sample showed similar protein distribution across all the 
passages. More specifically, Western blotting analysis and immunofluorescence 
staining were applied to monitor the expression of SMC-specific markers α-SMA, 
calponin and MHC throughout culture. In Western blotting, α-SMA was identified as 
a single band at 42 kDa and calponin with a primary band at 34 kDa from P7 to P13. 
Actin was found to be present in both HCASMCs and HCAECs, but α-actin (42 kDa) 
and calponin (34 kDa) were not identified in ECs. All of the three SMC-specific 
markers (α-SMA, calponin, MHC) were identified in immunocytochemical staining 
of HCASMCs, but not of ECs. Moreover, a parallel experiment showed a lack of two 
EC makers (vWF and CD31), which were detected in HCAECs but not in 
HCASMCs. Taken together, our results indicate that elongated primary HCASMCs 
express SMC-specific markers from P7 to P13, and there is little contamination of 
HCAEC among commercially obtained HCASMCs. Therefore, HCASMCs used in 
this project kept at low passages (P7-P13) are deemed as acceptable model. 
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Cells can respond to prolonged hypoxia in many ways to survive. For example, 
HIF-1 is a master regulator of transcriptional response under hypoxia that mediates 
many crucial physiological responses to low O2 concentrations including 
erythropoiesis, vascularization and anaerobic metabolism. However, VSMC 
proliferation and differentiation may also reflect the epidemic of many arterial 
diseases, in which development of a highly proliferative and synthetic phenotype of 
VSMCs plays a key pathogenic role [23, 312]. Because such phenotypic changes 
and cell replication are a highly energy dependent [284], we hypothesized that 
changes in cellular metabolism under hypoxia are likely to play a crucial role in 
regulating SMC plasticity.  
It is clear that VSMC proliferation results in an increase in cell number, and 
causes atherosclerosis and neo-intimal hyperplasia. However, the overall number of 
cells is dependent not only on cell growth and proliferation, but also cell death which 
is caused by apoptosis and necrosis [312-314]. Therefore, it is the balance between 
the two that maintains tissue homeostasis. Our results suggested both 5% and 1% O2 
caused cell proliferation (Figure 6.14). HCASMCs exhibited higher proliferation 
under 5% than 1% O2, we postulate that might be due to a shortage in energy for 
proliferation under severe hypoxia. When combined with cell cycle results, hypoxia 
induced cell number increase, maybe partly due to decreased cell death (Figure 
6.29). 
It is generally accepted K
+
 channels are necessary in the process of cell 
proliferation and migration. However, it is poorly understood in VSMCs how K
+
 
channel expression both in amount and distribution may change during cell 
proliferation and migration. Since the pioneering work in lymphocytes [315], there 
has been increasing evidence suggesting a role of K
+
 channels in cell proliferation. It 
has been reported SKCa/IKCa channels are not or only poorly expressed in healthy and 
freshly isolated VSMCs, while they increase dramatically in proliferating cells as in 
culture or vascular injury [96, 97]. When the cells are exposed to prolonged hypoxia, 
the expression of a wide range of O2 sensitive ion channels will increase [21]. It is 
reported that K
+
 channels are required in the initiation of G1 progression [291-293], 
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and electrical properties of the cells are regulated by K
+
 channels which will 
subsequently induce spatial and temporal organization of Ca
2+
 signaling. Meanwhile, 
Ca
2+
 is involved in G0/G1 transition [294-298]. Therefore, it is very likely that 
various K
+
 channel are involved in the process of VSMC proliferation [316]. Based 
on these, inhibition of K
+
 channels will result in a decrease in VSMC proliferation 
both under normoxia and hypoxia.  
Although many K
+
 channels are suggested as candidates in regulating VSMC 
growth, the unique gating properties of some channels (e.g. KCa channels) make them 
more likely to be important determinants in VSMC proliferation. The changes in K
+
 
channel function cause temporal organization of Ca
2+
 signaling, and thus lead to 
activation of gene expression and cell growth [316] (Figure 6.31). It was found that 
there is an increase in KCa3.1 channels in coronary vessels from patients with 
coronary artery disease, and pharmacological blockade or gene silencing of KCa3.1 
channel suppressed human VSMC proliferation and migration [317]. In HCASMCs, 
PDGF-BB induced cell proliferation was attenuated by lowering [Ca
2+
]i and 
enhanced by elevating [Ca
2+
]i, and KCa3.1 was found to be involved in 
PDGF-induced rise in [Ca
2+
]i which can be suppressed by A23187 in a dose 
dependent manner [318] (Figure 6.31). Our preliminary results suggest KATP 
channels may be important in cell proliferation, and KATP and KV7 channels maybe 
involved in hypoxia induced HCASMC proliferation. However, more studies are 
required to provide further evidence to these observations in the future. 
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Figure 6.31: The role that KCa channels play in regulating SMC plasticity. (A) In 
contractile SMCs, activation of BKCa channels by Ca
2+
 sparks results in decrease in 
vascular tone, and therefore vessel dilation. (B) Transition to synthetic phenotype is 
associated with a loss of BKCa and upregulation of IKCa and ROCs. (Modified from 
Neylon, 2002 [316]) 
 
In conclusion, cultured HCASMCs express characteristic markers specific to VSMCs, 
and these findings are of great relevance since the cells are from human coronary 
arteries. Our results suggest that at least during the passages relevant to this project, 
HCASMC did not experience a large shift in phenotype and maintained at least some 
native characteristics. Growth factors, hypoxia, as well as ion channels play crucial 
roles in HCASMC phenotype switch, and therefore may constitute a new therapeutic 
target for cardiovascular diseases [318, 319]. 
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Chapter 7 
Discussion 
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7.1 Introduction 
It was first described by Roy and Brown that when O2 supply cannot meet the 
demand of metabolically active tissues, the cardiovascular system responded with 
vasodilation and a subsequent increase in local blood flow [320]. The coronary 
circulation is adapted to provide high rates of flow to meet basal metabolic demand, 
coupled with an ability to further increase flow more than ~5 fold in response to 
increased cardiac work, for example during exercise [1, 2] (Figure 7.1). This direct 
link between blood supply and metabolic demand is a hallmark of coronary 
circulation. A number of parallel mechanisms to achieve this may exist, and 
interpretation of studies where only one of these pathways was blocked has been 
problematic due to this redundancy [2]. Thus, lack of effect in inhibiting one 
mechanism does not automatically prove it is not important as the true effect could 
be masked by alternative pathways picking up what is eliminated. Presumably the 
multiple mechanisms acts as a safety net, ensuring supply of blood is guaranteed and 
must not fail, and this is a reflection of the absolute importance of coronary 
metabolic vasodilation. With this caveat, broadly two major hypotheses have been 
advanced to account for coronary metabolic vasodilation: (i) the release of 
vasodilator metabolites from cardiac myocytes (e.g. adenosine, K
+
 and H
+
), and (ii) 
the direct vasodilatory effects of hypoxia on VSMCs. This project investigated the 
possible cellular mechanisms underlying direct hypoxic vasodilation of HCASMCs, 
with particular emphasis on the role of K
+
 channels. In addition to the acute effect on 
vascular tone, we also looked at the effect of prolonged hypoxia on HCASMC 
proliferation and migration. Many studies have reported that hypoxia activates 
various K
+
 channels in systemic arteries at different locations and of different species 
[21, 34, 38, 321]. However, this is the first study to specifically look at the role of K
+
 
channels as targets of hypoxic vasodilation in human coronary vasculature at cellular 
level. Furthermore, the use of human cells can provide a more direct and relevant 
way of studying human pathophysiological settings than use animal cells.  
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Figure 7.1: Relationship between O2 consumption and coronary blood flow. The 
diagram shows that coronary blood flow increases when there is a growing cardiac 
work, shown as a rise in O2 consumption in dog (Reproduced from Berne and 
Sperekalis, 1979 [322]). 
 
7.2 K
+
 channels as cellular targets in hypoxic vasodilation 
It has been reported that KATP and Kir channels, along with the "leak" channels, 
are involved in establishing the resting membrane potential of VSMCs [1, 43, 90, 91, 
323]. Glibenclamide and Ba
2+
 caused membrane potential depolarization, indicating 
that KATP and Kir channels are playing the major roles in setting resting membrane 
potential of HCASMCs (Figure 5.21). Reverse transcription polymerase chain 
reaction (RT-PCR) and electrophysiological experiments showed the expression of 
KCa and KATP channel subunits in HCASMCs (work by M Yang and Megan Kitching, 
data not shown). Pharmacological modulation of K
+
 channels also corroborated the 
evidence of these channels in coronary artery SMCs as shown by previous work from 
others [34, 73, 99, 324-326]. KATP channels were activated by pinacidil and inhibited 
by glibenlcamide (Figure 5.23). BKCa channels showed acute and large responses to 
various channels openers, including NS1619 and NS11021 (Figure 5.24&5.25). 
Addition of SKA31 caused membrane potential hyperpolarization, and this effect is 
fully abolished by tram34 plus apamin (Figure 5.26), suggesting a role of SKCa/IKCa 
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in HCASMCs. Thus, HCASMCs functionally express KATP, BKCa and SKCa/IKCa 
channels, and any of these could be potentially activated by hypoxia. Since the first 
study demonstrated that K
+
 currents in carotid body type I cells were reversibly 
reduced by 25 to 50 percent in hypoxia (PO2 from 150 to 10 millimeters of mercury) 
[32], O2 sensitivity of ion channels, particularly K
+
 channels received more attention 
and studies were carried out in various tissues which response to hypoxia [34, 38, 
39]. 
Initially, it was uncertain whether cultured HCASMCs had a capacity to sense 
and respond to hypoxic insults. If these cells do not respond to low O2 level, it could 
be argued that whole project does not make sense. Our [Ca
2+
]i measurement results 
showed that reducing O2 tension from 20% to 1% resulted in decreases in Ca
2+
 
oscillations in HCASMCs (Section 5.3.1.4). We also found that membrane potential, 
measured by DiBAC4(3) hyperpolarized with hypoxia (1% O2) (Figure 5.30). Taken 
together, HCASMCs can respond to hypoxia, and these results suggest that hypoxia 
vasodilation of human coronary smooth muscle may be caused by a direct effect on 
[Ca
2+
]i as well as indirectly through the change of membrane potential. The change 
in membrane potential under hypoxia could be blocked by high K
+
 (60 mM) solution, 
but inhibiting K
+
 channels including KATP channels (glibenclamide), Kir channels 
(BaCl2), BKCa channels (IbTX or Penitrem A), or KATP plus Kir channels 
(glibenclamide plus BaCl2) did not completely inhibit hypoxia induced 
hyperpolarization. This suggested that more than one K
+
 channels may be involved 
in this phenomenon. Also, K2P channels were not investigated in this thesis as there 
are not specific inhibitors that can be used to dissect out the role of these channels. 
Moreover, the sensitivity of K
+
 channels to inhibitors may be reduced during hypoxia 
[327]. Knocking down individual K
+
 channels using techniques including KO mice 
and siRNA might be useful to address some of these unanswered questions. 
 
7.3 KATP channels in hypoxic vasodilation 
KATP channels are inhibited by intracellular ATP and activated by intracellular 
ADP, making them uniquely placed to couple cellular metabolic state to membrane 
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excitability. For example, these channels are responsible for glucose sensation in 
pancreatic β-cells where an increase in blood glucose causes channel closure through 
cellular ATP production (or, more precisely, via a change in the ATP:ADP ratio). The 
resulting β-cell membrane depolarization triggers Ca2+ entry through opening of 
VDCCs and so insulin secretion. The anti-diabetic sulphonylurea drugs such as 
glibenclamide cause insulin secretion by directly inhibiting KATP channels in β -cells. 
In the cardiovascular system, KATP channels have multiple functions. In cardiac 
myocytes, the channel opens during severe and prolonged anoxia due to reduced ATP 
and increased ADP levels. This reduces cellular excitability, so preventing action 
potential generation and cell contraction [33]. Ultimately this protects the 
myocardium from damage by preventing complete depletion of intracellular ATP, 
which would trigger cell death. In the vasculature, KATP channel have diverse 
functions (summarized in reviews referenced) [33, 132] (Figure 7.2). KATP channels 
are activated by vasodilators coupled to cAMP-dependent protein kinase and are 
inhibited by vasoconstrictors coupled to PKC [328]. The resulting membrane 
potential changes are important in the actions of vasodilators and vasoconstrictors. 
Co-localization of KATP channels and protein kinases within specific plasma 
membrane microdomains, termed caveolae, appears important for modulation [157, 
165, 245]. Most recently, we have shown that the novel cellular cAMP sensor, EPAC, 
causes channel inhibition via Ca
2+
-dependent protein phophatase 2B [329]. 
Importantly, vascular KATP channels are activated by the anti-anginal compound 
nicorandil, and are inhibited by the sulphonylureas. 
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Figure 7.2: Regulation of vascular KATP channels. AC, adenylyl cyclase; AKAP, 
A-kinase anchor protein; cAMP, cyclic AMP; EPAC, exchange protein activated by 
cAMP; Gs, G-protein (stimulatory); OXPHOS, oxidative phosphorylation; PIP2, 
phosphatidylinositol (4,5)-bisphosphate; PKC, protein kinase C; PLC, phospholipase 
C; PP2B, protein phosphatase 2B. 
 
Although KATP channel is regulated by vasoconstrictors and vasodilators acting 
through second messengers and enzymes, it is the nucleotide sensitivity of the 
channel itself that has made it an obvious target for metabolic regulation of blood 
flow. The hypothesis is that hypoxia would cause a fall in cellular ATP and a rise in 
ADP, both of which would lead to activation of KATP channels and so membrane 
hyperpolarization and vasodilation. Many studies have addressed this issue at the 
level of intact coronary artery or heart in animal models, and many, though certainly 
not all, have provided evidence for a role of KATP channels in hypoxic vasodilation. 
The first report was made by Daut et al in 1990, in which vasodilation induced by 
hypoxia was inhibited by glibenclamide in intact guinea-pig heart [330]. Using a 
Langendorf heart preparation it was suggested that hypoxic vasodilation occurred via 
activation of coronary artery KATP channels in guinea-pig, probably as a consequence 
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of the effect on cellular nucleotide levels [331]. The results of a large number of 
functional studies in animal models are summarized in recent reviews [2, 21, 33]. 
However, we know of only two attempts to address this issue in human coronary 
arteries. In arteries isolated from the right atrial appendage hypoxia caused dilation 
that was not dependent on surrounding cardiac myocytes or the presence of the 
endothelium [332, 333]. In one study pharmacological inhibition of KATP channels 
using a sulphonylrea (glibenclamide) blunted the hypoxic response [332], whilst in 
the other study glibenclamide was without effect [333]. KATP channels have been 
identified in cultured HCASMCs but there have been no studies looking at metabolic 
or other regulation of these channels in single cells [334]. Regarding the 
physiological role of the KATP channel in the coronary circulation, it is of interest that 
genetic knockout in mice results in hypertension, coronary artery vasospasm and 
sudden cardiac death [335, 336]. The effects of knockout have been linked to 
Prinzmetal angina, although it is not known if KATP channel mutations cause this 
disease in humans. 
Despite the functional studies cited above, the apparently simple hypothesis that 
hypoxia changes cellular nucleotide levels to a degree sufficient to activate vascular 
KATP channels has proved to be very difficult to address [33]. Thus KATP channels 
appear to be closed at levels of ATP normally encountered in cells, and cytochrome 
oxidase, the key O2 sensitive enzyme involved in mitochondrial ATP generation, is 
fully O2 saturated unless O2 drops to very low levels (<1 mmHg, essentially 
equivalent to anoxia). In contrast, hypoxic vasodilation can occur at much higher 
oxygen levels (~30 mmHg) [2]. Indeed, a major recent review on the subject states 
that it remains unclear what the adenosine nucleotide levels are in the VSM 
myocytes and whether cellular metabolism changes sufficiently to dynamically 
regulate VSM KATP channel activity under physiological condition [33]. KATP 
currents in pig coronary artery are activated by hypoxia (PO2 ~35 mmHg) [34]. In 
contrast, KATP currents in rat femoral artery are not activated by hypoxia but are 
activated during anoxia (PO2< 1 mmHg) [203]. This difference may reflect origin of 
artery (i.e. species, vascular bed, small vs large). 
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In order to answer the question whether hypoxia changes cellular nucleotide 
levels to a degree sufficient to activate KATP channels, a series of experiments were 
designed to investigate the cellular metabolism of HCASMCs during metabolic 
inhibition and hypoxia. Bioenergetic profile of HCASMCs was characterized by 
Seahorse technique, in which it showed that the cells rely on ~54.53% of ATP 
production from OXPHOS (138.93±8.88 mol/min per 2x104 cells or 15.04±0.59 
pmol/min per µg protein) (Figure 3.15). In aerobic respiration, O2 is the final 
electron acceptor of ETC during OXPHOS, in which free energy is generated for 
various cell functions. When cell OCR was compartmentalized by a sequential 
application of metabolic inhibitors, we found that basal OCR encompasses 72.6% of 
mitochondrial O2 consumption and 27.40% of non-mitochondrial O2 consumption. In 
mitochondrial O2 consumption, 23.91% is due to proton leak, which is consistent 
with previous report showing proton leak from a range of vertebrate and invertebrate 
species is approximately ~20% [173, 177]. In our experimental conditions, switching 
off one metabolic pathway caused cells to resort to increase ATP production rate 
from the other. The changes in bioenergetic phenotype after the application of a drug 
can be used to predict the cellular energy status and explain some of the malfunctions 
in pathology.  
 After the bioenergetic profile of the cells has been determined, we then 
measured the changes in cellular nucleotides under metabolic inhibitors and hypoxia. 
In the extracellular solution containing 10 mM glucose, inhibiting either glycolysis 
(2-DG) or OXPHOS (oligomycin) caused a small change in [ATP]i, but blocking 
both pathways induced significant changes in [ATP]i (Figure 3.26). In the absence of 
glucose, either inhibiting glycolysis or OXPHOS resulted in significant changes in 
[ATP]i, and an even larger effect was observed when 2-DG and oligomycin were 
co-applied (Figure 3.26). Because the absolute amount of ATP, ADP and AMP can 
vary widely among cells, measurement of intracellular ATP:ADP and ATP:AMP 
ratios will provide more reliable information of cellular metabolism [185, 187]. 
Hydrolysis of one molecular ATP produces one molecular diphosphate ADP and one 
molecular inorganic phosphate (Pi), making ATP:ADP ratio a direct indicator of 
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cellular energy charge and phosphorylation potential. Using transient transfection, 
Perceval/PercevalHR, were introduced to the cells to report intracellular ATP:ADP 
ratio. Removal of substrate (glucose) and inhibition of either glycolysis or OXPHOS 
with metabolic inhibitors all resulted in decreases in cellular ATP:ADP ratio 
(Section 3.4.3). Hypoxia also induced a decrease in cellular ATP:ADP ratio (Section 
3.4.3.4).  
When cells were transfected using lentivirus technique, however, hypoxia 
caused no change in ATP:ADP ratio. These contradictory results from cells 
expressing reporter genes may be due to the different methods used for gene delivery. 
The cells transfected with lentivirus may be in a more physiological and healthier 
condition compared to the ones transiently transfected. The morphology of the 
former was more closely matched to the untransfected cells (Figure 4.10&6.2), and 
this may indicate that lentivirus transfected cells are more resilient to hypoxic insult. 
That said, it may be also possible to argue that those cells need to be “working” in 
order to examine the effect of hypoxia. Although cells require ATP to be just alive, 
somewhat contracting cells that would be seen in the artery with tone need 
substantially more ATP, and thus hypoxia challenge need to be investigated using 
working cells. In any case, the change seen in Perceval/PercevalHR signals are 
unlikely to be artifact as inhibiting glycolysis or OXPHOS induced no change or a 
small change in [pH]i in cell culture medium or HCO3
-
 buffered PSS in the majority 
of the cell, reported by pHRed [197]. Therefore, the changes in Perceval/PercevalHR 
fluorescence are true changes owing to changes of intracellular ATP:ADP ratio. At 
the same time, if KATP channels are activated, the effect due to a change in pH could 
be ruled out.  
It has been reported that ATP binding site on Kir6.2 subunit is estimated to be 
~2 nm below the membrane and at the interface between adjacent Kir6.2 [166]. 
Therefore, the ATP:ADP ratio in the plasma membrane microdomains will be more 
relevant and important in KATP channel gating. Even within a single cell, ATP:ADP 
ratio is very likely to be distinctive due to ATP compartmentalization and localized 
energy production and consumption. Evidence has suggested that local nucleotide 
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level is modified when bulk ATP was transmitted over the diffusional barrier into the 
sub-membrane space due to the effect from metabolic enzymes [33, 123, 167]. AMP 
is suggested to regulate ATP:ADP ratio in the near membrane area by being involved 
in the phosphotransfer reactions mediated by AK, resulting in a change sufficient to 
cause KATP channel opening [168]. Meanwhile, ATP is largely consumed by many 
physiological processes in the cell membrane, for example, the pumps work as 
ATPases while the ions and small molecules are moved across cell membrane 
against a chemical concentration gradient or electric potential. Given the importance 
of ATP:ADP ratio in the immediate vicinity of KATP channels in controlling channel 
activity, further experiments were designed to assess ATP:ADP ratio in KATP channel 
microdomains. This aim was attempted in this project by either adding a membrane 
targeting sequence to PercevalHR or TIRF imaging. Preliminary studies with both 
methods showed successful measurement of ATP:ADP ratio and detection of its 
changes in the sub-membrane area. Due to the time limitation, we just proved the 
application of these methods and showed some promising preliminary results at this 
stage.  
To summarize, metabolic inhibitors (e.g. antimycin) caused membrane 
hyperpolarization by activating KATP channels. Exposuring cells to hypoxia also 
resulted in membrane potential hyperpolarization through the activation of K
+
 
channels since this effect could be abolished with high K
+
 (60 mM). However, it is 
not known whether hypoxia affects ATP:ADP ratio to a level low enough in the 
sub-membrane area to stimulate KATP channel activity. 
 
7.4 Other K
+
 channels in hypoxic vasodilation 
Although the nucleotide sensitivity of KATP channel makes it an obvious target 
for regulation by cellular metabolism, both BKCa and Kir channels have also been 
reported to be activated during hypoxia in the vasculature [38, 321]. Kir channels are 
activated by hypoxia in rabbit coronary VSMCs, and this underlies hypoxic 
vasodilation in these vessels [321, 337]. We were the first group to record Kir 
channels in single VSMCs, initially in rat cerebral arteries and later in pig coronary 
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arteries [99, 252]. An interesting feature of these channels in the coronary circulation 
is that they are expressed only in arteries < 200 μm in diameter [99]. These small or 
resistance-sized arteries are responsible for the majority of resistance to blood flow 
and are therefore key to understanding hypoxic vasodilation [2]. Kir channels are 
activated by extracellular K
+
, and this triggers membrane potential hyperpolarization 
and relaxation of VSMCs in response to elevated [K
+
]o [73]. K
+
 is released from 
cardiac myocytes during cardiac action potential and also proposed as a metabolic 
vasodilator in the coronary circulation. Accumulation of extracellular K
+
, for 
instance during ischemia, is pro-arrhythmic, and vascular Kir channel may limit local 
K
+
 accumulation in the myocardium through increased blood flow. Whether Kir or 
BKCa channels are activated by hypoxia in human coronary arteries is currently 
unknown. 
 
7.5 VDCCs in hypoxic vasodilation 
VDCCs are the major route of Ca
2+
 entry into SMCs and Ca
2+
 channels blockers 
are routinely used to lower BP and to treat angina. Hypoxia directly inhibits VDCCs 
in the cells isolated from systemic arteries, including human coronary arteries [77, 
203]. Interestingly, hypoxia activates VDCCs in pulmonary artery myocytes, where a 
fall in O2 leads to hypoxic pulmonary vasoconstriction, which serves to balance 
ventilation to perfusion in the lung [338]. It has been suggested that this reflects a 
fundamental difference between mitochondria in systemic arteries and pulmonary 
arteries [64]. Although the principle of hypoxic inhibition of VDCCs in VSMCs 
from systemic arteries has been established, the mechanism is unclear. Our data in 
HCASMCs further corroborated the evidence that hypoxia caused changes in [Ca
2+
]i 
independent of K
+
 channel activation, in which the changes in Em was abolished by 
high [K
+
]o. It has been suggested that the direct inhibitory effect on VDCCs from 
hypoxia is through the modulation of cysteine residues in the pore forming 
α1-subunit which is redox sensitive [339-341]. The decrease in [Ca2+]i of the 
coronary was also ascribed by a mechanism in which metabotropic CCICR was 
inhibited by hypoxia [79]. 
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7.6 Limitations and future work 
The major limitation of this study is that it was conducted on cultured cells. 
Even though the signature SMC proteins were not fundamentally changing during 
the course of cell culture (Figure 6.5 and 6.6), we are aware that this does not mean 
cultured cells would behave the same way seen in vivo, and this might affect the 
results. However, apart from it is not practical to dissociate SMCs from cadaver for 
every experiment, culturing is currently the only way to introduce biosensors such as 
PercevalHR. Another important limitation of the current work is that HCASMCs 
were examined in isolation. It is very likely that even hypoxic vasodilation is a local 
event, contractile state of a SMC may be influenced by cardiac cells, ECs and even 
other SMCs. Such cell to cell interactions and communications are lost in cultured 
dish, and ultimately any results obtained from single cells studies need to be placed 
into a bigger picture. 
In this study, we investigated the possible roles of K
+
 channels and VDCCs as 
O2 sensors in hypoxic vasodilation. Our findings have suggested that hypoxia causes 
membrane potential hyperpolarization, which can be abolished by high [K
+
]o, 
suggesting a role of K
+
 channels. However, this effect is not fully blocked by 
inhibiting single K
+
 channel or both KATP and Kir channels. Thus, currently the 
identity of K
+
 channels that underlies the hypoxia induced hyperpolarization in 
HCASMCs is unknown. Of course, one must be careful in interpreting the data 
obtained from fluorescent probe experiments as ultimately the hyperpolarizing effect 
of hypoxia must be examined using current clamp technique (or sharp microelectrode 
membrane potential measurement using tissues). Future studies measuring electrical 
conductance through whole cell patch clamp recording of currents will provide more 
detailed information and allow the examination in the role of a specific K
+
 channel in 
hypoxic vasodilation, using appropriate voltage protocols and pharmacological tools 
[99, 203, 252].  
Preliminary studies have shown that hypoxia had no effect on bulk ATP:ADP 
ratio measured in HCASMCs expressing FUGW-PercevalHR, and hypoxia caused 
no change in mitochondrial membrane potential in the majority of the experiments (4 
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in 5 experiments). It is not known whether a much lower oxygen concentration will 
result in a change in ATP:ADP ratio sufficient to stimulate KATP channels in 
HCASMCs. The standard criticism is that the key O2 sensitive enzyme cytochrome c 
has an extremely low O2 affinity thus it is fully saturated at physiological hypoxia. 
KATP channels in rat femoral artery were shown to be activated only when O2 drops 
to less than 1 mmHg, which is equivalent to anoxia [203]. It would be interesting to 
see whether decreasing O2 to anoxia will cause changes in ATP:ADP ratio and 
mitochondrial membrane potential in HCASMCs.  
Due to the nucleotide compartmentalization, there is a difference between 
global and local concentrations of ATP/ ATP:ADP ratio. In order to further examine 
the potential link between cellular metabolism and KATP channel activity, it is more 
relevant to examine the ATP:ADP ratio levels in the channel microenvironment. 
Both membrane targeted PercevalHR and TIRF imaging are exciting tools to 
continue the work in this area. The compatibility of live cell imaging with other 
techniques, such as electrophysiology will allow cellular energy and channel activity 
to be determined at the same time, providing a direct relationship and valuable 
detailed information. In this way, we will be able to better characterize the possible 
roles of KATP channels in hypoxic vasodilation of coronary arteries with different 
sizes [186]. More importantly, these techniques involved in this project are valuable 
tools in study various biological and pathophysiological functions of the cells, 
therefore can be widely applied for future work.   
 
7.7 Conclusion remarks 
Hypoxic vasodilation is crucial to the regulation of human coronary blood low 
and the cellular and molecular mechanisms involved in are beginning to come out 
about what happened (Figure 7.3). Previous work from our lab and others suggested 
that the vasodilator effects of hypoxia are transduced by actions on Ca
2+
 and K
+
 
channels in SMCs. The data within this thesis further corroborated this hypothesis. 
However, more work is needed to show which K
+
 channels are involved and play a 
major role in acute O2 sensing in human coronary vasculature. Because altered Ca
2+
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and K
+
 channel function may be important in the coronary artery vascular changes 
seen in angina, diabetes and metabolic syndrome [287, 332, 335, 336, 342], this 
study therefore provided a basis for understanding these disease states. The 
application of some vasodilatory substrates may provide beneficial effects and reveal 
potential therapeutic strategies to treat diseases associated with hypoxia/ischemia by 
inducing local vasodilation. 
 
 
Figure 7.3: Hypothesised mechanisms of metabolic/hypoxic vasodilation of 
HCASMCs. The schematic diagram shows the cellular and molecular mechanisms 
proposed for metabolic/hypoxic vasodilation. Metabolic inhibitors cause vasodilation 
by decreasing intracellular ATP:ADP ratio to a level sufficient to activate KATP 
channels. Hypoxia does not reduce global ATP:ADP ratio, but it may cause a 
decrease in ATP:ADP ratio in the vicinity of the channels and lead to channel open. 
Metabolic enzymes such as AK and CK may play a role and make KATP channels 
more sensitive to small changes of ATP:ADP ratio in the channel microdomains. 
Diminished ROS production from both mitochondria and NADPH oxidase during 
hypoxia leads to smooth muscle relaxation through the enhanced K
+
 channel activity, 
thus subsequent membrane hyperpolarization and a decrease in [Ca
2+
]i [64, 343, 344]. 
A decrease in the flux of PPP under hypoxia results in decreased NADPH and [Ca
2+
]i 
which is due to both of reduced extracellular Ca
2+
 influx and enhanced ER Ca
2+
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uptake [61]. The reduction in [Ca
2+
]i could also be a direct inhibitory effect on 
VDCCs from hypoxia through the modulation of cysteine residues in the pore 
forming α1-subunit which is redox sensitive [339-341]. The decrease in [Ca2+]i 
subsequently initiates relaxation. A recent study suggested that heme-protein 
myoglobin in VSMCs produces NO through the reduction of endogenous nitrite 
under hypoxia and leads to vasodilation, which is independent of the well-known 
endothelial NO synthase (eNOS) [345]. A direct effect of hypoxia on K
+
 channels 
cannot be excluded, and perhaps hypoxic relaxation of the VSMCs is through 
an intrinsic O2 sensor which is a part of the K
+
 channel subunits. (Modified from 
Larsen et al., 2006 and Flagg et al., 2010 [33, 61]) 
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